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 3 
Summary 
 
 
Cancer is the name given to a group of related diseases characterized by 
uncontrolled cell growth and proliferation. In this project, we focused on the cell 
cycle regulator Cyclin-dependent kinase 4 (CDK4), which contributes to cell 
proliferation. Since this protein is commonly deregulated in cancer, CDK4 inhibitors 
have become a useful therapeutic tool for cancer treatment. The function of this 
protein is not limited to the control of the cell cycle; CDK4 also participates in the 
control of metabolism, always favoring anabolism and repressing catabolism. 
However, the exact mechanism by which CDK4 controls cell metabolism is not yet 
elucidated. It has been recently shown that CDK4 cross-talks with the master 
regulator of cell growth and metabolism, mammalian target of rapamycin (mTOR). 
This protein has also been effectively targeted in cancer treatments, since it is 
commonly hyperactive in cancer cells to maintain protein synthesis, cell growth and 
other anabolic processes. mTOR functions as two complexes: mTOR complex I 
(mTORC1) and mTOR complex II (mTORC2). Lysosomes, the main degradative 
organelles of the cell, are crucial for mTORC1 activation; mTORC1 is recruited to the 
surface of these organelles in response to extrinsic amino acids, or amino acids 
originated by the lysosomal degradation of macromolecules.  
Here, we show that, on one hand, CDK4 phosphorylates FLCN, a regulator of 
mTORC1 translocation to the lysosomal surface, thus facilitating mTORC1 
activation. On the other hand, we demonstrate that CDK4 promotes lysosomal 
degradation, which also results in mTORC1 activation. Finally, and most importantly 
for cancer therapy, we take advantage of this novel function of CDK4 to propose a 
new therapeutic strategy to treat triple-negative breast cancer (TNBC). We combined 
a CDK4 inhibitor, which impairs lysosomal function, with an inducer of autophagy (a 
degradative process in the cell in which lysosomal function is required) to trigger 
cancer cell death.  
Overall, this project describes a novel role for CDK4 in the control of 
lysosomal biology and the mTOR pathway in cancer cells, and proposes a promising 
therapeutic strategy for cancer treatment. 
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Résumé 
 
 
Le cancer comprend un ensemble de maladies caractérisées par une 
dérégulation de la croissance et de la prolifération cellulaires. Au cours de ce projet, 
nous nous sommes intéressés à un régulateur du cycle cellulaire, CDK4 (Cyclin-
dependent kinase 4), qui contribue à la prolifération cellulaire. Cette protéine étant 
communément dérégulée au cours du cancer, les inhibiteurs de CDK4 sont utilisés 
comme traitements contre le cancer. De plus, les fonctions de CDK4 ne se limitent 
pas au contrôle du cycle cellulaire : il participe également au contrôle du 
métabolisme, à la fois en stimulant les voies anaboliques et inhibant les voies 
cataboliques. Cependant, le mécanisme exact par lequel CDK4 contrôle le 
métabolisme cellulaire n’a pas encore été élucidé. Récemment, il a été montré que 
CDK4 interagit avec mTOR (mammalian target of rapamycin), l’un des principaux 
régulateurs de la croissance cellulaire et du métabolisme. Cette protéine a également 
été utilisée comme cible de traitements contre le cancer puisqu’elle est hyperactive 
dans les cellules cancéreuses afin de maintenir la synthèse protéique, la croissance 
cellulaire et d’autres processus anaboliques. mTOR agit sous la forme de deux 
complexes, mTORC1 (mTOR complex 1) and mTORC2. Les lysosomes, qui sont les 
principaux organites en charge de la dégradation de macromolécules et de matériel 
cellulaire, sont essentiels à l’activation de mTORC1 : en effet, mTORC1 est recruté à 
la surface de ces organites en réponse aux acides aminés exogènes ou issus de la 
dégradation lysosomale de macromolécules. 
Ici, nous montrons d’une part que CDK4 phosphoryle FLCN, un régulateur de 
la translocation de mTORC1 à la surface des lysosomes, facilitant ainsi l’activation de 
mTORC1. D’autre part, nous démontrons que CDK4 stimule la dégradation 
lysosomale, qui favorise également l’activation de mTORC1. Enfin, dans le but de 
développer une nouvelle approche thérapeutique contre le cancer, nous avons utilisé 
cette nouvelle fonction de CDK4 pour traiter le cancer du sein triple négatif. Nous 
avons combiné un inhibiteur de CDK4, qui altère la fonction lysosomale, avec un 
inducteur de l’autophagie, un processus qui requiert la dégradation lysosomale, pour 
induire la mort des cellules cancéreuses. 
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Dans l’ensemble, ce travail décrit un nouveau rôle de CDK4 dans le contrôle 
de la biologie lysosomale et de la voie mTOR dans les cellules cancéreuses, et 
propose une nouvelle stratégie thérapeutique prometteuse pour le traitement du 
cancer. 
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Chapter 1. Introduction 
 
 
I. CDK4 in cell cycle, metabolism and cancer 
 
1.  Cell cycle and Cyclin-dependent Kinases (CDKs) 
 
The cell cycle is a highly ordered set of events, involving cellular growth and 
chromosome duplication that culminates in the division of a single cell into two 
daughter cells (Nurse, 2000). The cell cycle of most eukaryotic cells is divided into 
four phases: G1, S, G2 and M. In the G1 phase, metabolic changes prepare the cell for 
division. If certain conditions are met, the cell is committed to division and moves to 
the S phase. The S phase is the period during which DNA replication occurs. In the 
G2 phase, the cell undergoes more growth and checks the replicated DNA to ensure 
that the cell is safe to move on to cell division. A nuclear division (Mitosis) followed 
by a cell division (Cytokinesis) occurs in the M phase. The cell cycle can also be 
divided into two major stages: Interphase (which includes the G1, S and G2 phases), 
where the cells grow and prepare themselves for division, and Mitosis-Cytokinesis (M 
phase). The G0 phase is a state outside of the replicative cell cycle in which cells rest 
in a quiescent state. Classically, it was thought that nutrient deprivation was the cause 
of G0 phase entry. However, it has been shown that G0 entry occurs for multiple 
reasons. For example, cells enter to this phase in the context of cell differentiation. 
The G0 phase is reversible; cells can receive intrinsic or extrinsic signals to re-enter in 
the G1 phase (Barnum & O'Connell, 2014).   
The central machineries that drive cell cycle progression are some members of 
Cyclin-dependent Kinases (CDKs), which is a large family of serine/threonine protein 
kinases. CDK1, CDK2, CDK4 and CDK6 are the best-known members of this family 
that regulate the cell cycle progression. The expression of CDKs is constant, but they 
lack kinase activity until they bind to their corresponding Cyclin partners, which 
allow CDKs to adopt an active configuration (Lohka, Hayes, & Maller, 1988). 
Cyclins are tightly regulated at the levels of synthesis and ubiquitin-dependent 
proteolysis (Malumbres & Barbacid, 2005), and they are differently expressed at each 
 10 
phase of the cell cycle. In that way, different CDKs/Cyclin complexes are formed in 
each phase of the cell cycle (Figure 1). CDK4/Cyclin D and CDK6/Cyclin D are the 
main complexes of the G1 phase (Matsushime et al., 1992; Meyerson & Harlow, 
1994), CDK2/Cyclin E complex in the S phase (Koff et al., 1992; Ohtsubo, 
Theodoras, Schumacher, Roberts, & Pagano, 1995), and CDK1/Cyclin B complex 
during the transition G2/M phases (Draetta & Beach, 1989; Pines & Hunter, 1992).  
 
Figure 1. Cyclin expression and kinase activity of the differen types of Cyclins and CDK/Cyclin 
complexes. 
 
Moreover, the binding of small inhibitory proteins, CDK inhibitors (CKIs), 
can modulate the activity of CDKs. Also, CDKs can be phosphorylated to activate or 
to block the phosphate transfer to substrates (Barnum & O'Connell, 2014). 
Indeed, the large family of CDKs includes members whose function is not 
directly related to cell cycle regulation. CDK7 forms a trimeric complex with Cyclin 
H and MAT1, and functions as a CDK-activating kinase (CAK). In addition, CDK7 is 
an important component of the transcription factor II H (TFIIH), which is involved in 
transcription initiation and DNA repair. CDK8 and CDK9 are essentially implicated 
in the transcriptional machinery of RNA polymerase II. This protein is thought to 
serve as a direct link between the regulation of transcription and the cell cycle (Fisher, 
2005). CDK11/Cyclin L complex interacts with a variety of elongation factors to 
facilitate transcription elongation (Trembley et al., 2005). It is additionally involved 
in RNA processing co-transcriptionally through its association with and 
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phosphorylation of factors responsible for pre-mRNA splicing (Dickinson, Edgar, 
Ehley, & Gottesfeld, 2002; Hu, Mayeda, Trembley, Lahti, & Kidd, 2003; Loyer et al., 
2008). Little is known about the partners or the phosphorylation targets of CDK10. 
However, it has been studied that CDK10 plays a role in cancer progression (Leman 
et al., 2009; Yu et al., 2012; Zhong et al., 2012). 
All CDKs have a conserved sequence in N-terminal which corresponds to the 
Cyclin-binding site: xGxPxxxxREx; (G, glycin; P, prolin; R, arginine; E, glutamic 
acid; and x, any amino acid). In addition, they phosphorylate substrates that contain 
the following motif: [S/T]-Px- [K/R] (S, serine; T, threonine; P, proline; K, lysine; R, 
arginine; and x, any amino acid). This phosphorylation confers conformational 
modifications to the target proteins, providing them with new properties. 
 
 
2. CDK4/Cyclin D-RB-E2F axis 
 
In 1987, Hanks identified CDK4 by hybridizing a HeLa cell cDNA library 
with oligonucleotide probes homologous to known serine/threonine kinases. It was 
first named PSK-J3 (termed for putative serine/threonine kinase, filter J colony 3). 
During the Cold Spring Harbor Symposium on Cell Cycle in 1991, to unify the 
nomenclature for CDK family, PSK-J3 was renamed CDK4 (Hanks, 1987; 
Malumbres & Barbacid, 2005).   
CDK4 controls the progression from the G1 phase to the S phase of the cell 
cycle. The activation of CDK4 is due to a conformational change when it forms a 
complex with the D-type Cyclins in response to mitogenic signals. Cyclin D is one of 
the major cyclins produced in terms of its functional importance. Drosophila and 
many other organisms only have one cyclin D protein. In mice and humans, three 
types of D-type Cyclins have been identified: cyclin D1, D2 and D3. These three 
types of Cyclin D are expressed in most proliferating cells. However, their abundance 
differs in various cell types.  
The activity of CDK4 also requires their activating phosphorylation on Thr172 
by CDK7. Active CDK4/Cyclin D complexes are able to phosphorylate protein 
targets, such as the members of the retinoblastoma (RB) protein family (RB1, RBL1, 
and RBL2). Phosphorylated RB releases the transcription factor E2F1, which is then 
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able to activate its target genes, such as E-type Cyclins, which are thought to be 
necessary for CDK2 activation and for the proper completion of the G1 phase (Figure 
2). This process corresponds to the “restriction point”: the stage during the G1 in 
which cells no longer require mitogenic stimuli to undergo cell division.  
Importantly, CDK6 also controls the transition from the G1 to the S phase of 
the cell cycle through RB phosphorylation. Moreover, in the case of irreversible 
inactivation of CDK4 or CDK6, CDK2-Cyclin E is thought to phosphorylate RB 
(Bockstaele, Coulonval, Kooken, Paternot, & Roger, 2006; Neganova & Lako, 2008).  
 
 
 
Figure 2. Cyclin D1/ CDK4 and CDK6/ Rb/ E2F pathway for G₁ to S transition. 
 
 
In addition, CDK4 activity is regulated by two families of proteins: 1) the 
INK4 family (p16ink4A, p15INK4B, p18INK4C, p19INK4D), which inhibit CDK4/Cyclin D 
activity by directly binding to the CDK and 2) the Cip and Kip family (particularly 
p21CIP1, p27kip1, and the less known p57kip2) which have context-dependent positive 
(stabilizing) and negative (inhibiting) effects on CDK4/6 activity (Canepa et al., 
2007).  
The activity of CDK4 in the cell cycle is only required for the G1 to S phase 
transition. Thus, after the phosphorylation of RB, CDK4/Cyclin D complex is 
translocated from the nucleus to cytoplasm, allowing the activity of other 
CDK/Cyclin complexes. 
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3. Non-canonical roles of CDK4 
 
The availability of knockout mouse models has uncovered the general and 
tissue-specific functions of CDKs and their partner Cyclins. Knockout mice of CDKs 
that regulate the transition from G1 to S phase of cell cycle (not only CDK4 but also 
CDK2 and CDK6) demonstrated that they were individually dispensable for cell 
proliferation, but displayed additional tissue specific roles (Jayapal et al., 2015; Sherr 
& Roberts, 2004). CDK4 knockout mice are viable, although they are infertile and 
small. In addition, they present abnormalities in hypothalamic-pituitary axis, and 
develop diabetes (Mettus & Rane, 2003; Rane et al., 1999; Tsutsui et al., 1999). 
Indeed, these observations led to the initiation of research in the non-canonical roles 
of CDK4.  
CDK4 has been shown to regulate insulin secretion in insulin-producing 
pancreatic β-cells through the CDK4-RB-E2F1 pathway. In response to high glucose, 
CDK4 kinase activity is increased through the insulin pathway, resulting in RB 
phosphorylation. Phosphorylated RB releases the E2F1-DP complex activating the 
transcription of the Kir6.2 gene, which codes for a key component of the KATP 
channel involved in insulin secretion (Annicotte et al., 2009).  
In hepatocytes, and also through insulin signaling pathway, CDK4 has been 
found to regulate glucose uptake by phosphorylating the histone acetyltransferase 
general control non-derepressible 5 (GCN5). GCN5 subsequently acetylates the 
PPAR-γ coactivator 1α (PGC-1α), thereby inhibiting the expression of gluconeogenic 
genes. Thus, CDK4 is responsible for controlling glucose metabolism by suppressing 
hepatic glucose production in mice (Y. Lee et al., 2014). 
Importantly, none of the above situations were proliferating conditions, 
suggesting that the effects of CDK4 in those cell types were cell cycle independent 
(Annicotte et al., 2009; Y. Lee et al., 2014).  
In other cell types, CDK4 has been shown to play an essential role in cell 
differentiation, additionally to its role in cell proliferation. This is the case of 
hematopoiesis and adipogenesis. During hematopoiesis, CDK4 is regulated by 
GATA-1 and required for megakaryocyte growth and polyploidization (Muntean et 
al., 2007). CDK4 is also been found to play a role in lymphocyte adhesion and 
migration through endothelial cell matrix (Chow et al., 2010). On the other hand, 
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CDK4 deletion in 3T3-L1 cells blocks adipogenesis, while the hyperactive form of 
CDK4 (R24C) favors it; CDK4 regulates the nuclear receptor peroxisome 
proliferator-activated receptor gamma (PPARγ) and terminal differentiation and 
function of adipocytes (Abella et al., 2005). 
Also in adipocytes, insulin activates the CDK4/Cyclin D3 complex, which 
subsequently phosphorylates the insulin receptor substrate 2 (IRS2). This generates a 
positive feedback loop maintaining insulin signaling pathway activated (Lagarrigue et 
al., 2016). CDK4-deficient mice display decreased lipogenesis and increased lipolysis 
in white adipose tissue, indicating that CDK4 is essential for promoting anabolic 
metabolism in adipocytes (Lagarrigue et al., 2016).  
Furthermore, it has been recently shown that CDK4 is able to promote 
anabolism while directly repressing catabolism, by inhibiting the metabolic regulator 
5' AMP-activated protein kinase (AMPK). Phosphorylation of the alpha-2 subunit of 
AMPK (AMPKα2) by CDK4 is associated with increased glycolysis and decreased 
fatty acid oxidation in mouse embryonic fibroblasts. In addition, CDK4 knockout 
mice increased their oxidative metabolism and exercise capacity in an AMPK- 
dependent manner (Lopez-Mejia et al., 2017). 
In Drosophila, as in mammalian cells, CDK4 interacts genetically with the 
Drosophila RB family member RBF. However, CDK4 is not essential for progression 
through the cell cycle or for development to the adult stage. Nevertheless, CDK4 is 
clearly required for normal fertility and growth of cells and organisms (Meyer et al., 
2000). Another study in the same model showed that CDK4/Cyclin D is able to 
activate TORC1 by phosphorylating one of its negative regulators, tuberous sclerosis 
complex 2 (TSC2) (Romero-Pozuelo, Demetriades, Schroeder, & Teleman, 2017). 
TORC1 is the homolog in drosophila of mammalian target of rapamycin complex 1 
(mTORC1), as later on detailed, the master regulator of cell growth and metabolism.  
Overall, these evidences highlight the importance of CDK4; a kinase that, on 
one hand regulates the G1 to S phase transition of the cell cycle through 
phosphorylation of RB, and on the other hand, have many other phosphorylation 
targets for modulating metabolism in proliferating and differentiated cells, as well as 
at a whole body level.  
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4. CDK4 and its inhibition in Cancer  
 
Irregular entry into the cell cycle and uncontrolled cell proliferation are 
hallmarks of cancer. Hence, it is not surprising that the deregulation of CDKs plays a 
vital role in tumorigenesis. Specially, the hyperactivity of CDK4/Cyclin D-RB-E2F 
axis is known for being implicated in the abnormal proliferation of cancer cells 
(Malumbres & Barbacid, 2009). The retinoblastoma protein (RB) represents a 
checkpoint regulator in mammalian cells. When it is phosphorylated, RB enhances the 
expression of proteins that are essential for commitment to S phase and progression 
through the cell cycle. Normally, this step is tightly regulated, but in malignancy, this 
transition point can become less closely regulated, allowing for less controlled 
proliferation.  
The importance of the CDK4 locus in human cancer first became evident 
following the identification of a germ line CDK4-Arg24Cys (R24C) mutation, which 
abolishes the ability of CDK4 to bind to its repressor p16INK4a (Rane, Cosenza, 
Mettus, & Reddy, 2002). Indeed, mice with R24C mutation develop endocrine, 
epithelial tumors and sarcomas (Malumbres & Barbacid, 2009). Later on, CDK4 had 
been found mutated in other forms of human cancer including glioma, sarcoma, 
breast, lung, ovary and oral cavity carcinomas (Mejia-Guerrero et al., 2010; Sabir, 
Baig, Mahjabeen, & Kayani, 2012; Wikman et al., 2005). Furthermore, Cyclin D1 
mutations (mostly amplifications and overexpressions) have also been found in 
molecular analyses of many human cancers (Lantsov et al., 2005).  
Given that the abnormal function of CDK4/Cyclin D complex might promote 
cell proliferation, CDK4 have become a genetically validated therapeutic target for 
cancer treatment (Salazar-Roa & Malumbres, 2017). First-generation of CDK 
inhibitors tended to be less specific, targeting other CDKs in a broad manner and were 
associated with chemotherapy-like toxicities and unacceptable safety profiles. A new 
generation of inhibitors of CDK4/Cyclin D complex, which also inhibit CDK6/Cyclin 
D due to their similarities, has been developed. Three drugs have been recently 
designed to bind to the ATP-binding pocket contained within the protein kinases, and 
thereby, block CDK4/6-mediated phosphorylation of RB: Palbociclib (PD0332991; 
Pfizer, USA), Ribociclib (LEE011; Novartis, Switzerland) and Abemaciclib 
(LY2835219; Eli Lilly, USA) (Figure 3).  
 
 16 
 
 
 
 
 
 
 
 
 
Figure 3. Chemical structures of selective CDK4/6 inhibitors in clinical development. 
 
 
These three CDK4/6 inhibitors have shown to be effective especially for 
breast cancer, which often has aberrations throughout the Cyclin D-CDK4-RB 
pathway, particularly in Cyclin D1 gene or protein. Breast cancer is categorized into 
five distinct molecular subtypes including luminal A, luminal B, human epidermal 
growth factor receptor 2 (HER2)-enriched, basal-like, and claudin-low. Most types of 
breast cancers belong to luminal-type, and are characterized with the expression of 
estrogen receptor (ER) and/or progesterone receptor (PR), which can be effectively 
targeted with hormone therapy. By contrast, basal-like breast cancers, also known as 
triple-negative breast cancer (TNBC), due to the absent status of ER, PR and HER2, 
have comparatively aggressive phenotype and still lack efficient treatment strategy 
(Xu et al., 2017).  
The administration of CDK4/6 inhibitors represents an important therapeutic 
advancement in breast oncology. All three CDK4/6 inhibitors have completed 
evaluation on randomized phase III studies and have received approval by the US 
Food and Drug Administration (FDA) for use in hormone receptor (HR)-positive 
breast cancers. Additionally, the drugs are being looked at preclinically and clinically 
in a variety of other tumor types as well, including melanoma, glioblastoma, 
pancreatic cancer, and colorectal cancer (Iams, Sosman, & Chandra, 2017; Knudsen 
et al., 2019; Olmez et al., 2018; J. Zhang, Zhou, Zhao, Dicker, & El-Deiry, 2017).  
There is some evidence that manipulating metabolic pathways may be a useful 
addition of CDK4/6 inhibition. Ongoing studies include combinations of CDK4/6 
inhibitors with other agents (Table 1), such as phosphatidylinositol 3-kinase (PI3K) 
and mammalian target of rapamycin (mTOR) pathway inhibitors, and with selective 
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RAF and MEK inhibitors for tumors with alterations in the mitogen activated protein 
kinase (MAPK) pathway. Also some studies combined CDK4/6 inhibitors with 
immunotherapy and chemotherapy (Pernas, Tolaney, Winer, & Goel, 2018).  
In addition, a number of non-RB targets for CDK4/6 have been identified in 
the metabolic machinery. Importantly, the use of CDK4/6 inhibitors for cancer 
treatment has shown that it suppresses the activity of the master regulator of cell 
growth and metabolism, mammalian target of rapamycin complex I (mTORC1), in 
HER2-positive breast cancer and glioblastoma (Goel et al., 2016; Olmez et al., 2017). 
The exact mechanism by which CDK4 regulates mTORC1 is not yet elucidated. 
However, the changes in metabolism after CDK4/6 inhibition may depend on the 
context and the oncogenic drivers, since opposite results were found in pancreatic 
ductal adenocarcinoma (Franco, Balaji, Freinkman, Witkiewicz, & Knudsen, 2016). 
This establishes new vulnerabilities in the use of CDK4/6 inhibitors and opens new 
venues for further investigation (Klein, Kovatcheva, Davis, Tap, & Koff, 2018).  
Despite providing clear benefits, there are other challenges in the use and 
optimization of CDK4/6 inhibitors in clinical practice. For example, there is still a 
lack of predictive biomarkers to screen the appropriate population who can benefit the 
most from these treatments. Although several studies have implied some potential 
candidates for sensitivity prediction, such as the protein levels of RB and p16, further 
extensive clinical trials are needed to validate this finding (Polk, Kolmos, Kumler, & 
Nielsen, 2016; Xu et al., 2017).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 18 
 
 
 
 
 
 
Table 1. List of clinical trials with CDK4/6 inhibitors in combination with other agents 
(Klein et al 2018). 
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II. mTOR,	lysosomes	and	autophagy		
 
1. mTOR	pathway	
 
The mammalian target of rapamycin (mTOR), also known as the mechanistic 
target of rapamycin and FK506-binding protein 12-rapamycin-associated protein 
1 (FRAP1), is a serine/threonine kinase belonging to the PI3K-related kinase family. 
It is conserved throughout evolution, and is encoded by the MTOR gene in humans. 
mTOR links with other proteins and serves as a core component (catalytic subunit) of 
two distinct protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2) (Laplante and Sabatini, 2012).  
As a core component of mTORC1, mTOR regulates cell growth, cell 
proliferation, cell motility, cell survival, protein synthesis, autophagy and 
transcription. mTORC1 is formed by mTOR, regulatory-associated protein of mTOR 
(RAPTOR) and mammalian lethal with Sec13 protein 8 (mLST8, also known as 
GβL).  Proline-rich AKT substrate 40 kDa (PRAS40) and DEP-domain-containing 
mTOR-interacting protein (DEPTOR) are negative regulators of mTORC1 which are 
recruited to the complex for its inhibition (Peterson et al., 2009). mTORC1 responds 
to amino acids, stress, oxygen, energy, and growth factors, and is acutely sensitive to 
rapamycin (Laplante and Sabatini, 2012). 
As a core component of mTORC2, mTOR participates in the activation of 
AKT via direct phosphorylation at Ser472/3; the full activation of AKT requires also 
another phosphorylation at Thr308 by phosphoinositide-dependent kinase 1 (PDK1), 
after the activation of insulin signaling pathway. Thus, since AKT is an important 
promoter of cell survival, metabolism and proliferation, mTORC2 is also stimulating 
these processes (Manning & Cantley, 2007). In addition, mTORC2 regulates actin 
cytoskeleton by promoting protein kinase Cα (PKCα) phosphorylation, 
phosphorylation of paxillin and its relocalization to focal adhesions, and GTP loading 
of RhoA and Rac1. However, the molecular mechanisms by which mTORC2 regulate 
these processes have not been determined yet (Jacinto et al., 2004). Like mTORC1, 
mTORC2 is a large complex. It is formed by mTOR, rapamycin-insensitive 
companion of mTOR (RICTOR), mammalian stress-activated protein kinase 
interacting protein (mSIN1), protein observed with RICTOR-1 (PROTOR-1) and 
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mLST8. Similar to mTORC1, DEPTOR negatively regulates the complex (Laplante 
and Sabatini, 2012). The signaling pathways that lead to mTORC2 activation are not 
well characterized. Since growth factors increase mTORC2 kinase activity and AKT 
phosphorylation at Ser473, they are considered to be a plausible signal for regulating 
this pathway (Guertin & Sabatini, 2007). mTORC2 is insensitive to acute rapamycin 
treatment but chronic exposure to the drug can disrupt its structure.  
mTOR signaling pathway integrates both intracellular and extracellular 
signals, and serves as a central regulator of cell metabolism, growth, proliferation and 
survival. Due to its relevance in cancer models and its role in the regulation of 
lysosomal biology, in this project we focused mainly on mTORC1.  
 
 
2. mTORC1:	the	master	regulator	of	cell	growth	and	metabolism	
 
 
mTORC1 upstream signaling: 
 
mTORC1 integrates four major signals (growth factors, amino acids, oxygen 
and energy status) to regulate many processes that are involved in the promotion of 
cell growth (Figure 4A-B).  
Growth factors, such as insulin or insulin growth factors (IGFs), stimulate 
mTORC1 through the activation of the canonical insulin-signaling pathway. The 
binding of insulin or IGFs to their cell-surface receptor promotes the tyrosine kinase 
activity of the insulin receptor, the recruitment of insulin receptor substrate (IRS), the 
production of phosphatidylinositol 3-phosphate (PI3P) through the activation of PI3K, 
and followed by the activation of AKT. Once AKT is fully active, it can activate 
mTORC1 either by promoting the phosphorylation and dissociation of PRAS40 from 
mTORC1, or via the phosphorylation of tuberous sclerosis complex (TSC) (Laplante 
& Sabatini, 2012). TSC complex is a heterodimer comprised by TSC1 and TSC2. 
TSC1/2 functions as a GTPase-activating protein (GAP) for the small Ras-related 
GTPase RHEB (Ras homolog enriched in brain). As a RHEB-specific GAP, TSC1/2 
negatively regulates mTORC1 signaling by converting RHEB into its inactive GDP-
bound state. The active one, GTP-bound form of RHEB, directly interacts with 
mTORC1 to stimulate its activity (Inoki, Li, Xu, & Guan, 2003). mTORC1 can also 
be activated by the phosphorylation of TSC complex with RAS signaling pathway, 
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also promoted by growth factors. On the other hand, activation of mTORC1 
negatively regulates the PI3K-AKT axis, given that p70 ribosomal S6 kinase 1 
(S6K1) phosphorylates IRS1 and reduces its stability (Harrington, Findlay, & Lamb, 
2005) (Figure 4A-B).  
Amino acids such as leucine, arginine, glutamine, and serine (Carroll et al., 
2016; Fan et al., 2016; Jewell et al., 2015; Wang et al., 2015) are also crucial for 
mTORC1 activation. Precisely, the presence of amino acids promotes the 
relocalization of mTORC1 from discrete locations of the cell to the surface of the 
lysosomes, where is activated by RHEB. Amino acids, not only from the cytosol, but 
also the ones accumulated in the lysosomes (Sagne et al., 2001), activate Rag 
GTPases. Rag GTPases localize on the lysosomal surface and are essential for 
communicating amino acid availability to mTORC1 through their binding with 
RAPTOR (Sancak et al., 2008). In mammals, there are four members of the Rag 
subfamily: RagA, RagB, RagC and RagD, which function as heterodimers (Kim & 
Kim, 2016). RagA/B form heterodimeric pairs with RagC/D, suggesting the existence 
of four possible independent heterodimeric pairs. During amino acid starvation, 
RagA/B binds GDP and is quickly exchanged for GTP after amino acid restimulation, 
for recruiting mTORC1 to the lysosomal surface. The Rag GTPases are regulated by a 
complex signaling network, in which activators and inhibitors tightly modulate their 
nucleotide-bound state. Ragulator, GATOR1, GATOR2, FLCN-FNIP and KICSTOR 
are some of Rag GTPases regulators. In addition, the lysosomal membrane transporter 
SLC38A9, Sestrin2 and CASTOR1 have been recently identified as nutrient sensors, 
which modulate mTORC1 activation (Bar-Peled & Sabatini, 2014) (Figure 4B). 
In the present work, we focus on Folliculin (FLCN), a protein that in humans 
is associated with Birt-Hogg-Dubé syndrome and hereditary spontaneous 
pneumothorax, but also has been identified as a tumor suppressor. FLCN, together 
with its binding partner Folliculin interacting protein 1 (FNIP1), function as a GAP 
for RagC/D, but not as a Guanine nucleotide exchange factor (GEF) for RagA/B, thus 
providing another avenue of control over mTORC1 translocation (Petit, Roczniak-
Ferguson, & Ferguson, 2013).  In addition, its intracellular positioning changes in 
response to amino acids: FLCN localizes in the lysosomal surface under amino acid 
starvation conditions, suppressing Rags activity, and moves to the cytosol in the 
presence of amino acids, allowing mTORC1 to be recruited to the lysosomal surface. 
In addition, FLCN has been shown to interact with AMPK.  
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AMPK is the master sensor of intracellular energy status, another of the 
signals that regulate mTORC1. AMPK negatively regulates mTORC1 in response to 
energy depletion (low ATP:ADP ratio) via TSC2 phosphorylation (Hardie, 2007). 
Additionally, AMPK can reduce mTORC1 activity in response to energy depletion by 
directly phosphorylating RAPTOR (Gwinn et al., 2008) (Figure 4B). 
mTORC1 activity is also affected by oxygen levels through multiple 
pathways. Under conditions of hypoxia, low ATP:AMP ratio activates AMPK, which 
promotes TSC1/2 activation and inhibits mTORC1 signaling. Hypoxia can also 
activate TSC1/2 through transcriptional regulation of DNA damage response 1 
(REDD1). Furthermore, promyelocytic leukemia (PML) tumor suppressor and 
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) reduce 
mTORC1 signaling during hypoxia by dissociating mTOR from its positive regulator 
RHEB (Wouters & Koritzinsky, 2008). 
In addition to the four major signals described above, mTORC1 activity can 
be regulated by other cellular conditions and signaling pathways, such as genotoxic 
stress (like DNA damage), inflammation, Wnt ligand and phosphatidic acid (Laplante 
& Sabatini, 2012). 
 
 
 
Figure 4. (A) Coincidence detector model for how mTORC1 integrates signals from nutrients and 
growth factors to regulate growth. (B) Schematic showing components of the nutrient-sensing pathway 
upstream of mTORC1 (Sabatini, 2017).  
 
 
 
 23 
mTORC1 downstream signaling:  
mTORC1 has pleiotropic functions by phosphorylating a wide range of 
substrates and affecting many cellular compartments, always favouring anabolic 
metabolism (Laplante & Sabatini, 2012, 2013). 
The most known mTORC1 function is to promote protein synthesis, which is 
required for cell growth, through phosphorylation of its downstream targets: 4E 
binding protein 1 (4E-PB1) and S6K1. 4E-BP1 is a repressor of mRNA translation. 
When phosphorylated by mTORC1, 4E-BP1 is unable to bind to eukaryotic 
translation initiation factor 4E (eIF4E), which allows it to promote cap-dependent 
translation (Richter & Sonenberg, 2005). The main target of S6K1 is the S6 ribosomal 
protein. Active (phosphorylated) S6K1 increases mRNA biogenesis, cap-dependent 
translation and elongation, and the translation of ribosomal proteins through 
regulating of the activity of many proteins (Chung, Kuo, Crabtree, & Blenis, 1992).  
  mTORC1 is also able to promote de novo lipid synthesis through sterol-
responsive element-binding protein (SREBP) transcription factors, which control the 
expression of numerous genes involved in fatty acid and cholesterol 
synthesis. SREBP can be activated either by S6K1 or by another mTORC1 substrate, 
the phosphatidate phosphatase lipin 1. By contrast, lipin 1 inhibits SREBP1 when 
mTORC1 signaling is inactivated (Meng, Frank, & Jewell, 2018). In 
addition, mTORC1 also promotes the expression and activity of PPAR-γ, the master 
regulator of adipogenesis (H. H. Zhang et al., 2009). 
To regulate cellular metabolism and produce ATP, mTORC1 increases 
glycolytic flux by activating the transcription and the translation of a positive 
regulator of many glycolytic genes, the hypoxia inducible factor 1α (HIF1α) 
(Brugarolas et al., 2004; Duvel et al., 2010). Additionally, mTORC1 has been 
reported to increase mitochondrial DNA copy number, as well as the expression of 
many genes encoding proteins involved in oxidative metabolism. Even though 
additional evidence is needed, this happens in part by mediating the physical 
interaction in the nucleus between PGC1α and the transcription factor Ying-Yang 1 
(YY1), which positively regulates mitochondrial biogenesis and oxidative function 
(Cunningham et al., 2007). 
Paradoxically, mTORC1 also promotes growth by negatively regulating 
catabolic processes, such as autophagy, the central degradative process in cells, and 
lysosomal biogenesis, the creation of new degradative organelles. Both processes are 
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controlled by the transcription factor EB (TFEB), which is repressed by mTORC1 
phosphorylation; when mTORC1 is active, phosphorylated TFEB remains inactive at 
the lysosomal membrane. Inactivated mTORC1 induces TFEB localization to the 
nucleus to activate lysosomal and autophagosomal gene transcription, thus initiating 
lysosomal biogenesis and autophagy. In addition, mTORC1 represses autophagy by 
phosphorylating and therefore repressing unc-51-like kinase 1 (ULK1) and ATG13. 
ULK1 can also be phosphorylated by the mTORC1 antagonist, AMPK, but in this 
case, to activate autophagy (Egan, Kim, Shaw, & Guan, 2011). 
The complexity of mTOR signaling pathway is notable (Figure 5). In the 
recent years, much attention has been paid to this field due to its importance in many 
pathological conditions. As a result, more and more proteins are being identified as 
key players in the regulation of this signaling pathway. 
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Figure  5. mTOR signaling at a glance (Laplante & Sabatini, 2009). 
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3. Lysosomes 
 
Text adapted from the review of which I am first author, enclosed in Annex. 
Contribution to other articles: “Cancer: linking powerhouses to suicidal bags” 
(Martinez-Carreres, Nasrallah, & Fajas, 2017). 
 
Christian de Duve first described lysosomes, also known as “suicidal bags,” in 
1950s as single membrane-enclosed vesicles containing hydrolases. Lysosomes 
function as a digestive system and are found in all eukaryotic cells, except for mature 
erythrocytes. The hydrolytic enzymes that they contain include proteases, nucleases, 
and lipases. These enzymes can break down proteins, nucleic acids, and lipids to their 
simplest subunits (De Duve, Pressman, Gianetto, Wattiaux, & Appelmans, 1955).  
Lysosomes are formed when material from outside the cell is internalized in 
clathrin-coated endocytic vesicles creating early endosomes. These early endosomes 
undergo a process of maturation with the delivery of lysosomal acid hydrolases from 
the trans Golgi network, which contribute lowering of the internal pH to about 5.5. 
Late endosomes then mature into lysosomes as they acquire a full complement of acid 
hydrolases, which digest the molecules originally taken up by endocytosis, 
phagocytosis, and autophagy (Cooper, GM. The Cell: A Molecular Approach. 2000). 
Nevertheless, many investigations have proved that lysosomes are not only 
degradative organelles but also participate in metabolism of the entire cell at different 
levels, and their modifications can promote or repress cell proliferation. 
On one hand, lysosomes repair damaged plasma membranes through a 
mechanism consisting in Ca2+ regulated exocytosis: they secreting their content into 
the extracellular space, and repairing their damaged plasma membranes; when the 
plasma membrane is injured, lysosomes quickly move to the site of damage and fuse 
with the plasma membrane. This allows effective resealing (Morgan, Platt, Lloyd-
Evans, & Galione, 2011).  
On the other hand, they can sense nutrient availability, which controls energy 
metabolism and mediates the starvation response (Settembre, Fraldi, Medina, & 
Ballabio, 2013). Zoncu et al. proposed that amino acids have to be detected in the 
lysosomal lumen, signaling to the Rag GTPases in a manner that is vacuolar H+-
ATPase (V-ATPase)-dependent. This is known as the “inside-out” mechanism (Zoncu 
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et al., 2011). Leucine, among other amino acids, must accumulate in the lumen of the 
lysosome to trigger the central regulator of cellular and organismal growth, mTORC1 
(Bar-Peled & Sabatini, 2014). As mentioned above, mTORC1 is recruited by Rag 
GTPases on the lysosomal surface in response to amino acids, the site of activation by 
RHEB (Ras homolog enriched in brain), when growth factor-stimulated PI3K–AKT 
signaling is on (Dibble & Cantley, 2015; Shimobayashi & Hall, 2016). Upon amino 
acid and growth factors removal, Rag GTPases release mTORC1. mTORC1, then, 
become cytoplasmic and inactive. In those conditions, the negative regulator of 
RHEB, TSC2, is lysosomally localized. Thus, lysosomal proteins change depending 
on the nutrient status of the cells (Demetriades, Doumpas, & Teleman, 2014; Zheng et 
al., 2016). 
In the recent years, lysosomes have also been found to be essential for many 
other cellular processes, such as killing of intracellular pathogens, antigen 
presentation, cell adhesion and migration, tumor invasion and metastasis, and gene 
regulation.  
Additionally, the leakage of lysosomal content into the cytoplasm, known as 
lysosomal membrane permeabilization (LMP), can trigger apoptotic or necrotic 
pathways, depending on the cellular content and the extent of the leakage occurring 
into the cytosol. This phenomenon is called “lysosomal cell death” (Kirkegaard & 
Jaattela, 2009). 
Overall, lysosomes are essential organelles in the cell, not only for their role in 
the degradation and recycling of macromolecules, but also for their roles in membrane 
repair, activation of metabolic pathways and cell death, among other functions. 
Lysosomal defects, for example the lack of a particular enzyme, perturb lysosomal 
homeostasis because excess products destined for breakdown and recycling remain 
stored in the cell. This is the main characteristic of lysosomal storage diseases 
(LSDs), a family of 50 rare inherited metabolic disorders. In addition to primary 
lysosomal dysfunction, cellular pathways associated with other membrane-bound 
organelles are perturbed in these disorders. The majority of LSDs are associated with 
neurological features, including developmental delay, behavioral/psychiatric 
disturbances, seizures, acroparesthesia, motor weakness, cerebrovascular ischemic 
events and extra-pyramidal signs (Pastores & Maegawa, 2013; Platt, Boland, & van 
der Spoel, 2012). 
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4. Autophagy	
 
Autophagy is a catabolic process that is important for eliminating damaged 
components of the cell, providing a quality control of proteins and organelles, as well 
recycling the degraded products into biosynthetic and metabolic pathways. There are 
three types of autophagy in eukaryotic cells, with distinct mechanisms: 
macroautophagy, microautophagy and chaperone-mediated autophagy. 
In this work, we focus on macroautophagy, hereafter referred to as autophagy. 
This process starts with an isolation membrane, known as phagophore, derived from 
endoplasmic reticulum and/or the trans-Golgi and endosomes (Glick, Barth, & 
Macleod, 2010). The phagophore is able to engulf intra-cellular cargo like protein 
aggregates, organelles and ribosomes, and sequesters the material in a double-
membraned autophagosome. Autophagosomes filled with cargo, after some 
maturation steps, fuse with lysosomes. The lysosomal proteases and the acidic 
environment of these organelles are the optimal conditions to degrade the material 
from the autophagosomal cargo. Lysosomes also contain permeases and transporters 
on their membranes to export amino acids and other by-products of degradation to the 
cytoplasm for being re-used to build new macromolecules (Glick et al., 2010) (Figure 
6).  
Autophagy has been described as a survival mechanism that is activated under 
physiological and stress conditions. It is also important during celular development 
and differentiation, and has diverse roles in innate and adaptative immunity (Z. Yang 
& Klionsky, 2009). 
More than 30 proteins are involved in the coordination of the autophagic 
process. Most of them are encoded by genes belonging to the family of Autophagy-
related genes (Atg). The step of autophagosome formation is mediated by two kinase 
complexes. The first one is composed of the class III PI3K Vps34, Atg6/Beclin1, 
Atg14 and Vps15/p150. The other complex is formed by ULK (in yeast Atg1), which 
binds to focal adhesion kinase family interacting protein 200KDa (FIP200), Atg101 
and Atg13 (Zachari & Ganley, 2017).  
The elongation step involves two ubiquitin-like conjugation pathways, both 
activated by Atg7 in an ATP-dependent manner. The first one involves Atg12 and 
Atg5. Both proteins are linked covalently, and their mode of conjugation is similar to 
 29 
that of ubiquination. Another Atg, Atg16L (Atg16 in yeast) binds only to Atg5 and 
not to Atg12, and this conjugate is essential for elongation. These proteins associate 
with the convex surface of the isolation membrane, and dissociate from the membrane 
when autophagosome formation is complete; thus, this complex is not present in the 
mature autophagosome.  The other ubiquitin-like conjugation involves one of the 
ortologues of the yeast Atg8, the microtubule-associated protein light chain 3 (LC3B) 
(other ortologues of yeast the Atg8 in mammals are GATE-16 and GABARAB). The 
mentioned LC3B protein has two isoforms: LC3B-I, the active and cytosolic form, 
and LC3B-II, after a series of ubiquitin-like reactions by Atg4. In fact, the above-
mentioned Atg7 is the one that activates Atg4. LC3B-II is tightly membrane bound 
and is attached to phagophores and autophagosomes. This isoform is the only credible 
marker of the autophagosome in mammal cells, since its amounts reflect the relative 
abundance of autophagosomes (Mizushima, 2007; Rubinsztein, Bento, & Deretic, 
2015). 
In mammalian cells, autophagosome fusion with lysosomes is a complex 
process in which the autophagosome requires a series of maturation steps prior to its 
fusion with the lysosome. Some monomeric GTPases (Rab22, Rab24), mammalian 
orthologs of SNARE protein family members and the NSF protein are needed for the 
correct autophagosome maturation. Autophagosome maturation consists in their 
fusion with endosomes or endosome-derived vesicles. Rab7 is involved in this step. 
For autophagosome maturation and autophagosome-lysosome fusion, cytoskeletal 
elements are also crucial. After their fusion, the degradation of autophagic bodies in 
lysosomes requires a low pH and different proteinases and lipases to digest the 
material and recycle the macromolecules for use in the synthesis of essential 
components during nutrient stress (Y. P. Yang, Liang, Gu, & Qin, 2005).  
Atg proteins as well as the whole process are regulated by nutrients, energy, 
and stress and their corresponding signaling pathways: mTOR, AMPK and HIF. 
Indeed, upon nutrient rich conditions, mTORC1 represses autophagy through 
phosphorylation of ULK1 (Rubinsztein et al., 2015). This phosphorylation results in 
suppression of ULK1 catalytic activity and inhibition of autophagy initiation. In 
addition, upon energy depletion, AMPK is able to modulate this complex: it does not 
only phosphorylate ULK1, activating its kinase activity, but also Atg13, in an 
inhibitory fashion, synergizing with mTORC1 phosphorylation of the complex. 
Therefore, the timing and context of these phosphorylation events are likely to be 
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critical in determining the autophagic output (Zachari & Ganley, 2017). It has been 
proposed that mTORC1 is also able to regulate ULK1 in a more indirect manner by 
phosphorylating other players of the pathway, such as autophagy and beclin 1 
regulator 1 (AMBRA1). This protein is the responsible to take the E3-ligase TNF 
receptor associated factor 6 (TRAF6) to ULK1, thus enhancing ULK1 activity and 
autophagy induction (Zachari & Ganley, 2017) (Figure 6). 
 Other than nutrient deprivation, hypoxia or reactive oxygen species can trigger 
autophagy by different mechanisms to prevent cell death (Fang, Tan, & Zhang, 2015). 
Despite being described as a survival mechanism, autophagy, however, may also 
induce cell death, known as autophagic cell death (ACD) (Kroemer & Levine, 2008; 
Yonekawa & Thorburn, 2013). 
 
 
 
 
 
 
 
Figure  6. Autophagy scheme. Nutrient or energy deprivation trigger autophagy initiation. Autophagy 
consists in the processes of nucleation, elongation and cargo recruitment, completion (autophagosome 
maturation) and autophagosome-lysosome fusion (Rubinsztein et al., 2015).  
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5. Dysregulation of mTOR, lysosomes and autophagy in Cancer	
	
Text adapted from the review of which I am first author, enclosed in Annex. 
Contribution to other articles: “Cancer: linking powerhouses to suicidal bags” 
(Martinez-Carreres et al., 2017) 
	
mTOR promotes protein synthesis, aerobic glycolysis, de novo lipid 
synthesis, de novo nucleotide synthesis, and represses autophagy and lysosomal 
biogenesis. These anabolic processes are critical for tumorigenesis (Populo, Lopes, & 
Soares, 2012). Genes that encode components of the PI3K–AKT–mTOR pathway are 
frequently mutated in cancer, but despite few mutations have been characterized in 
mTOR, many tumor types present mTOR hyperactivation, thus promoting 
tumorigenesis (Alayev & Holz, 2013). In addition, the loss of p53, a very common 
event in cancer, promotes mTORC1 activation (Laplante & Sabatini, 2012). 
Importantly, inflammatory mediators, which are common in tumor angiogenesis, also 
signal to mTORC1 via TSC1/2 (D. F. Lee et al., 2007). Therefore, mTOR inhibition 
has become a great anti-cancer strategy. However, the use of mTOR inhibitors in 
oncology presents some limitations. The fact that the classic mTOR inhibitor, 
rapamycin, inhibits only some of the effects of mTOR, the existence of several 
feedback loops, and the crucial importance of mTOR in normal physiology are some 
examples of the limitations on the use of mTOR inhibitors for cancer treatment (Xie, 
Wang, & Proud, 2016).  
On the other hand, lysosomes also undergo major changes in cancer cells. In 
some cases, lysosomes can become hyperactive to fulfill the needs of tumorigenic 
cells; they can show increased volume and protease activity, together with 
increased lysosomal protease secretion (Hamalisto & Jaattela, 2016). In addition, it 
has been recently found a correlation between lysosomal movement and tumor cell 
invasion, which was induced by tumor microenvironment stimuli (Steffan et al., 
2014). In particular, acidic extracellular pH induced lysosomal movement toward 
the cell peripheries, successively leading to Cathepsin B exocytosis from the 
lysosomes. This eventually promoted protease-dependent tumor invasion (Friedl & 
Wolf, 2003, 2008). The increased secretions of lysosomal proteases render these 
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lysosomes pro-oncogenic, because this results in an increased neoplastic 
progression, via proteolytic pathway initiation (Mohamed & Sloane, 2006). In 
contrast, cathepsins are also depicted as proteases with tumor suppressor abilities 
for their role in inducing cell death through LMP (Jaattela, 2004; Lopez-Otin & 
Matrisian, 2007). Lysosome-associated membrane protein 1 (LAMP-1) has also 
been suggested to have a role in cell–cell adhesion and migration, since it was 
detected on the surface of highly metastatic cancer cells, particularly from colon 
cancer (Furuta et al., 2001). 
Targeting lysosomes for cancer treatment is an emerging strategy (Piao & 
Amaravadi, 2016). The inhibition of these organelles can affect multiple activities 
that are needed for tumor cell survival and growth (nutrient sensing, metabolic 
pathways, degradation, exocytosis, immune responses, etc.) (Towers & Thorburn, 
2017). The strategies currently investigated that target the lysosome in cancer are: 
1) inhibiting autophagolysosome formation with drugs like hydroxychloroquine 
(HCQ) and Lyso 5; 2) inhibiting lysosomal acidification with inhibitors of the 
Vacuolar H+-ATPase (Bafylomicin A1, Archazolid, Cleistanthin A or Manzamine 
A); 3) targeting the acid sphingomyelinase (ASM) with cationic amphiphilic drugs; 
4) inhibiting lysosomal hydrolases with different cathepsin inhibitors; and 5) 
targeting HPS70, a protein which protects lysosomal membrane integrity and 
promotes tumor cell metastasis. Among all this agents, only HCQ has been widely 
tested in many clinical trials in combination with other anticancer therapies (Piao & 
Amaravadi, 2016). In addition, a minimally invasive anticancer modality called 
Photodynamic therapy (PDT) is being used for treating or relieving the symptoms 
of non-small cell lung cancer in patients and esophageal cancer patients. PDT 
combines a drug (a photosensiting agent) with a precise light wavelength, inducing 
ROS generation and killing tumor cells through LMP. However, this technique 
cannot be used for treating large tumors or metastasis (Buytaert, Dewaele, & 
Agostinis, 2007). Moreover, lysosomes are key players in cancer drug resistance. 
They can sequester cancer drugs into their acidic milieu, thus, blunting the drugs’ 
effects (Gotink et al., 2011). This phenomenon is called “lysosomal trapping”. This 
fact further proves that targeting lysosomes may be a promising new therapeutic 
strategy for cancer. 
Lastly, the role of autophagy in cancer is still not clear and context specific. 
Some cancers are dependent on autophagy for survival and other cancers use 
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autophagy as a mechanism of cell death. In some models, autophagy suppresses 
cancer initiation by evading the toxic accumulation of damaged organelles, 
specifically mitochondria. On the short run, this helps in limiting oxidative stress. 
On the long run, it restricts chronic tissue damage and oncogenic signaling. So, in 
this context, autophagy stimulation might help suppress and/or prevent cancer 
initiation. Though, other cancers depend on autophagy for survival. In order to fit 
the high metabolic needs of growth and proliferation, cancers (such as the 
pancreatic) use autophagy-mediated recycling to their own advantage (S. Yang et 
al., 2011). Hence, inhibiting autophagy in this case could be an insight for selective 
cancer therapy, since these tumors are more dependent on autophagy than normal 
tissues (Guo & White, 2016). 
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Chapter 2. Aims of the project 
 
 
In our lab, we are interested in studying the interplay between cell cycle and 
metabolism. The use of CDK4 inhibitors for cancer treatment has unraveled the 
metabolic role of CDK4 in the activation of mTOR pathway, specifically mTORC1, 
through a yet to know mechanism.  
Our main objective is to further study the role of CDK4 in the mTOR 
signaling pathway. Particularly, we focused in a cancer model, since both CDK4 and 
mTOR are crucial for cancer progression.  
Due to the kinase properties of CDK4, we would like to identify novel 
phosphorylation targets of CDK4 in proteins related to mTORC1 pathway. This will 
shed some light on the mechanism by which CDK4 regulates mTORC1.  
 mTORC1 activation is tightly related to lysosomes. Here, we aim to 
investigate whether the effects of CDK4 on mTORC1 are mediated by lysosomal 
changes.  
Our final purpose is to evaluate the impact of our findings on cancer 
treatment. For this purpose, the use of an in vivo murine xenograft model will be 
fundamental.  					
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Chapter 3. CDK4 regulates lysosomal 
function and mTORC1 activation to 
promote cancer cell survival 	 	
This chapter is based on the article “CDK4 regulates lysosomal function and 
mTORC1 activation to promote cancer cell survival” (Martinez-Carreres L et al 
2019), which is under review in Cancer Research (submitted on February 2019).  
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1. Abstract	
	
 CDK4 has been at the centerstage of cancer research for years. However, its 
role on cancer metabolism, especially in the mTOR signaling pathway, is as yet 
undefined. For the first time, in this study we connect CDK4 with lysosomes, the 
emerging metabolic organelles, crucial for mTORC1 activation. On one hand, we 
show that CDK4 phosphorylates the tumor suppressor FLCN, which regulates 
mTORC1 recruitment to the lysosomal surface in response to amino acids. On the 
other hand, we unravel that CDK4 has a direct role in lysosomal function and is 
essential for lysosomal degradation, ultimately regulating mTORC1 activity. We 
show here that chemical inhibition or genetic inactivation of CDK4, other than 
retaining FLCN at the lysosomal surface, lead to the accumulation of undigested 
material inside lysosomes, impairing the autophagic flux and inducing cancer cell 
senescence in vitro and xenograft models. Importantly, the use of CDK4 inhibitors in 
therapy results in cancer cell senescence but not in cell death. To overcome this 
resistance, and based on our findings, we increased the autophagic flux in cancer cells 
by using an AMPK activator in combination with a CDK4 inhibitor. We prove that 
the cotreatment induces autophagy (AMPK), and impairs lysosomal function (CDK4), 
finally resulting in cell death and tumor regression. Altogether we uncovered a 
previously unknown role for CDK4 in lysosomal biology and propose a novel 
therapeutic strategy to kill cancer cells.  
 
 
2. Introduction	
	
 Cyclin-dependent kinase 4 (CDK4) has a well-established major role in cell 
cycle control (Malumbres and Barbacid, 2009) and CDK4-cyclin complexes are 
commonly deregulated in tumorigenesis (Deshpande, Sicinski, & Hinds, 2005). These 
complexes are of great interest as therapeutic targets, especially since the FDA has 
approved the specific CDK4/6 kinase inhibitors PD0332991 (palbociclib), LEE011 
(ribociclib) and LY2835219 (abemaciclib) for treating advanced or metastatic 
hormone receptor (HR)-positive and HER2-negative breast cancer. Clinical studies 
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using CDK4/6 inhibitors to treat other malignancies are being conducted (O'Leary, 
Finn, & Turner, 2016).  
 Research from our group and others has shown that the role of CDK4 is not 
limited to the control of the cell cycle. Indeed CDK4 is also a major regulator of 
energy homeostasis (Aguilar & Fajas, 2010; Y. Lee et al., 2014; Salazar-Roa & 
Malumbres, 2017) through E2F1-RB complex (Blanchet et al., 2011), AMP-activated 
protein kinase (AMPK) (Lopez-Mejia et al., 2017) and insulin receptor substrate 2 
(IRS2) (Lagarrigue et al., 2016). Importantly, the CDK4 pathway has been shown to 
cross-talk with the mechanistic target of Rapamycin (mTOR) pathway, which is a 
major regulator of cell growth and metabolism (Albert & Hall, 2015; Saxton & 
Sabatini, 2017). CDK4/6 inhibition attenuates mTOR Complex 1 (mTORC1) activity 
in some cancer models (Goel et al., 2016; Olmez et al., 2017), yet the effects of 
CDK4/6 inhibitors on mTORC1 seem to be cell-type specific, since opposite results 
were found in pancreatic ductal adenocarcinoma (Franco, Balaji, Freinkman, 
Witkiewicz, & Knudsen, 2016). Given that mTOR activity is amplified in numerous 
cancer types and participates in the translational regulation of several oncogenic 
proteins, mTOR inactivation is an attractive strategy for cancer treatment (Wang & 
Sun, 2009). The exact mechanism underlying the CDK4-mTOR cross-talk in 
mammals is unknown, although in Drosophila it occurs via the phosphorylation of 
TSC2 (Romero-Pozuelo, Demetriades, Schroeder, & Teleman, 2017).  
Lysosomes, considered for years as only the digestive system of the cell, have 
since become key effectors in metabolism, due to their role as platforms in the 
activation of mTOR pathway (Bar-Peled & Sabatini, 2014; Dibble & Cantley, 2015; 
Puertollano, 2014). mTORC1 is recruited to the surface of lysosomes in a complex 
procedure sensitive to amino-acids (Bar-Peled & Sabatini, 2014). Among the multiple 
regulators of this process, we focused on FLCN, a tumor suppressor which functions 
as a complex with its partner FNIP. FLCN-FNIP complex interacts with the Rag 
GTPases in the absence of amino acids repressing their activity, and when amino 
acids are sensed, FLCN-FNIP complex dissociate from Rag GTPases eliciting their 
activation. Rag GTPases activation is crucial for mTORC1 recruitment to lysosomes 
(Petit, Roczniak-Ferguson, & Ferguson, 2013). Importantly, mTORC1 activation is 
also triggered by the accumulation of amino acids in the lysosomal lumen (Zoncu et 
al., 2011). Therefore, alterations in lysosomal function directly impact mTORC1 
activity (Jia et al., 2018; Li et al., 2013). For this reason, and because these organelles 
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also play a role in cell survival and cell proliferation, lysosomes have become 
emerging targets for cancer therapy (Fehrenbacher & Jaattela, 2005; Martinez-
Carreres, Nasrallah, & Fajas, 2017; Piao & Amaravadi, 2016). 
In this study we reveal that CDK4 is capable of modulating mTORC1 activity 
in a direct manner, through the phosphorylation of FLCN, and in an indirect manner, 
by promoting lysosomal function. Indeed, CDK4 chemical inhibition or genetic 
inactivation prevent mTORC1 recruitment to lysosomal surface, not only due to the 
lack of FLCN phosphorylation, but also because of the accumulation of undigested 
material inside the lysosomes. This lack of lysosomal function, in turn, induces 
senescence in triple-negative breast cancer (TNBC) cells, as well as in a mouse 
xenograft model. CDK4 inhibition as single treatment reduces notably tumor size 
since cells enter to senescent programs. Moreover, a combination between AMPK 
activation and CDK4 inhibition was used in an attempt to trigger autophagy in 
conditions when lysosomes are dysfunctional, and results in cell death and tumor 
regression. This finding is of a high relevance in TNBC, a highly invasive and 
aggressive cancer type that does not have a clear therapeutic strategy yet (Elsamany & 
Abdullah, 2014).  
 
 
3. Results	
	
CDK4 activity is required for mTORC1 localization at lysosomes 
It was previously demonstrated that CDK4/6 inhibition results in the 
deregulation of mTORC1 in certain models of human cancer, suggesting a cross-talk 
between the two pathways (Franco et al., 2016; Goel et al., 2016; Olmez et al., 2017). 
To determine the cell-type specificity of this cross-talk, eight human cancer cell lines 
were stimulated with IGF-1 to induce mTORC1 activation in the presence or absence 
of the CDK4/6 inhibitor LY2835219 (abemaciclib). The efficiency of CDK4/6 
inhibition was measured by RB-Ser780 phosphorylation. Treatment with LY2835219 
caused a decrease in p70S6K and 4E-BP1 phosphorylation (two well-known targets 
of mTORC1 used as a readout of its activity), both in the unstimulated and in the IGF-
1 stimulated conditions (Sup. Figure 1A). mTORC1 activity showed the highest 
sensitivity to CDK4/6 inhibition in CCRF-CEM, MDA-MB-231 and HT29 cells, 
whereas IB115, MCF7 and PC3 were the least responsive. It is worth noting that, 
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despite showing considerable mTORC1 inhibition, some cell lines showed only a 
mild decrease in AKT phosphorylation in the presence of LY2835219 (HCT116, 
IB115, MDA-MB-231, SKOV3, PC3), suggesting that the effects observed in 
mTORC1 activity were at least partially independent of decreased AKT signaling. 
We decided to focus our experiments on the triple negative breast cancer 
(TNBC) cell line MDA-MB-231 because it was one of the most responsive to 
CDK4/6 inhibition and due to the lack of a clearly defined treatment strategy for this 
cancer type.  We first investigated whether CDK4 inhibition or depletion affects the 
translocation of mTORC1 to the lysosomal surface, a key step for mTORC1 
activation. We found that MDA-MB-231 wild-type (WT) cells treated with the 
CDK4/6 inhibitor LY2835219 or CDK4 knock-out (KO) MDA-MB-231 cells showed 
impaired translocation of mTORC1 to lysosomes in response to amino acids (Figure 
1A–B) and decreased mTORC1 activity, as measured by the phosphorylation of 4E-
BP1 and p70S6K (Figure 1C-D). Inhibition of glutaminolysis has been shown to 
prevent lysosomal recruitment and subsequent activation of mTORC1 (Duran et al., 
2012). To check whether mTORC1 translocation was affected due to an impairment 
in glutamine metabolism, we treated MDA-MB-231 cells with a cell-permeable α-
ketoglutarate analog. We found that α-ketoglutarate stimulation could not rescue the 
defective translocation of mTORC1 to the lysosomal surface upon CDK4 inhibition 
or depletion (Sup. Fig 2 A-B), indicating that CDK4 inhibition or depletion does not 
affect mTORC1 translocation to the lysosomal surface by impairing glutamine 
metabolism. 
 Interestingly, MDA-MB-231 cells lacking E2F1 showed normal mTORC1 
translocation to the lysosomal surface and increased mTORC1 activation (Sup. Fig 2 
C-D-E–F) but were still sensitive to CDK4 inhibition. This suggests that the effects of 
CDK4 on mTORC1 activity are independent of E2F1 transcriptional activity, pointing 
to other cell cycle-independent targets of CDK4. 
 
CDK4 regulates mTORC1 activity through phosphorylating FLCN 
Given the kinase properties of CDK4, we hypothesize that CDK4 potentially 
regulates mTORC1 pathway through phosphorylation of one of its regulators. To test 
our hypothesis, first, we performed a bioinformatics search of the proteins of 
mTORC1 pathway containing the putative phosphorylation site for CDK4: 
[ST]Px[KRP]. Due to the tight relationship of FLCN with lysosomes and nutrient 
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sensing, we decided to focus on this protein. We performed in vitro kinase assays 
with CDK4/CycD3 recombinant protein and gluthatione S-transferase (GST) fusion 
of full length FLCN. The Mass Spectrometry analysis of post-translational 
modifications revealed that FLCN could be phosphorylated by recombinant 
CDK4/CycD3 at different sites, being S62, S73, T227 and S571 the ones with higher 
score (Figure 2A). Importantly, S62, S73 and S571 phosphorylation sites were found 
when we overexpressed and immunoprecipitated FLCN in MDA-MB-231 cells upon 
amino acid and IGF-1 stimulation (Figure 2B). 
We, then, monitored the localization of overexpressed FLCN by 
immunofluorescence under amino acid depletion or stimulation in wild type MDA-
MB-231 cells untreated or treated with LY2835219, and in CDK4 KO MDA-MB-231 
cells. In the absence of amino acids, FLCN is localized at the surface of lysosomes, 
preventing mTORC1 recruitment to lysosomal surface. When amino acids are sensed, 
FLCN translocates to the cytoplasm, allowing the RagGTPases to recruit mTORC1. 
Importantly, we found that FLCN is retained at the lysosomes in the presence of 
amino acids upon CDK4 inhibition or depletion (Figure 2C). Therefore, our results 
suggests that CDK4 phosphorylations on FLCN are necessary for mTORC1 
activation.   
 
CDK4 inhibition or depletion increases lysosomal mass 
Lysosomal biogenesis is a biological process coordinated by transcription 
factor EB (TFEB), which is repressed by mTORC1. Under nutrient-rich conditions, 
TFEB is phosphorylated by mTORC1, causing its retention in the cytoplasm. By 
contrast, when mTORC1 is inactivated, unphosphorylated TFEB translocates to the 
nucleus and promotes the transcription of genes encoding numerous lysosomal and 
autophagic proteins (Puertollano, 2014). To test whether CDK4 inhibition or 
depletion affected TFEB transcription and the resulting upregulation of lysosomal 
biogenesis genes, we treated WT and CDK4 KO MDA-MB-231 cells with complete 
or serum-starvation media, with or without the CDK4/6 inhibitor LY2835219, and 
studied the expression of TFEB target genes.  As expected, under starvation 
conditions, WT MDA-MB-231 cells showed an increase in the expression of genes 
regulated by TFEB (Figure 3A; cathepsins B and D and SQSTM1). Moreover, we 
found that CDK4/6 inhibition synergized with starvation to further increase the 
expression of those genes. CDK4 KO cells also presented increased expression of 
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those genes under basal conditions, but no further increase was found upon CDK4/6 
inhibition (Figure 3A). 
We next used LysoTracker staining and flow cytometry to look at the 
percentage of lysosome-positive cells upon CDK4 inhibition or depletion. The 
percentage of LysoTracker positive cells and the size of the LysoTracker positive 
particles were consistently and markedly increased in the absence of CDK4 activity 
(Figure 3B-C-D). Similarly, when we quantified the size of lysosomal-associated 
membrane protein 1 (LAMP1)-positive particles, we found a significant increase in 
lysosomal density in CDK4 KO cells compared to WT MDA-MB-231 cells (Figure 
3E-F). These results suggested a new function of CDK4 in the control of lysosomal 
biology.  
 
CDK4 is required for lysosomal function 
It is well known that the inhibition of mTORC1 results in the induction of 
autophagy, a conserved catabolic process that triggers the degradation of intracellular 
constituents and organelles in the lysosome (Kaur & Debnath, 2015). To investigate 
the effects of CDK4 inhibition on autophagy, we treated MDA-MB-231 cells for 24h 
with LY2835219. Also we used the mTOR inhibitor rapamycin and serum-starvation 
(-FBS) media as autophagy inducers. Then, we measured the amounts of the 
autophagosome marker LC3-II and the degradation marker SQSTM1.  As expected, 
serum-starvation conditions, as well as mTOR inhibition by rapamycin, increased the 
amounts of the autophagosome marker LC3-II (Figure 4A-B, long exposure). 
CDK4/6 inhibition also increased LC3-II levels to the same extent (Figure 4A-B). 
Moreover, CDK4 KO cells showed increased levels of LC3-II in basal conditions and 
were more sensitive to starvation-mediated autophagic stimuli (Figure 4A-B). The 
observed increase of LC3-II levels suggested that there is either an increase of 
autophagosome biogenesis or an impairment of the autophagic flux. Indeed, these 
effects could be secondary to mTOR inactivation, since the decreased mTORC1 
activity caused by CDK4 inhibition or depletion shown in Figure 1 could ultimately 
induce lysosomal biogenesis.  
To further study the autophagic flux, we treated cells as described above 
(Figure 4A-B), including the addition of bafilomycin A1 (BafA1), a potent V-ATPase 
inhibitor that blocks autophagosome-lysosome fusion. In WT cells, under starvation 
conditions and in the presence of rapamycin treatment, BafA1 further increased LC3-
 47 
II levels, indicating that rapamycin induces autophagosome biogenesis.  In contrast, in 
CDK4 KO cells or cells treated with CDK4 inhibitor, BafA1 failed to cause any 
additional increase in LC3-II levels (Figure 4A-C). These results suggested that 
CDK4 does not directly participate in autophagosome biogenesis. On the other hand, 
no abnormal SQSTM1 accumulation was observed after CDK4 inhibition or 
depletion, despite observing a consistent SQSTM1 increase with BafA1 (Figure 4A). 
SQSTM1 protein levels are often negatively correlated with autophagic degradation. 
However, it has been already observed that the expression of SQSTM1 does not 
always inversely correlate with autophagic activity, given that they can be restored 
during prolonged starvation (Sahani, Itakura, & Mizushima, 2014). 
Given that CDK4 inhibition or depletion result in an increase in lysosomal and 
autophagosomal markers, we next used transmission electron microscopy (TEM) to 
analyze the ultrastructure of these organelles in WT and CDK4 KO MDA-MB-231 
cells incubated with serum-starvation media to trigger autophagy. As expected, 
serum-starvation medium induced autophagosome and lysosome formation in MDA-
MB-231 WT cells. Interestingly, CDK4 KO MDA-MB-231 cells displayed higher 
densities of autophagosomes and lysosomes than WT cells, in agreement with our 
previous results. Moreover, TEM analysis revealed that the lysosomes in CDK4 KO 
cells were full of electron-dense material, indicating that they accumulated undigested 
material inside the lysosomes under both complete and serum-free conditions (Figure 
5A-B-C-D, Sup. Figure 3A). LY2835219 treated WT cells yielded the same results as 
CDK4 KO cells (Figure 5E-F-G-H, Sup. Figure 3B). To further investigate these 
observations, we measured intracellular lysosomal activity and cathepsin B activity 
and found that both were decreased in CDK4 KO cells (Figure 5I-J).  
Overall, these results suggest that CDK4 is fundamental for the activity of 
lysosomes and that its absence impairs autophagic flux at the lysosomal degradation 
step. 
 
Dysfunctional lysosomes, but not mTORC1 inhibition, induce senescence 
The above results suggest that CDK4 has a direct impact on lysosomal 
function and that CDK4 depletion or inhibition leads to the accumulation of enlarged 
and non-functional lysosomes that impair autophagic flux. Lysosomal processes are 
associated with aging and longevity (Carmona-Gutierrez, Hughes, Madeo, & 
Ruckenstuhl, 2016), and the increase of lysosomal content is characteristic of 
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senescence progression (Cho & Hwang, 2012). This led us to investigate the fate of 
cells lacking CDK4 activity. We therefore measured levels of proliferation, apoptosis 
and senescence in cells after treatment with CDK4/6 inhibitor. Analysis of Ki-67 
levels showed that CDK4/6 inhibition significantly decreased the proliferation rate of 
cells in complete medium (Figure 6A). Yet, when the cells were serum-starved, no 
differences were observed in response to CDK4/6 inhibition (Figure 6A). Apoptosis, 
measured by Annexin V staining, was not significantly induced when cells were 
treated with the CDK4/6 inhibitor in complete medium (Figure 6B). A slight increase 
of apoptosis was seen when CDK4/6 inhibition was combined with serum starvation, 
but the overall percentage of apoptotic cells was relatively low (Figure 6B). 
Interestingly, when WT and CDK4 KO cells were incubated for eight days with 
LY2835219 in complete medium, we observed increased senescence, as measured by 
senescence-associated beta-galactosidase (SA-βGal) staining. Moreover, CDK4 KO 
cells in complete medium showed abundant SA-βGal staining under basal conditions, 
an indication of increased senescence (Figure 6C-D). When the same experiment was 
conducted in serum starvation conditions, senescence was induced in WT cells but 
was not further increased in CDK4 KO cells. To test whether these effects were 
dependent on mTORC1, we also treated cells with rapamycin. Levels of SA-βGal 
staining in the rapamycin treated cells were similar to those of untreated cells, 
indicating that the induction of senescence in the absence of CDK4 was not due to 
mTORC1 inhibition (Figure 6C-E).  
 To further characterize the senescent phenotype in cells lacking CDK4 
activity, we additionally measured the expression of senescence markers in MDA-
MB-231 WT cells cultured in complete medium after an eight-days treatment with 
DMSO, LY2835219 or rapamycin (Figure 6F). Consistently with the SA-βGal data, 
LY2835219 treatment induced the expression of most of the senescence-related genes 
evaluated (Figure 6F). Some of the genes that did not respond to CDK4/6 inhibition 
are p53-regulated genes, reinforcing the idea of a cell cycle-independent induction of 
senescence. It is worth noting that MDA-MB-231 cells lack CDKN2A, a p53 target 
gene that is known to promote cellular senescence. Additionally, similar to SA-βGal 
data in Figure 6C-E, mTOR inhibition by rapamycin failed to induce the expression 
of genes related to senescence. Only RKHD3 and IGFBP5 were induced by 
rapamycin, but always to a minor extent than with LY2835219 treatment (Figure 6F). 
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Our results suggest that the lysosomal dysfunction induced by CDK4 
inhibition or depletion is the cause of the senescent phenotype in these cells, and that 
mTORC1 inhibition is a secondary effect of the impairment of lysosomal function. In 
fact, SA-βGal derives from a lysosomal enzyme, and the increase of this parameter in 
senescent cells is likely due to an expansion of the lysosomal compartment (reviewed 
in Kuilman et al 2010).  
 
The CDK4 inhibitor LY2835219 alters lysosomal function, attenuates 
mTORC1 activity, and decreases tumor growth in a breast cancer xenograft 
mouse model 
To investigate the effects of CDK4/6 inhibition on lysosomal function in vivo, 
we used a breast cancer xenograft model created by injecting MDA-MB-231 cells 
into the mammary glands of NSG mice. Intratumoral inhibition of RB 
phosphorylation in mice treated eight days with LY2835219 compared with vehicle 
confirmed that CDK4/6 was effectively inhibited in the tumor (Figure 7A-B). 
Consistent with the previously observed anticancer activity of CDK4 inhibition 
(Hamilton & Infante, 2016), we observed that the tumors from LY2835219-treated 
group halted their growth (Figure 7C) and reduced cell proliferation (Figure 7D-E) 
whereas the untreated ones continued growing and highly proliferating. Of note, the 
observed effects of CDK4/6 inhibition in tumor size are independent of the immune 
system in our model because NSG mice are immunodeficient. This was confirmed by 
the lack of immune cell infiltration in the H-E staining of the tumors in any of the 
groups (Sup. Figure 4A).   
Consistent with our in vitro data, xenograft tumors treated with LY2835219 
had increased expression levels of the lysosomal marker LAMP1 (Figure 7F-G) and 
increased expression levels of TFEB target genes (Sup. Figure 4B). In addition, 
LY2835219 treatment also decreased the activity of mTORC1, assessed by the 
phosphorylation of p70S6K Thr389 (Figure 7H-I). Ultrastructural analysis by TEM 
confirmed that tumors from LY2835219 treated mice had higher densities of 
autophagosomes and lysosomes, and that those lysosomes accumulated non-digested 
material (Figure 7J-K-L-M, Sup. Figure 4C). Furthermore, we show that the tumors 
of mice treated with LY2835219, which harbored non-functional lysosomes, had 
increased SA-βGal staining (Figure 7N) and increased expression of senescence 
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markers (Sup. Figure 4D), revealing that the tumor cells had become senescent, in 
agreement with our in vitro data. Together, these results further demonstrate that 
CDK4 plays an essential role in the regulation of lysosomal function in vivo, and that 
this alteration in lysosomal function leads to tumor cell senescence in a mouse model 
of breast cancer.   
 
The CDK4 inhibitor LY2835219 in combination with the AMPK activator 
A769662 induces cell death in breast cancer cells and tumors.  
Given that lysosomes are essential for autophagy, we set to determine the 
consequences of the activation of autophagy in conditions when lysosomes were 
dysfunctional. Thus, we tested the combination of LY2835219, to impair lysosomal 
function, with the AMPK activator A769662, to induce autophagy. Breast cancer 
xenografts of NSG mice co-treated for eight days with A769662 and LY2835219 
showed smaller tumor size than the ones treated only with LY2835219, whereas 
tumors from mice treated only with A769662 were similar in size than the untreated 
ones (DMSO group) (Figure 8A-B). Strikingly, the combination treatment resulted in 
tumor regression; almost 50% of the tumors decreased their size upon the co-
treatment using both A769662 and LY2835219. In contrast, no reduction in tumor 
size was observed when individual drugs were used (Figure 8C-D). Cell proliferation 
in tumors, assessed by Ki67 staining, significantly decreased with LY2835219 
treatment. However, comparing this group with de co-treated group, there was only a 
light tendency for the percentage of Ki67 positive cells to further decrease in the co-
treated group (Figure 8E-F).  Moreover, cleaved-Caspase-3 staining revealed a 
significant induction of intratumoral cell death when mice were co-treated with 
A769662 and LY2835219, which was at least six-fold higher than the apoptosis rate 
in mice treated with LY2835219 as a single agent (Figure 8E-G). This result 
suggested that increased apoptosis was underlying the decrease in tumor size in the 
co-treatment group. 
In vitro studies with MDA-MB-231 cell line in culture were consistent with 
the in vivo data; CDK4 inhibition and AMPK activation as single treatments failed to 
induce cell death after one week treatment as shown by the low levels of Annexin V-
positive cells (Sup. Figure 5A). Only the combination of LY2835219 with A769662 
increased notably the percentage of Annexin V-positive cells (Sup. Figure 5A).  
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As previously reported, CDK4 inhibition resulted in the intratumoral decrease 
of RB phosphorylation, but no differences were observed between LY2835219 and 
the co-treated tumors (Figure 8H-I).  As for mTORC1 activity, LY2835219 treatment 
as well as AMPK activation decreased p70S6K phosphorylation (Figure 8H-J). 
However, mTORC1 inactivation by A769662 treatment was not sufficient to decrease 
tumor size in our model. Importantly, and consistent with other studies (Lopez-Mejia 
et al., 2017), CDK4 inhibition was able to trigger AMPK activation, as observed with 
the increased phosphorylation of Acetyl-CoA Carboxylase (ACC), a known target of 
AMPK (Figure 8H-K).  
TEM analysis of the tumors revealed that the percentage of the 
autophagosome and lysosome area per cell was increased in the single treatments, as 
well as in the A769662 and LY2835219 co-treated group (Sup. Figure 5B-C-D). 
When we quantified the percentage of autolysosomes with digested material, we 
found that the mice co-treated with both A769662 and LY2835219 still display a 
significant decrease in this parameter, despite LY2835219 as a single treatment 
showed a greater decrease (Sup. Figure 5B-E). The underlying mechanism of this 
apparent paradox could be that A769662 induced cell death only in cells in which 
LY2835219 treatment impaired lysosomal function. Indeed, some of the co-treated 
cells displayed mixed morphological features of apoptotic cell death (highly 
condensed chromatin, shrinkage of the cytoplasm) and autophagic cell death 
(numerous autophagosomes and autolysosomes, focal swelling of the perinuclear 
membrane (Sup. Figure 5B (indicated by *)).  
Taken together, these results showed that the combination treatment using 
A769662 and LY2835219 provided a better outcome than LY2835219 alone, 
inducing cell death and tumor regression in the MDA-MB-231 breast cancer 
xenograft model.   
 
 
4. Discussion		
We show here for the first time that CDK4 regulates lysosomal function and 
mTORC1 activity in cancer cells. We demonstrate that CDK4, through 
phosphorylation of FLCN in specific residues, facilitates the migration of mTOR to 
the lysosomes in order to be activated. The abrogation of mTOR activation by 
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depletion or chemical inhibition of CDK4 consequently resulted in a substantial 
increase in the numbers of lysosomes and autophagosomes. This proves that CDK4 is 
necessary for the dissociation of FLCN from the lysosomes, and for the subsequent 
recruitment and activation of mTORC1. 
 However, this increase was not correlated with greater lysosomal activity, 
which suggested that CDK4 has an mTOR-independent role in this process. 
Importantly, we prove that CDK4 inhibition or depletion leads to the accumulation of 
intra-lysosomal undigested material, which, through recycling of amino acids, might 
serve as a signal to mTORC1. mTORC1 activation is initiated at the lysosome and 
requires the presence of amino acids, products of macromolecule degradation, in the 
cytosol, but also in the lysosomal lumen (Zoncu et al., 2011). We show now that an 
additional mechanism by which CDK4 favors mTORC1 activation by promoting the 
digestion of proteins in the lysosome, in turn providing metabolic intermediates that 
sustain cell growth and survival via downstream effectors. This pathway would be 
particularly crucial during prolonged starvation conditions, such as the typical 
environment of some tumors.  
 Cells initially respond to nutrient deprivation by inactivating their energy-
consuming processes, such as protein or lipid biosynthesis, and by activating 
catabolism. At the same time, other mechanisms are activated to recycle molecules to 
provide the cell with enough substrates and metabolic intermediates to survive – an 
important function of autophagy. In the long term, autophagy reactivates the 
mTORC1 pathway by replenishing the lysosomes with digested proteins and amino 
acids (Tan, Sim, & Long, 2017). CDK4 inhibition or depletion could therefore mimic 
a starvation signal. This hypothesis is in agreement with previous studies showing that 
CDK4/6 inhibitors induce autophagy (Bourdeau & Ferbeyre, 2016; Iriyama et al., 
2018). We also observed an increase in the number of autophagosomes upon CDK4 
inhibition in this study. However, when analyzing the ultimate fate of the 
autophagosomes, we found that they accumulate due to the impairment of lysosomal 
degradation upon CDK4 inhibition or depletion. Indeed, others have demonstrated 
that the inhibition of lysosomal activity causes decreased fusion with autophagosomes 
and vice-versa (Renna et al., 2011; Seranova et al., 2017; Settembre & Ballabio, 
2014). In this study, we showed that inhibiting or depleting CDK4, in addition to 
inducing autophagy, likely through mTORC1 inactivation, impairs the autophagic 
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flux at the lysosomal degradation step. This observation may explain the increased 
susceptibility of CDK4 KO cells to autophagic stimuli.  
 We also found that CDK4 inhibition or depletion increased the expression of 
many lysosomal genes. It is well known that mTORC1 negatively regulates lysosomal 
biogenesis (Zhou et al., 2013). This could be secondary to mTORC1 inhibition, or due 
to a compensatory mechanism to create new lysosomes as the existing ones are 
dysfunctional and ensure their function.   
CDK4/6 inhibitors have been shown to accumulate into lysosomes, a 
phenomenon called lysosomal trapping (Llanos et al., 2019). However, the use of 
CDK4 KO cells in our work demonstrates that CDK4 rather stimulates lysosomal 
function, and that the lysosomal trapping of the drug is secondary to the lysosomal 
impairment induced by CDK4 inhibition. In addition, CDK4/6 inhibition has been 
found to result in proteasomal activation (Miettinen et al., 2018). Moreover, a 
negative-feedback exist between proteasomal activity and autophagic flux (J. H. Lee, 
Park, Kim, & Lee, 2019). Thus, the impairment of autophagic flux at the lysosomal 
degradation step can result in proteasomal activation and viceversa. 
Despite the known requirement for lysosomes in cell cycle progression (Hubbi 
et al., 2014; Jin & Weisman, 2015), little is known about the relationship between 
lysosomes and senescence. Importantly, in eukaryotes, autophagy impairment via 
lysosomal dysfunction has been described to be an important characteristic of 
oxidative stress-induced senescence (Tai et al., 2017). Our findings suggest that the 
ultimate fate of cells that lack CDK4 is the activation of senescence due to lysosomal 
dysfunction. The absence of senescence when cells are treated with rapamycin further 
demonstrates that mTORC1 inactivation is a consequence of lysosomal impairment 
due to CDK4 inhibition or depletion. However, the CDK4 inhibitor induced 
lysosomal dysfunction, was not sufficient to induce cell death in the tumors of the 
treated mice. Instead, cancer cells were arrested, but were still alive, which explained 
that the tumor burden was not decreased, but only stabilized (Figure 7). We reasoned 
that further forcing the autophagic flux would create an additional stress that could 
kill these tumor cells. With this aim, we used the AMPK activator A769662, which is 
known to increase autophagy, in combination with the CDK4 inhibitor. Indeed, co-
treatment of the cells resulted in increased cancer cell death and therefore tumor 
regression (Figure 8). This is a major finding that represents a paradigm switch 
regarding the use of CDK4 inhibitors for the treatment of cancer. Strikingly, and 
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consistent with our findings, CDK4 inhibitors are not efficient as a single drug in the 
clinical practice and are often used in combination with other drugs (Klein, 
Kovatcheva, Davis, Tap, & Koff, 2018b; Ku et al., 2016; Michaloglou et al., 2018). 
We show here that the effects of CDK4 in MDA-MB-231 cells are 
independent of E2F1, the transcription factor modulated by CDK4 during the cell 
cycle. It has been reported, however, that E2F1 regulates lysosomal positioning and 
activates mTORC1 by promoting its recruitment to the lysosomal surface (Meo-Evoli 
et al., 2015; Real, Meo-Evoli, Espada, & Tauler, 2011). This suggests a dual and 
complementary role for CDK4 in the regulation of the mTORC1 pathway: first, 
through regulation of the lysosomal function; and second, through FLCN 
phosphorylation .   
It was previously described that CDK4/6 inhibitors display anti-tumor activity 
only in RB-positive cells (Polk, Kolmos, Kumler, & Nielsen, 2016). In addition, it 
was unclear whether CDK4/6 inhibition had an effect on TNBCs. Our findings are 
consistent with other studies showing that CDK4/6 inhibitors still have some effects 
on RB-negative cells (Rivadeneira et al., 2010), and that CDK4/6 inhibitors do have 
anti-tumor effects in TNBCs. Indeed, depending on the cell type, CDK4/6 inhibition 
triggers either a quiescence or senescence response, not necessarily via the canonical 
RB-E2F pathway (reviewed in (Klein, Kovatcheva, Davis, Tap, & Koff, 2018a); 
(Brown et al., 2012)). 
Overall, the present study demonstrates a new role for CDK4 in the regulation 
of lysosomal function, which ultimately leads to senescence in cancer cells and 
mTORC1 inactivation. , In addition, we highlight the importance of lysosomes in 
cancer and we propose that CDK4/6 inhibitors could be used in combination with 
other drugs to target lysosomal function as a novel anticancer strategy.  
 
 
5. Materials	and	Methods	
	
Materials 
LY2835219 (abemaciclib), a specific CDK4/6 inhibitor, was purchased from 
MedChem Express and used at a concentration of 0.5 µM for cancer cell lines. R3 
human IGF-1 (I11146, Sigma) was used at a concentration of 30 ng/ml. Minimal 
Essential Media (MEM) Amino Acids Solution (50X, ThermoFisher) was used at the 
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indicated concentrations. Rapamycin was kindly provided by Professor Pedro Romero 
(Université de Lausanne, Switzerland) and was used at the indicated concentrations. 
Bafilomycin A1 (BafA1) was purchased from Enzo Life Sciences (ALX-380-030-
M001) and used at a concentration of 0.3 µM. 
 
Cell culture and transfection 
The cancer cell lines MDA-MB-231, CCRF-CEM, HTC116, IB115, HT29, 
SKOV, MCF7 and PC3 were cultured in RPMI 1640 (1×) + GlutaMAX media (Life 
Technologies, USA) containing 10% fetal bovine serum (FBS) (PAA Laboratories), 
1% HEPES (Life Technologies) and 1% sodium pyruvate (Sigma).  
MDA-MB-231 CDK4 knockout (KO) and E2F1 KO stable cell lines were 
generated with CRISPR/cas9 technology. The lentiCRISPR v2 plasmid was a gift 
from Feng Zhang (Cambridge University, Cambridge, England; Addgene plasmid # 
52961); a description of this plasmid can be found in Shalem et al. 2014 (Shalem et 
al., 2014). The pMD2.G and psPAX2 plasmids were gifts from Didier Trono 
(Université de Lausanne; Addgene plasmids # 12259 and # 12260, respectively). The 
target sequences for the guide RNA were as follows: 
 
Table S1. Oligonucleotides used as guide RNA in CRISPR/cas9 technology for the 
generation of KO stable cell lines. 
CDK4 
5’-CACCGCTTGCCAGCCGAAACGATCA-3’ 
5’-AAACTGATCGTTTCGGCTGGCAAGC-3’ 
E2F1 
5’-CACCGTCTGACCACCAAGCGCTTCC-3’ 
5’-AACGGAAGCGCTTGGTGGTCAGAC-3’ 
 
The oligonucleotides were synthesized and cloned into the digested 
LentiCrispR vector as described by Shalem et al., 2014. Lentiviral production was 
based on the standard protocol established by Salmon and Trono, 2006 (Salmon & 
Trono, 2006). The resulting lentivirus (2ml) was then used to infect MDA-MB-231 
cells for 72 hours. Infected cells were treated with 5 µg/ml puromycin for five 
consecutive days. Western blotting was performed to ensure that the protein of 
interest was not expressed. 
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For pRK5-FLAG-FLCN (Addgene #72290) transfection, cells were grown in 
10cm diameter dishes. 10µg of plasmid were transfected with X-treme gene HP in a 
ratio 1:2 (µg DNA: µl reagent) in Optimem media. The following day the media was 
changed to the normal growing media, and cells were grown for 48h.  
 
Cell treatments 
For insulin pathway stimulation, the different tumor cell lines were first 
treated with a CDK4/6 inhibitor (or the same volume of DMSO as a control) diluted 
in FBS-free media for 15 h. The cells were subsequently treated with IGF-1 for 20 
min before lysis or fixation. 
For amino acid stimulation, after a 15 h treatment with FBS-free media with or 
without the CDK4/6 inhibitor, the cells were incubated for two hours in KRBB media 
containing 111 mM NaCl, 25 mM NaHCO3, 5 mM KCl, 2.5 mM CaCl2, 1 mM 
MgCl2, 25 mM HEPES, 25 mM glucose and dialyzed FBS with or without the 
CDK4/6 inhibitor. For the last 20 min, 2× MEM amino acids solution and 2 mM 
glutamine were added to the cells. 
 
Western blotting  
Cell lysates were obtained with M-PER mammalian extraction buffer (Thermo 
Scientific) containing 1:100 Halt phosphatase inhibitor cocktail (Thermo Scientific) 
and 1:100 Halt EDTA-free protease inhibitor cocktail (Thermo Scientific). Lysate 
proteins were separated by SDS-PAGE and transferred onto nitrocellulose 
membranes. The membranes were incubated overnight at 4°C with the corresponding 
primary antibodies and then incubated with the corresponding secondary antibodies 
and developed with ECL. The band intensities on the developed films, fusion FX 
images and ChemiDoc images were quantified using the Fiji image-processing 
package (Schindelin et al., 2012). The following antibodies were used for Western 
blot analysis: anti-CDK4 (clone H22), anti-CDK6 (clone C21) and anti-RB (C15) 
from Santa Cruz Biotechnology; anti-phospho Rb-S780 (clone D59B7), anti-phospho 
P70S6K-T389 (clone 108D2), anti-4E-BP1 (clone 53H11), anti-phospho AKT-T308 
(clone 244F9), anti-phospho AKT- S472/3 (clone D9E), anti-p70S6 kinase (49D7), 
anti-LC3B (polyclonal), anti-SQSTM1 (polyclonal), anti AcetylCoA Carboxylase (p-
ACC) (polyclonal) and anti phospho AcetylCoA Carboxylase (p-ACC) from Cell 
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Signaling Technology; and anti-alpha-tubulin (clone DM1A) from Sigma-Aldrich. 
The bands were quantified with FIJI software (Schindelin et al., 2012).  
 
Immunofluorescence 
For in vitro immunofluorescence, cells were grown on glass coverslips. After 
the different treatments or stimulation, the slides were rinsed with PBS once and fixed 
for 15 min with 4% paraformaldehyde in PBS at room temperature (RT). The slides 
were rinsed twice with PBS, permeabilized with 0.01% saponin for 10 min and 
blocked with PBS containing 2% BSA and 0.05% Tween 20 for 30-60 min, then, 
incubated with the primary antibodies for 2-3 h at RT. After 3 washes with PBS, they 
were incubated with 1:1000 anti-mouse Alexa 488 and anti-rabbit Alexa 561 
secondary antibodies for 45 min. Finally, they were washed twice with PBS for 10 
minutes, and the nuclei were stained with Hoechst (1:10000 in PBS). The coverslips 
were mounted with Fluoromont mounting media on the glass slides. Images were 
obtained with a Zeiss LSM710 inverted confocal microscope with a 63× objective. 
The following antibodies were used for immunofluorescence experiments: anti-
mTOR (7C10), anti-FLCN (clone D14G9) and anti-Lamp1 (clone D401S) from Cell 
Signaling Technology (USA) and anti-CDK4 (clone EPR4513) from Abcam. Images 
were processed with Fiji software (Schindelin et al., 2012). Colocalization was 
analyzed with JACoP (Just Another Colocalization Plugin) for ImageJ, and the 
volume of LAMP1 positive particles was analyzed with Imaris 9.0.0.  
 For fluorescence immunohistochemistry in tissue sections, mouse xenograft 
tumors were dissected, fixed in 4% paraformaldehyde and embedded in paraffin. 
Next, 4-µm sections were deparaffined with xylene and rehydrated in a graded 
ethanol series. Antigen retrieval was performed by heating the sections in the 
microwave at 750 W for 10 minutes in citrate buffer (0.01 M, pH 6). After cooling, 
the sections were washed with PBS, and blocked for 1 hour with NGS 2.5%. Primary 
anti-LAMP1, Ki67 and Cleaved-Caspase-3 antibodies were incubated overnight at 
4°C. The following day, the sections were incubated with the corresponding Alexa 
488 or 568 secondary antibody and counterstained with DAPI. The sections were 
mounted and observed with a 20X objective and a fluorescence microscope. Images 
were processed and analyzed with Fiji software (Schindelin et al., 2012). 
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Immunoprecipitation 
48 h after pRK5-FLAG-FLCN transfection, cells were lysated as described 
above with M-PER buffer.  With 1 mg of total protein, FLAG was over night 
immunoprecipitated using FLAG-M2 affinity gel. After some washes with buffer, the 
samples were analyzed by western blotting.  
 
GST production 
pDON-FLCN and pDON-RB were cloned in pDEST pGEX-2T and expressed 
in BL21 bacteria. The GST-purified proteins were resuspended in 50mM Tris.HCl 
(pH 8), 100 mM NaCl, 5 mM DTT and 20% glycerol buffer. 
 
In vitro kinase assay 
Kinase assays were performed using GST-FLCN and recombinant RB protein 
(Santa Cruz) as a substrate in kinase buffer (25 mM Tris.HCl (pH 7.5), 150 mM 
NaCl, 10 mM MgCl2, 1 mM DTT, 5 mM Na4P2O7, 50 mM NaF, 
1 mM vanadate and protease inhibitor cocktail) with 40 µM ATP  (PAMGENE ATP- 
Perkin Elmer) for 30 min at 30°C.  Recombinant CDK4/cyclin D3 kinase (ProQinase) 
were used. RB was used as positive control. Boiling the samples for 5 min in the 
presence of denaturing sample buffer stopped the reaction. As an experimental 
control, westernblot with RB samples was done with phospho-RB antibody. FLCN 
samples were analyzed by mass spectrometry.  
 
Mass spectrometry  
Protein samples were loaded on a 10% mini polyacrylamide gel, and after 
Coomassie staining visible band between 75 and 100 kDa corresponding to FLCN-
GST or FLCN-FLAG construct was excised and digested with sequencing-grade 
trypsin (Promega) as described (Shevchenko, Tomas, Havlis, Olsen, & Mann, 2006). 
Extracted tryptic peptides were dried and resuspended in 0.05% trifluoroacetic acid, 
2% (v/v) acetonitrile, for mass spectrometry analyses. 
Tryptic peptide mixtures were injected on an Ultimate RSLC 3000 nanoHPLC system 
(Dionex, Sunnyvale, CA, USA) interfaced to an Orbitrap Fusion Tribrid or to a 
QExactive Plus high resolution mass spectrometer (Thermo Scientific, Bremen, 
Germany). Peptides were loaded onto a trapping microcolumn Acclaim PepMap100 
C18 (20 mm x 100 µm ID, 5 µm, 100Å, Thermo Scientific) before separation on a 
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reversed-phase analytical nanocolumn at a flowrate of 0.25 µl/min, using a gradient 
from 4 to 76% acetonitrile in 0.1% formic acid (total time: 140min). A custom packed 
nanocolumn was used with Fusion MS instrument (75 µm ID × 40 cm, 1.8 µm 
particles, Reprosil Pur, Dr. Maisch), and an Easy-Spray PepMap C18 column was 
used with QExactive MS (50 cm x 75 µm ID, 2 µm, 100Å, Thermo Scientific). In 
Fusion instrument, full survey scans were performed at a 120’000 resolution, and a 
top speed precursor selection strategy was applied to maximize acquisition of peptide 
tandem MS spectra with a maximum cycle time of 3s. HCD fragmentation mode was 
used at a normalized collision energy of 32%, with a precursor isolation window of 
1.6 m/z, and MS/MS spectra were acquired at a 15’000 resolution. Peptides selected 
for MS/MS were excluded from further fragmentation during 60s. In QExactive 
instrument, full MS survey scans were performed at 70’000 resolution, and the 10 
most intense multiple-charge precursor ions detected in the full MS survey scan were 
selected for higher energy collision-induced dissociation (HCD, normalized collision 
energy NCE=27 %) and analysis in the orbitrap at 17’500 resolution. The window for 
precursor isolation was of 1.5 m/z units around the precursor and selected fragments 
were excluded for 60s from further analysis. 
MS data were analyzed using Mascot 2.6 (Matrix Science, London, UK) set up 
to search the SwissProt database (www.uniprot.org) restricted to Homo sapiens 
taxonomy (December 2017 version, 20’245 sequences) and including common 
contaminants (keratins, digestion enzymes, etc.). Trypsin (cleavage at K,R) was used 
as the enzyme definition, allowing 3 missed cleavages. Mascot was searched with a 
parent ion tolerance of 10 ppm and a fragment ion mass tolerance of 0.02 Da. 
Iodoacetamide derivative of cysteine was specified in Mascot as a fixed modification. 
N-terminal acetylation of protein, oxidation of methionine, and phosphorylation of 
serine, threonine or tyrosine were specified as variable modifications. 
Scaffold software (version 4.8.4, Proteome Software Inc., Portland, OR) was 
used to validate MS/MS based peptide and protein identifications, and to perform 
dataset alignment. Peptide identifications were accepted if they could be established 
at greater than 90.0% probability by the Scaffold Local FDR algorithm. Protein 
identifications were accepted if they could be established at greater than 95.0% 
probability and contained at least 5 identified peptides. Protein probabilities were 
assigned by the Protein Prophet algorithm (Nesvizhskii, Keller, Kolker, & Aebersold, 
2003). Proteins that contained similar peptides and could not be differentiated based 
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on MS/MS analysis alone were grouped to satisfy the principles of parsimony. 
Proteins sharing significant peptide evidence were grouped into clusters. 
MsViz software (Martin-Campos et al., 2017) was used for comparison of sequence 
coverage and phosphorylation of FLCN protein in the different treatments. 
 
Flow cytometry 
To study cell death and proliferation following treatment with CDK4 
inhibitors, the amounts of Annexin V-PE and Ki67 expression were measured by flow 
cytometry. Cultured cells were trypsinized and stained with Annexin V-PE 
(BioLegend, 640907) according to the manufacturer’s protocol, and the cells were 
analyzed on either a Gallios™ (Beckman Coulter) or LSR II flow cytometer (BD 
Biosciences). For intracellular Ki67 staining, cells were fixed and permeabilized 
(Biolegend) according to the manufacturer’s protocol. Cells were then incubated with 
a permeabilization buffer that detects anti-Ki67-FITC (Biolegend) for 30 min on ice. 
After washing twice with permeabilization buffer, the cells were resuspended in PBS 
prior to analysis. For each sample, at least 10000 events were acquired. Flow 
cytometry analysis was performed with FlowJo software (Version 7.6.5, Treestar). 
 For the LysoTracker experiments, fluorescence was analyzed with an 
ImageStreem III Flow Cytometer. After treating the cells with the CDK4 inhibitor 
and/or IGF1, 100 nM Lysotracker Green DND-26 (Life Technologies) was added to 
live cells 1 h before fixation. The cells were then trypsinized and fixed in suspension 
with 4% PFA for 15 min at RT and washed twice with PBS. Nuclear staining was 
performed with DAPI, and the cells were resuspended in PBS with 2% FBS. For each 
sample, 10000 events were acquired at a magnification power equivalent to 60X. 
Flow cytometry was also used to analyze the intracellular lysosomal activity 
with a lysosomal intracellular activity assay kit (Cell-Based) (Biovision) according to 
the manufacturer’s instructions. Briefly, a self-quenched substrate was added to the 
cultured cells with freshly prepared media containing 0.5% FBS, incubated for one 
hour at 37°C with 5% CO2 and trypsinized; 1000 events were acquired with an 
ACCURI C6 flow cytometer. All flow cytometry analyses were performed with 
FlowJo software (Version 7.6.5, Treestar). 
 
Quantitative Real-Time PCR Analysis. 
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Total RNA was prepared using Trizol reagent (Sigma) and then reverse 
transcribed using Super Script II (Invitrogen). qPCR analysis was performed using 
SYBR green (Roche Diagnostics) and a 7900HT Fast Real-Time PCR System 
(Applied Biosystems). Relative mRNA expression levels were calculated from the 
comparative threshold cycle (Ct) values of the gene of interest relative to RS9 and 
TBP mRNA. Specific primer sequences are listed in Table S1, S2 and S3. 
 
Table S2. Primers used for qPCR Analysis of Transcription Factor EB (TFEB) 
regulated genes (human). 
Gene Forward Reverse 
ATP6V0E1 CATTGTGATGAGCGTGTTCTGG AACTCCCCGGTTAGGACCCTTA 
ATP6V1H GGAAGTGTCAGATGATCCCCA CCGTTTGCCTCGTGGATAAT 
CTSA CAGGCTTTGGTCTTCTCTCCA TCACGCATTCCAGGTCTTTG 
CTSB AGTGGAGAATGGCACACCCTA AAGAAGCCATTGTCACCCCA 
CTSD GCTGATTCAGGGCGAGTACATGAT TGCGACACCTTGAGCGTGTA 
CTSF ACAGAGGAGGAGTTCCGCACTA GCTTGCTTCATCTTGTTGCCA 
CTSL1 CACCGGCTTTGTGGACATC ATGACCTGCATCAATAGCAACA 
CTSO TAGATGCAGTGAGCTGGCAA AACGGAATCTGCAATACCACA 
LAMP1 ACGTTACAGCGTCCAGCTCAT TCTTTGGAGCTCGCATTGG 
SQSTM1 CACCTGTCTGAGGGCTTCTC CACACTCTCCCCAACGTTCT 
TFEB CCAGAAGCGAGAGCTCACAGAT TGTGATTGTCTTTCTTCTGCCG 
 
Table S3. Primers used for qPCR Analysis of Senescence genes (human). 
Gene Forward Reverse 
CDKN1A GACACCACTGGAGGGTGACT CAGGTCCACATGGTCTTCCT 
CDKN2A CCAACGCACCGAATAGTTACG GCGCTGCCCATCATCATG 
COL1A1 GGAGGAATTTCCGTGCCTGG CAATCCTCGAGCACCCTGAG 
CXCL14 GGACCCAAGATCCGCTACAG CTTCGTAGACCCTGCGCTTC 
MFAP2 AGCAGTGAACGGAGTCACAAA GCCGAGGAGTCACCTCTTGA 
MMP2 TGATGTCCAGCGAGTGGATG AAGAAGTAGCTGTGACCGCC 
P311 GGGGCTTTTGTCTGTTGGTC GAAGCCTTCCCTCCATGTCC 
RKHD3 GGGCGGCAAGGTTGTAAAAT TGTTCTTATTCCGGGAGGCG 
IGFBP5 GAAAGCAGTGCAAACCTTCCC AGGTGTGGCACTGAAAGTCC 
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RBL2 CGGGATCTCTGTGCCAAACT ACTTCTATACACCTGGCTCCG 
 
Table S4. Primers used for qPCR Analysis of housekeeping genes (human). 
Gene Forward Reverse 
RS9 CACACTCTCCCCAACGTTCT 
ACCACCTGCTTGCGGACCCTGA
TA 
TBP TGCACAGGAGCCAAGAGTGAA CACATCACAGCTCCCCACCA 
 
 
Cathepsin B activity assay kit (fluorometric) 
Cathepsin B activity was assessed with a fluorometric kit (ab65300, Abcam). 
Cell lysates that contain cathepsin B cleave the synthetic substrate RR-AFC to release 
free AFC, which emits fluorescence that can be measured. Cells were lysed with 
chilled cell lysis buffer provided in the kit; the lysates were then incubated on ice for 
10-30 minutes and centrifuged for 5 minutes at 4°C. The supernatants were saved, 
and the protein concentrations were measured. In a 96-well plate, 200 µg of protein 
was loaded per well, and 50 µl of cathepsin B reaction buffer and 2 µl of 10 mM 
cathepsin B substrate Ac-RR-AFC (200 µM final concentration) were added. The 
plates were incubated at 37°C for 1 hour in the dark, and the fluorescence was 
measured with a Tecan plate reader (Ex/Em = 400/505 nm). 
 
Colorimetric detection of senescence-associated β  galactosidase  
Senescence-associated β-galactosidase (SA-β-Gal) analysis was performed in 
cultured cells and mouse xenograft tumors. 
Cells in culture were fixed with 2% PFA and 0.2% glutaraldehyde for five 
minutes at RT, washed with PBS and stained with a solution containing 40 mM citric 
acid/Na phosphate buffer, 5 mM K4[Fe(CN)6] 3H2O, 5 mM K3[Fe(CN)6], 150 mM 
sodium chloride, 2 mM magnesium chloride and 1 mg ml − 1 X-gal in distilled water 
for 15h at 37°C. After staining, the cells were washed twice with PBS and once with 
methanol, and the plates were allowed to air dry. Bright field images were obtained 
with an upright light microscope (CarlZeiss) with a 20X objective. Positive cells and 
the total number of cells per field were counted manually. 
For SA-β-Gal analysis of mouse tumors, tissues were OCT embedded and 
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stored at -80°C. On the day of the experiment, the tissues were cut into 8-µm-thick 
sections and mounted onto glass slides. After air-drying for 30 minutes, the sections 
were fixed with 2% PFA and 0.2% glutaraldehyde and stained as previously for 
cultured cells. The sections were washed and counterstained with 0.1% Fast Red 
(Sigma). Images were taken at different magnifications with a bright field 
microscope. 
 
Electron microscopy 
Cells were plated on poly-L-lysine (0.01%, Sigma, catalog n°P4832)-coated 
glass slides (LabTek Chamber Slides, catalog n°177399) cultured for two days and 
treated with CDK4/6 inhibitor or DMSO as control. The cells were then fixed for two 
hours in 2.5% glutaraldehyde (Electron Microscopy Sciences, catalog n°16220) 
dissolved in 0.1 M phosphate buffer (PB), pH 7.4. After three washes with PB, the 
cells were post-fixed for one hour in 1% osmium tetroxide (Electron Microscopy 
Sciences, catalog n°19150) in PB and then stained with 70% ethanol containing 1% 
uranyl acetate (Sigma, catalog n°73943) for 20 minutes. The cells were dehydrated in 
a graded alcohol series and embedded in Epon (Electron Microscopy Sciences, 
catalog n°13940). Mouse tumors were cut into small pieces (approximately 1 mm3) 
and then analysed in the same way as cells, outlined below.  
For EM analysis, mouse tumors and cultured cells were fixed in a 2.5% 
glutaraldehyde solution (EMS, Hatfield, PA, US) in PB for one hour at RT. Then, 
they were rinsed three times for five minutes with PB buffer and post-fixed with a 
fresh mixture of 1% osmium tetroxide (EMS, Hatfield, PA, US) and 1.5% potassium 
ferrocyanide (Sigma, St Louis, MO, US) in PB buffer for one hour at RT. The 
samples were then washed three times with distilled water and dehydrated in acetone 
solutions (Sigma, St Louis, MO, US) of graded concentrations (30%-40 min; 50%-40 
min; 70%-40 min; 100%-3x1 h). This was followed by incubation with Epon (Sigma, 
St Louis, MO, US) at graded concentrations (Epon 1/3 acetone-2 h; Epon 3/1 acetone-
2 h, Epon 1/1-4 h; Epon 1/1-12 h) and finally polymerization for 48 h at 60°C in an 
oven. 
Ultrathin sections of 50 nm were cut on a Leica Ultracut (Leica Mikrosysteme 
GmbH, Vienna, Austria) and picked up on a 2x1 mm copper slot grid (EMS, Hatfield, 
PA, US) coated with a polystyrene film (Sigma, St Louis, MO, US). Sections were 
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post-stained with 4% uranyl acetate (Sigma, St Louis, MO, US) in H2O for 10 
minutes, rinsed several times with H2O followed by Reynolds lead citrate in H2O 
(Sigma, St Louis, MO, US) for 10 minutes and then again with H2O several times. 
Micrographs were taken with a Philips CM100 transmission electron microscope 
(Thermo Fisher Scientific, Waltham, MA USA) at an acceleration voltage of 80 kV 
with a TVIPS TemCam-F416 digital camera (TVIPS GmbH, Gauting, Germany). 
Large montage alignment was performed using the Blendmont command-line 
program from IMOD software (Kremer, Mastronarde, & McIntosh, 1996) (for the in 
vivo analyses) or Adobe Photoshop CC 2015 (for in vitro analyses). 
The areas of autolysosomes, autophagosomes and cell cytoplasm were 
measured using ImageJ software. The densities of the autolysosomes and 
autophagosomes were expressed as a percentage of the cell area using the formula: 
area of the autolysosomes (or autophagosomes) / area of the cell cytoplasm x 100. 
The mean autolysosome area per cell and the percentage of autolysosomes containing 
degraded material per cell were also analyzed.  
 
Animal studies  
MDA-MB-231 cells were injected into the fourth mammary gland of eight-
week-old female NSG mice (NOD.Cg-PrkdcscidIl2rgtm1Wjl/Sz strain, The Jackson 
Laboratory). Tumor growth and body weight were measured twice per week until the 
tumor size of each mouse reached 50 mm3.  Optical imaging measurements using an 
IVIS Xenogen system were conducted on mice under anesthesia once per week for 
the duration of the study to follow the progression of the primary tumor.  
For the first experiment, mice were divided randomly into two groups, one 
(n=15) for treatment with vehicle (DMSO) and the other (n=15) for treatment with a 
CDK4/6 inhibitor (LY2835219, 75 mg/kg, formulated in 1% HEC in distilled water). 
The treatments were administered orally (gavage), with approximately 300 µl of 
solution (depending on the body weight) gavaged every day for a total of 8 days. 
During this time, body weight and tumor growth were also monitored. After eight 
days, the animals were anesthetized with isoflurane (3%) in an induction chamber for 
3 minutes and were sacrificed by cervical dislocation. Tumors from n=10 mice from 
each treatment group were dissected and cut into two pieces; one piece was fixed in 
PFA for histological staining, and the other piece was snap frozen for protein and 
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RNA analysis. Tumors from n=5 mice from each treatment group were processed for 
transmission electron microscopy analysis and SA-β-Gal staining. 
The injections and monitoring for second experiment was exactly the same. 
However, mice were divided into four groups of n=9-10 as follows:  1. DMSO	gavage	+	intraperitoneal	injection	(IP)	NaCl	0.9%	2. DMSO	gavage	+	IP	A-769662		(20mg/kg)		3. LY2835219		gavage	(75	mg/Kg)	+	IP	NaCl	0.9%	4. LY2835219		gavage	(75	mg/Kg)	+	IP	A-769662	(20mg/kg)		
As before, the CDK4/6 inhibitor LY2835219 was administrated orally (gavage) in 
approximately 350µl of volume (depending on the body weight). A-769662 was 
administrated by intraperitoneal injection (IP) of 100µl in saline solution (NaCl 
0.9%).  
Quantification and Statistical Analyses  
The results are expressed as the means ± standard error of the means (S.E.M.). 
Comparisons between 2 groups were performed with an unpaired two-tailed Student’s 
t test, and multiple group comparisons were performed by unpaired one-way ANOVA 
and two-way ANOVA, both followed by Tukey’s test or otherwise indicated. All p-
values below 0.05 were considered significant. Statistically significant values are 
represented by asterisks corresponding to ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 
and ∗∗∗∗p < 0.0001. 
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6. Figures  
	
	
Figure 1.- CDK4 inhibition or depletion prevents the recruitment of mTOR to 
the lysosomal surface in response to amino acid stimulation. A, Confocal 
immunofluorescence analysis showing the colocalization of mTOR with lysosomes 
(visualized by LAMP1 and mTOR staining) in WT and CDK4 KO MDA-MB-231 
cells, with or without amino acid stimulation and in the presence of 0.5 µM of the 
CDK4/6 inhibitor LY2835219 or vehicle control (DMSO). B, Quantification of 
mTOR-LAMP1 colocalization from A using Pearson’s coefficient. At least 40 fields 
per treatment condition from 3 independent experiments were analyzed. C, Western 
blot showing levels of phospho-RB (S780), CDK4, mTORC1 target genes (phospho-
p70S6K (T389) and 4E-BP1). α-tubulin was used as a loading control in WT and 
CDK4 KO MDA-MB-231 cells with or without amino acid stimulation and in 
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presence or absence of 0.5 µM LY2835219. D, Quantification of phospho-p70S6K 
(T389) levels from three independent experiments like C normalized to α-tubulin.
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Figure 2.- CDK4 regulates mTORC1 activity through phosphorylating FLCN. A, 
Representation of the phosphorylation sites detected by mass spectrometry analysis in 
the In vitro kinase assay with FLCN-GST and CDK4/CyclinD3. In green is 
represented the protein sequence. Blue dots represent the phosphorylation sites, and 
their size correlates with their abundance. Conditions without ATP (-ATP) were used 
as negative control. B, Representation of the phosphorylation sites detected by mass 
spectrometry analysis in the overexpressed and immunoprecipitated FLCN-FLAG. As 
in A, green represents the protein sequence. Blue dots represent the phosphorylation 
sites, the size of which correlates with their abundance. C, Confocal 
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immunofluorescence analysis showing the colocalization of overexpressed FLCN 
with lysosomes (visualized by LAMP1 and FLCN staining) in WT and CDK4 KO 
MDA-MB-231 cells, with or without amino acid stimulation and in the presence of 
0.5 µM of the CDK4/6 inhibitor LY2835219 or vehicle control (DMSO).  
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Figure 3.- CDK4 inhibition or depletion increases lysosomal mass. A, Quantitative 
PCR analysis showing the expression of transcription factor EB (TFEB) regulated 
genes that are involved in lysosomal or autophagic processes (cathepsins B and D and 
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SQSTM1) in WT or CDK4 KO MDA-MB-231 cells in complete (+FBS) or serum-
starvation media (-FBS), treated with or without 0.5µM LY2835219. Each condition 
was assessed in duplicates for three independent experiments. B, Representative flow 
cytometry images of WT or CDK4 KO MDA-MB-231 cells treated with or without 
LY2835219 and stained with LysoTracker Green DND-26 under the indicated 
conditions. C, Proportions of cells containing lysosomes, estimated by quantification 
of fluorescence from LysoTracker Green DND-26 stained cells from two independent 
experiments. At least 10.000 events were acquired. Data are subdivided into 
categories of the number of lysosomes per cell. Significant differences between WT 
and KO MDA-MB-231 cells are indicated by: * total lysosomal particles (P<0.05); $ 
lysosomal particles per cell (3-5 particles) (P<0.05); & lysosomal particles per cell 
(>5 particles) (P<0.05); Two-way ANOVA followed by Tukey’s multiple 
comparisons test. D, As for panel C, but subdivided into categories of the sizes of 
lysosomes per cell. Significant differences between WT and KO MDA-MB-231 cells 
are indicated by: * lysosomal particles <0.5µm2 (P<0.05); $ lysosomal particles per 
cell (<0.5 µm2) (P<0.05). E, Immunofluorescence analysis showing LAMP1 and 
CDK4 expression in WT and CDK4 KO MDA-MB-231 cells in complete media. F, 
Quantification of the total volume of LAMP1-positive particles in z-stack images. At 
least 30 cells in total from three independent experiments were analyzed.
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Figure 4.- Autophagic flux is impaired when CDK4 is inhibited or depleted. A, 
Western blot analysis of autophagosomal markers LC3-I, LC3-II, SQSTM1 in WT 
and CDK4 KO MDA-MB-231 cells treated 24h with complete media (+FBS) or 
serum-starvation media (-FBS), presence/absence of the mTOR inhibitor 0.5 µM 
rapamycin and of the CDK4 inhibitor 0.5 µM LY2835219 and presence/absence of 
0.3 µM bafilomycin A1, 6 h before the treatment. B, Quantification of protein 
expression of LC3-II normalized to α-tubulin from three independent experiments 
like A, only the conditions without bafilomycin A1. C, Quantification of protein 
expression of LC3-II normalized to α-tubulin from three independent experiments 
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like A, only the conditions with bafilomycin A1. Statistical analysis was performed 
using a paired sample T-test.  
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Figure 5.- Absence of CDK4 alters lysosomal function. A, Representative electron 
micrographs of WT and CDK4 KO MDA-MB-321 cells showing that cells lacking 
CDK4 have increased autolysosome (arrows) density and size. In CDK4 KO cells, 
autolysosomes accumulated non-degraded material, such as undegraded 
autophagosomes (arrowheads), in both complete (+FBS) and serum-starvation media 
(-FBS). In cell cultures without FBS, an increase in autophagosomes (arrowheads) 
was also observed in CDK4 KO cells as compared to wild-type cells. N: nucleus. B–
D, Quantification of the autophagosome (B) and autolysosome (C) area per cell, and 
the percentage of autolysosomes containing degraded material (D), quantified for the 
conditions shown in Figure 4A. n = 20 cells per condition. E, Representative electron 
micrographs of MDA-MB-321 cells showing increased density of autolysosomes 
(arrows), accumulation of non-degraded materials (including undegraded 
autophagosomes; arrowheads) and autophagosomes (arrowheads) in DMSO or 
LY2835219-treated WT MDA-MB-321 cells in complete and serum-starvation 
media. N: nucleus. F–H, Quantification of autophagosome area per cell (F), 
autolysosome area per cell (G) and percentage of autolysosomes containing degraded 
material per cell (H) quantified for conditions shown in Figure 4E. n = 20 cells per 
condition. I, Quantification of intracellular lysosomal activity of WT and CDK4 KO 
MDA-MB-231 cells in complete media. J, Quantification of cathepsin B activity in 
WT and CDK4 KO MDA-MB-231 cells in complete media. 
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Figure 6.- Dysfunctional lysosomes, but not mTORC1 inhibition, induce 
senescence. A, Proliferation of WT MDA-MB-231 cells cultured in either complete 
(+FBS) or serum- starvation (-FBS) media, with or without LY2835219, as shown by 
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the percentage of Ki67-positive cells. B, Apoptosis under the same conditions, as 
shown by the percentage of Annexin V-positive cells. C, mTOR-independent 
induction of senescence by LY2835219, visualized by colorimetric senescence-
associated β-Galactosidase (SA-β-Gal) staining of WT and CDK4 KO MDA-MB-231 
cells cultured in -/+ FBS media for the last 16 h of 8 days’ treatment with DMSO, 0.5 
µM LY2835219, or 0.5µM rapamycin. D, Quantification of the percentage of SA-β-
Gal-positive WT and CDK4 KO MDA-MB-231 cells from triplicates, at least five 
fields per replicate. E, Quantification of the fold induction of SA-β-Gal induced by 
LY2835219 or rapamycin treatment from triplicates, at least five fields per replicate. 
F, Quantitative PCR analysis showing expression of genes usually upregulated in 
senescence (including p53-regulated genes), in WT MDA-MB-231 cells treated for 8 
days with DMSO, LY2835219, or rapamycin in complete media. Each condition was 
assessed in triplicates.  
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Figure 7- The CDK4/6 inhibitor LY2835219 alters lysosome morphology in a 
breast cancer xenograft mouse model. A, Western blot for RB and phospho-RB 
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(S780) in tumor protein extracts of mice from both groups as a control for CDK4/6 
inhibition. B, Quantification of A, as arbitrary levels of phospho-RB (S780) 
normalized to total RB. C, Volume of MDA-MB-231 tumors from mice throughout 
the entire experiment from 8 or 9 mice per condition. When the tumors reached a 
volume of 50 mm3 (day 25), gavage with either DMSO or LY2835219 started and 
lasted for 8 days. D, Immunohistochemistry with Ki67 antibody and DAPI for tumor 
sections from DMSO- or LY2835219-gavaged mice. E, Percentage of Ki67-positive 
cells from D. Three images per section were analyzed for 8 or 9 mice.  F, 
Immunohistochemistry with LAMP1 antibody and DAPI of tumor sections from 
mouse xenograft models treated with either LY2835219 or DMSO. G, Quantification 
in arbitrary units of the area of LAMP1 staining normalized to the number of nuclei 
per field. Three images per section were analyzed for 8 or 9 mice.  H, Western blot 
for the mTOR target protein p70S6K and its phosphorylated variant (phospho-
p70S6K (T389)) from mouse tumor xenograft lysate, following gavage with either 
DMSO or LY2835219. I, Quantification of H, showing arbitrary levels of phospho-
p70S6K (T389) normalized to total p70S6K. J, Representative electron micrographs 
of mouse tumor xenograft cells, showing that LY2835219 treatment increases notably 
the density of autolysosomes (arrows) and that these autolysosomes accumulate non-
degraded materials, such as undegraded autophagosomes (arrowheads). N: nucleus. 
K-M, Quantification for conditions shown in J, as percentage of autophagosome area 
per cell (K), percentage of autolysosome area per cell (L) and the percentage of 
autolysosomes containing degraded material per cell (M) from EM images of mouse 
xenograft tumors treated with LY2835219 or control. n = 30 cells per condition. N, 
Colorimetric SA-β-Gal staining of tumor cell senescence in tumor xenograft sections 
taken from mice gavaged with LY2835219 or DMSO. O, Schematic representation of 
the proposed model. In cancer cells, activated CDK4 (left) promotes cancer cell 
proliferation through regulating cell cycle, but also through FLCN phosphorylation to 
ensure mTORC1 recruitment to lysosomes in the presence of amino acids (AA). In 
addition, CDK4 can also promote lysosomal degradation to generate amino acids, 
which also serve to activate mTORC1. When CDK4 is inhibited or depleted (right), 
cancer cell senescence is induced through impairment of cell cycle progression, and 
by suppressing lysosomal function, which results in mTORC1 inactivation, lysosomal 
biogenesis and impairment of autophagic flux. mTORC1 is dually inhibited, since 
 80 
unphosphorylated FLCN is retained at the surface of lysosomes also abrogating 
mTORC1 recruitment.   
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Figure 8- The CDK4 inhibitor LY2835219 in combination with the AMPK 
activator A769661 induces cell death in breast cancer cells and tumors.  A, Tumor 
volume of breast cancer xenograft in NSG mice was monitored throughout the whole 
experiment. Treatment started on day 21 and lasted for 8 days (n=9-10). B, 
Representative images from tumors at the day of sacrifice, after the corresponding 
treatment. C, Increment of tumor volume per mouse: Vol day29/Vol day21. D, 
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Representation of percentage of tumors, which increases more than 1.5 fold, from 1 to 1.5 
folds or less than 1 fold. E, Ki67 and Cleaved Caspase-3 immunostaining in tumor 
sections after the corresponding treatment. F, Quantification from E of % Ki67 positive 
cells. G, Quantification from E of Cleaved-Caspase-3 area per field, comparing 
LY2835219 and A769662+LY2935219. H, Westernblot analysis of activation of RB, 
p70S6K and ACC proteins in tumor samples. I, Quantification from H of phospho-RB 
normalized with total RB. J, Quantification from H of phospho-p70S6K normalized with 
total p70S6K. K, Quantification from H of phospho-ACC, normalized with total ACC. 
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7. Supplementary	Figures	
 
 
Sup. Figure 1.- CDK4 inhibition or depletion decreases mTORC1 activity in 
several cancer cell lines. A, Western blot showing the impact of the lack of CDK4 on 
downstream PI3K pathway proteins in different cancer cell lines, with or without the 
PI3K pathway stimulating ligand IGF-1. The relative phosphorylation level 
normalized to α-tubulin is indicated below the corresponding panels normalized to 1 
in every cell line.  
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Sup. Figure 2.- CDK4 effects on mTORC1 are α-ketoglutarate and E2F1-
independent. To check whether the effects of LY2835219 on MDA-MB-231 cells 
were due to an impairment in glutamine metabolism, we treated the cells with a cell-
permeable α-ketoglutarate analog. A, Confocal immunofluorescence analysis showing 
mTOR colocalization with lysosomes (Lamp1) in WT and CDK4 KO MDA-MB-231, 
with or without 5 mM α-KG and/or 0.5 µM LY2835219. B, Quantification of 
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colocalization from A using Pearson’s coefficient. At least 20 fields per condition 
were analyzed. C, Effect of CDK4 inhibition on the colocalization of mTORC1, 
examined using confocal immunofluorescence analysis of mTOR colocalization with 
lysosomes (Lamp1) in MDA-MB-231 cells lacking E2F1, and the sensitivity of these 
cells to LY2835219 in presence or absence of amino acid stimulation. D, 
Quantification of the colocalization in C using Pearson’s coefficient. At least 20 fields 
per condition were analyzed. E, Western blot analysis of phospho-p70S6K (T389), 
4E-BP1, phospho-RB (S780), E2F1 and α-tubulin in WT and E2F1 KO MDA-MB-
231 cells, in the presence of glutamine and different concentrations of amino acids 
(AA) (0×, 1× or 2× Minimal Essential Media AA) and in the presence of DMSO or 
0.5 µM LY2835219. F, Quantification of Western blot analysis in E showing 
phosphorylation levels of mTORC1 target molecule phospho-p70S6K (T389) 
normalized to α-tubulin from three independent experiments like E.  
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Sup. Figure 3.- CDK4 inhibition or depletion increases lysosomal mass. A, 
Quantifications of the mean autolysosome area per cell from electron microscope 
images in MDA-MB-321 WT and CDK4 KO cells, either in complete medium 
(+FBS) or in serum starvation conditions (-FBS). B, Quantifications of the mean 
autolysosome area per cell from electron microscope images in MDA-MB-321 WT 
cells under DMSO or LY2835219 treatment, either in complete medium or in 
starvation conditions (medium - FBS). n = 20 cells per condition. 
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Sup. Figure 4.- Hematoxylin and eosin staining and gene expression analysis of 
tumors from mice treated with or without LY2835219. 
A, Hematoxylin and eosin staining of tumor sections from DMSO- or LY2835219-
treated mice, to confirm the lack of immune cell infiltration (whole tumor and with 
20X objective). B, Gene expression of all lysosomal and autophagic genes examined 
by qPCR from DMSO- or LY2835219-treated mice. 8 or 9 mice per condition were 
analyzed C, Quantifications of the mean autolysosome area per cell from electron 
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microscope images of tumor sections from DMSO- or LY2835219-treated mice. n=30 
cells per condition. D, Gene expression of genes usually upregulated in senescence 
(including p53-regulated genes) examined by qPCR from DMSO- or LY2835219-
treated mice. 8 or 9 mice per condition were analyzed. 
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Sup. Figure 5. In vitro cell death analysis and in vivo electron microscopy analysis of 
tumors treated with DMSO, LY2835219, A769662 and the combination of A769662 
with LY2835219. A, Percentage of Annexin V positive cells assessed by flow cytometry 
of MDA-MB-231 cells cultured for 8 days with the corresponding treatment. B, 
Representative electron micrographs of tumors from mice treated with DMSO, 
LY2835219, A769662 and the combination of A769662 with LY2835219. The 
arrowheads represent the autophagosomes and the arrows, the autolysosomes with 
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undigested material inside. * Indicates the focal swelling of the perinulear membrane, 
and N represents nucleus. C, Quantification from B, of the percentage of autophagosome 
area per cell. D, Quantification from B, of the percentage of lysosome area per cell. E, 
Quantification from B, of the percentage of autolysosomes with digested material inside. 
n = 30 cells per condition. Values are mean ± SEM, *P < 0.05;***P < 0.001 
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Chapter 4. General discussion  	
1. General discussion 
 
The role of CDKs in the control of cell cycle has been extensively studied. 
Cell cycle progression requires great metabolic adaptation, given the high demand of 
energy for anabolic processes (Lopez-Mejia & Fajas, 2015). Growing evidence about 
cell cycle regulators being the sensors and effectors of this metabolic adaptation is 
found. Cell cycle regulators respond to mitogenic extracellular stimuli (Duronio & 
Xiong, 2013). In addition, many metabolic targets of CDKs have been identified, 
including metabolic enzymes, metabolic regulators and molecules involved in 
organismal energy homeostasis. These findings highlight, not only the tight link 
between cell cycle and metabolism, but also the role of CDKs in the regulation of 
metabolism (Solaki & Ewald, 2018). 
The laboratory of Prof. Fajas has focused for years on elucidating the 
metabolic roles of cell cycle regulators, including CDK4. It is well known that CDK4 
promotes the transition from the G1 to S phase of the cell cycle. This occurs in the 
nucleus of the cell. However, CDK4 is also found in the cytoplasm playing additional 
roles in metabolism (Aguilar & Fajas, 2010). It is known that CDK4 is translocated to 
the cytoplasm once it accomplishes its cell cycle task. However, it was thought that 
this translocation occurs for CDK4 to be degraded. It is yet to be elucidated whether 
two pools of CDK4 co-exist in a cell, or whether the same CDK4, once it 
accomplishes its task in the nucleus, is translocated to the cytoplasm to perform 
metabolic functions.  
During my PhD, I contributed in unraveling new roles of CDK4 in 
metabolism. In 2016 we published that CDK4, through phosphorylation of IRS2, 
maintains the insulin signaling pathway activated in adipocytes (Lagarrigue et al., 
2016) (enclosed in ANNEX. Contribution to other articles). These findings place 
CDK4 at the initiation of the insulin signaling pathway, a pathway usually 
deregulated in metabolic disorders such as obesity and insulin resistance. The 
following year, we found that CDK4 represses catabolism by directly targeting the α2 
subunit of AMPK in mouse embryonic fibroblasts and also in vivo, in muscle tissues 
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from mice. This finding uncovered the role of CDK4 in the control of the whole-body 
energy homeostasis and exercise performance (Lopez-Mejia et al., 2017) (enclosed in 
ANNEX. Contribution to other articles). Interestingly, in both cases, CDK4 acts 
independently of E2F1 to regulate metabolism. In addition, it also has been shown 
that one of the main proteins of insulin signaling pathway, AKT, can negatively 
regulate AMPK through phosphorylating its α1 subunit (Hawley et al., 2014). This 
places CDK4 at two different levels of the same signaling pathway with the same 
purpose: to promote anabolism and repress catabolism.  
The results shown in this thesis (Chapter 3) depicted a new role of CDK4 in 
metabolism. We show here that this kinase, also independently of E2F1, regulates 
lysosomal function and mTORC1 activation in a TNBC model. Once again, we are 
describing that CDK4 promotes an anabolic process, but this time, through a novel 
mechanism. We show for the first time that CDK4 can phosphorylate FLCN, a 
regulator of mTORC1, and that CDK4 phosphorylations on FLCN are necessary for 
mTORC1 activation at the surface of lysosomes. In addition, we show that CDK4 
inhibition or depletion impairs lysosomal function, thus, also resulting in mTORC1 
inhibition. The lack of evidences of FLCN playing a role in lysosomal function 
suggested these dual effects with the same result. Lysosomal function is important 
mainly for autophagy, to degrade damaged organelles or proteins to be recycled to 
create new ones, or to be exported outside the cell. mTORC1, since is the main 
promoter protein synthesis, can sense amino acids resulting from lysosomal 
degradation to become activated and start its functions. mTORC1 is also activated by 
insulin signaling pathway. In addition, it is a negative regulator of AMPK and vice 
versa. The results shown in Chapter 3 further places CDK4 as an important regulator 
of the insulin signaling pathway, this time regulating mTORC1 activity. However, 
these three studies are conducted in different models. Further investigations are 
needed to elucidate whether all these roles of CDK4 in metabolism can occur in the 
same cell type, or they are context specific.  
The role of CDK4 in the regulation of lysosomal function is specially 
important for cancer treatment. Firstly, CDK4 appears to be hyperactive in many 
cancer types, and the use of CDK4 inhibitors have already provided successful results 
in clinical trials. In addition, lysosomes play multiple roles in the cell, they can be 
deregulated in tumorigenesis, and targeting these organelles is an emerging strategy to 
treat cancer. Our investigations were conducted in a TNBC model, a highly 
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aggressive breast cancer type, and provide a new therapeutic strategy to treat this 
form of disease.  
It was already known that CDK4 inhibition does not induce cell death but 
senescence in cancer cells (Yoshida & Diehl, 2015). We have found that senescent 
cells with impaired lysosomal function (treated with CDK4 inhibitors) eventually die, 
if they are additionally treated with an activator of AMPK, which induces autophagy. 
The combination of both drugs reduced tumor size and offered a better outcome than 
single treatments. These findings highlight the importance of targeting lysosomes for 
cancer treatment, and offer another application for CDK4 inhibitors.   
In summary, our research uncovers the interesting roles of CDK4 in 
metabolism, that are not only essential for basic cell cycle biology, but may open new 
avenues for the treatment of different pathologies, such as metabolic disorders or 
cancer. 
 
 
2. Conclusions		- CDK4 is not only a cell cycle regulator. It is also an important metabolic 
effector that promotes anabolism while repressing catabolism.  - In MDA-MB-231 in vitro and in xenografts models of TNBC, CDK4 
inhibition or depletion impairs lysosomal function. As a result, mTORC1 
pathway is downregulated. Cells with impaired lysosomal degradation become 
senescent.  - As cancer treatment, the combination of the CDK4 inhibitor LY2835219 
together with A769662 induces cell death and provides a better outcome for 
TNBC. - Targeting lysosomes is a promising approach to treat cancer.   
 
 
3. Future perspectives 
 
The results described in this thesis leave unresolved questions and open new 
perspectives in the study of the relationship between CDK4, mTOR and lysosomes.  
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Despite demonstrating that CDK4 promotes lysosomal function in a TNBC 
model, the underlying mechanism of this finding is still unknown. In order to find the 
pathways differentially activated in the presence or absence of CDK4, the use of 
PamStation, a new technology developed by PamGene and available in the lab, it 
would be very informative. This automated instrument contains different chips with 
more than 100 known peptides immobilized in array format. These peptides can be 
phosphorylated by the proteins from a cell or tissue lysate. A fluorescently labeled 
antibody detects the levels of phosphorylation of each peptide, which correlates with 
the intensity of the fluorescence. Later on, upstream analysis of the phosphorylated 
peptides can reveal which kinases are affected by CDK4 inhibition or depletion, and 
eventually the involved pathways. This will lead to the discovery of new potential 
CDK4 targets.   
In order to find its direct phosphorylation targets, we could use an analog-
sensitive CDK4. We would need to mutate the ATP binding site of the kinase and 
perform a kinase assay with labeled ATP. Only the direct CDK4 targets will acquire 
the labeled phosphate and they can be identified by immunoprecipitation. This 
technique has already been tested in the lab. However, further optimization is needed, 
given that the non-mutated CDK4 was able to use labeled ATP to phosphorylate our 
positive control, RB protein.  
In addition, preliminary data indicated that CDK4 KO MDA-MB-231 cells 
have increased basal respiration and increased mitochondria in number and size as 
compared to WT cells. With these observations, and also taking into account that 
lysosomal function is impaired in CDK4 KO cells, the next question to address would 
be if mitophagy is also altered in these conditions. Analysis of some mitophagy 
markers or analysis of electron microscopy images would be useful to elucidate this 
question.  
Furthermore, it would be interesting to study if the results obtained in a cancer 
model are also obtained in physiological conditions. For this purpose, since we have 
CDK4-/- mice available in our lab, it would be interesting to study whether they have 
defects in lysosomal function, and if so, what the metabolic impact of this phenotype 
is. For example, preliminary data indicates that the livers from CDK4-/- mice present 
enlargement of lysosomes as compared to CDK4+/+ mice, as measured by 
immunohistochemistry of LAMP1 in liver sections. Lysosomes have been shown to 
be essential for liver regeneration (Dwivedi, Kaur, Srivastava, & Krishna Murti, 
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1985), and their enlargement in CDK4-/- mice could be an indication of defects of this 
process. In addition, autophagy-lysosome system is a pathway of critical importance 
in the brain, where it contributes to neuronal plasticity and must protect 
nonreplaceable neurons from the potentially harmful accumulation of cellular waste 
(Sharma, di Ronza, Lotfi, & Sardiello, 2018). Some neurodegenerative diseases such 
as Alzheimer’s or Parkinson’s disease, present deregulations in lysosomes (Dehay et 
al., 2013; McBrayer & Nixon, 2013). In addition, the majority of LSDs are associated 
with neurological problems (Onyenwoke & Brenman, 2015). Therefore, it would be 
interesting to study whether CDK4-/-  mice present abnormalities in lysosomes in the 
brain, and to explore whether they present the neurological characteristics of the 
mentioned diseases.  
Overall, this work has led to the creation of a new line of investigation in Prof. 
Fajas lab to further study the role of CDK4 in lysosomal biology in various 
physiological and pathological models.  
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ANNEX. Contribution to other articles 		
1.  “Cancer: Linking lysosomes to suicidal bags” 
Martinez-Carreres, L., Nasrallah, A., and Fajas, L. (2017). Cancer: 
Linking Powerhouses to Suicidal Bags. Frontiers in oncology 7, 204. 
		
During my PhD I had the opportunity to write a literature review about the 
interplay between two essential organelles of the cell: mitochondria and lysosomes. 
Both organelles are crucial for cell proliferation and cell fate; their interaction in some 
cases can result in cell death, and in others, in tumorigenesis. This literature review 
explains the main mechanisms or processes by which this two organelles are 
connected and their deregulations in cancer. In addition, it explains the current 
treatments that target the interplay of both organelles and their implications for cancer 
therapy.  																		
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Cancer: Linking Powerhouses  
to Suicidal Bags
Laia Martinez-Carreres†, Anita Nasrallah† and Lluis Fajas*
Cancer and Metabolism Laboratory, Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
Membrane-bound organelles are integrated into cellular networks and work together for 
a common goal: regulating cell metabolism, cell signaling pathways, cell fate, cellular 
maintenance, and pathogen defense. Many of these interactions are well established, 
but little is known about the interplay between mitochondria and lysosomes, and their 
deregulation in cancer. The present review focuses on the common signaling pathways 
of both organelles, as well as the processes in which they both physically interact, their 
changes under pathological conditions, and the impact on targeting those organelles for 
treating cancer.
Keywords: cancer, mitochondria, lysosomes, mammalian target of rapamycin, Rab7, AMP-activated protein 
kinase, mitophagy, lysosomal membrane permeabilization
INTRODUCTION
Cancer is characterized by the unrestricted cellular growth and proliferation of abnormal cells. It 
exhibits properties of motility, invasion, angiogenesis, and metastasis. Recent studies identified 
diverse mechanisms of metabolic plasticity in cancer cells. These include increased glucose uptake 
in most tumors, elevated glycolytic intermediates, increased pentose phosphate pathway activities, 
increased glutamine catabolism, and increased use of lactate as a fuel in selective tumors (1).
According to the American Cancer Society, it is estimated that, in the US, almost 1.7 million new 
cases of cancer will be diagnosed in 2017. Mostly, general cancer treatments are limited to radia-
tion, chemotherapy, and surgery. However, these treatments encounter non-specific distribution 
of chemotherapeutic agents, insufficient drug concentrations to reach the tumor, and restricted 
ability to survey therapeutic responses (2). More efforts are targeted to find new therapies to help 
overpass these obstacles. Subcellular targeting is beneficial for therapy in several scenarios (3): 
(1) basic organelle malfunctions could be targeted, making the process more selective; (2) the quantity 
of drug required could be significantly reduced because of its specificity, which eventually helps in 
decreasing side effects; and (3) most importantly, intracellular drug targeting may surpass dangerous 
drawbacks of drug actions in cancer therapy, i.e., multidrug resistance (4, 5).
In most of the mechanisms of cancer initiation and progression, different organelles are involved, 
especially mitochondria and lysosomes, for their relevance in energy homeostasis and cell death 
(6). The purpose of this review is to shed light on the roles of mitochondria and lysosomes in cancer, 
as well as them being prominent targets for cancer therapy.
THE ROLE OF MITOCHONDRIA IN CANCER
Mitochondria, also called “powerhouses” of cells, are double membrane organelles, with their own 
genome, thought to have been originated from an ancient symbiosis that resulted when a nucleated 
cell engulfed an aerobic prokaryote. Through evolution, mitochondria conserved only a small part 
of prokaryotic bacterial genes, including the ones encoding 13 proteins of the respiratory chain (7). 
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In this manner, mitochondria gained a central role in the regula-
tion of metabolism, cell proliferation, and apoptosis, while many 
tasks were transmitted to the host cells (8).
Other than being cell’s powerhouses, mitochondria func-
tion as signaling organelles. They coordinate distinct metabolic 
pathways, producing metabolites required for cell survival and 
proliferation (9). In fact, mitochondria are key players in the 
calcium-signaling pathway (10). When toxic stimuli damage 
the cell, mitochondria release pro-apoptotic molecules, such as 
cytochrome c, thus regulating cell death (11). Moreover, mito-
chondria are established as the major site of production of free 
radicals, which are major signaling molecules in the cell (12). 
Recently, it has been shown that mitochondrial metabolites do 
not only have intermediary roles in energy generation but can 
also promote regulatory effects on post-translational modifica-
tions of proteins (13), as well as affecting chromatin structure and 
function (14).
Multiple human diseases have been strongly associated with 
impaired mitochondrial homeostasis. These include liver and 
cardiovascular diseases, neurological and muscular disorders, 
seizures, susceptibility to infections, and cancer (15–18). In 
cancer, mitochondrial roles vary as a function of genetic and 
environmental differences, as well as the tissue-of-origin of the 
diverse types of cancer. The main mitochondrial processes con-
tributing to tumorigenesis include mitochondrial biogenesis and 
mitophagy, fission and fusion dynamics, metabolism, oxidative 
stress, and cell death (19).
Compared to normal cells, cancer cells show many alterations 
in energy metabolism. In the 1920s, cancer metabolism studies 
commenced with Otto Warburg’s observation: to produce energy, 
cancer cells rely less on mitochondrial respiration and more on 
glycolysis. Warburg hypothesized that mitochondria must be 
dysfunctional, taking into consideration that glycolysis gives a 
lot less energy as compared to mitochondrial respiration (20). 
However, other scientists believed that the reduced mitochon-
drial activity is due to higher glycolysis. In some cases, Warburg’s 
proposal holds true. Nevertheless, there are reports showing that 
the mitochondrial function in cancer cells in some cases is intact, 
or mitochondrial biogenesis is increased (21).
Mitochondrial biogenesis could be described as the division 
and growth of pre-existing mitochondria. It is regulated at the 
transcriptional and post-transcriptional levels of gene expres-
sion (22). Regulating mitochondrial biogenesis is an attractive 
target of key oncogenic signaling pathways, since cancer cells 
induce it to increase ATP production for cellular proliferation. 
PGC-1α, through its interactions with numerous transcription 
factors, is a central regulator of mitochondrial biogenesis (23). 
It portrays a dual effect on cancer viability. On the one hand, 
PGC-1α acts as a tumor suppressor in some cancers, resulting 
in induced apoptosis upon overexpression. In human epithelial 
ovarian cancer, apoptosis was induced via the organized regula-
tion of Bcl-2 and Bcl-2-associated X protein (BAX) expression 
by PGC-1α (24). PGC-1α is considered a tumor suppressor not 
only because it induces apoptosis but also because it has been 
found to suppress the metastatic abilities of tumor cells via the 
direct regulation of transcriptional machinery (25, 26). For 
example, PGC-1α directly increases ID2 transcription that binds 
to the transcription factor TCF4, rendering it inactive. This in 
turn leads to a downregulation in metastasis-related genes, such 
as integrins, that are able to influence metastasis and invasion 
(25). On the other hand, the ability of PGC-1α in sustaining 
metabolic homeostasis can also promote cancer cell survival and 
tumor metastasis (27). In cancer cells, silencing PGC-1α resulted 
in deferred invasive potential and weakened metastatic ability 
without affecting proliferation and tumor growth. Consistently, 
the transition from primary lung tumor cells to metastatic can-
cer cells was coupled with more dependence on mitochondrial 
respiration, via PGC-1α, leading to an upregulation of PGC-1β, 
ERRα, and NRF1, which are mitochondrial-related biogenesis 
genes (28).
Another key activator of mitochondrial biogenesis in cancer is 
c-Myc, a transcription factor regulating cell cycle, proliferation, 
metabolism and cell death. Studies have demonstrated that the 
loss or gain of Myc decreases or increases mitochondrial mass, 
respectively. This is due to the fact that over 400 mitochondrial 
genes are identified as targets of c-Myc (29). A third effector of 
mitochondrial biogenesis is mammalian target of rapamycin 
(mTOR). It controls mitochondrial gene expression through the 
activation of PGC-1α/YY1 and represses the inhibitory 4E-BPs 
(eukaryotic translation initiation factor 4E-binding protein 1) 
that downregulates the translation of mitochondrial proteins (30).
During tumorigenesis, mitochondrial dynamics is very impor-
tant. It determines the equilibrium between cell death programs 
and mitochondrial energy production. Several studies demon-
strated, in cancer, an imbalance in mitochondrial fission and 
fusion activities, depicted in decreased fusion, and/or elevated 
fission that resulted in fragmented mitochondrial networks via 
the K-Ras-DRK1/2-Drp1 pathway (31, 32). Also, c-Myc affects 
mitochondrial dynamics by altering the expression of proteins 
implicated in the fission and fusion processes (33).
Furthermore, mitochondria have a tight relationship with the 
intrinsic (also called mitochondrial) apoptotic cell death program, 
since B-cell lymphoma-2 (BCL-2) family of proteins regulates the 
integrity of the outer mitochondrial membrane (OMM). Mainly 
two members of this family, BAX and Bcl-2-associated killer 
(BAK) can break the OMM in response to apoptotic stimuli. This 
releases apoptogenic factors from inside mitochondria, such as 
cytocrome c, inducing activation of caspases and subsequent cell 
death. In some cases, mitochondria can also participate in the 
extrinsic apoptotic pathway, which is initiated by cell membrane 
death receptors. For example, FAS receptor can truncate Bid 
protein, another member of the BCL-2 family, via caspase 8. Trun-
cated Bid (tBid) can then translocate to mitochondria to induce 
apoptosis (34).
Mitochondrial morphology is a hallmark for apoptotic suscep-
tibility. Even though fission and fusion do not regulate apoptosis 
per  se, the generated mitochondrial morphology supports the 
interaction with pro-apoptotic Bcl-2 proteins. Thus, mitochon-
drial hyper-fragmentation causes resistance to apoptosis due to 
the inability of mitochondrial membranes to interact with pro-
apoptotic proteins (35).
Mitochondria play major roles in metabolic reprograming, 
including the synthesis of macromolecules and cellular survival 
(1). One mechanism by which cancer drives these alterations in 
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metabolism is limiting pyruvate utilization by the mitochondria. 
This is achieved by regulating pyruvate kinases such as PKM 
isoforms (36), as well as downregulating mitochondrial pyruvate 
carriers: MPC1 and MPC2 (37). Moreover, in some tumor types, 
mutations in the enzymes of the tricarboxylic acid (TCA) cycle 
render the mitochondria dysfunctional. Cells from such tumors 
use glutamine-dependent reductive carboxylation rather than 
oxidative metabolism as the major pathway of citrate formation. 
This, in turn, leads to the major reprograming of amino acid 
metabolism and lipid synthesis (38).
There are multiple levels at which both mitochondrial biology 
and tumorigenic signaling vastly intersect. First, cellular physiol-
ogy and tumorigenesis are affected by direct signals from mito-
chondria. Metabolites generated by the mitochondrial pathways 
affect gene transcription through chromatin modification, and 
cytosolic signaling pathways (19). For example, the TCA cycle 
intermediate α-ketoglutarate (α-KG) is a co-substrate for many 
enzymes in the cytoplasm and nucleus, including families of 
chromatin-modifying ones. In the case of chromatin regulation, 
glutamine-derived α-KG contributes to TET-dependent dem-
ethylation reactions (38). Second, many mutations were identi-
fied as directly associated with cancer risk (39). Cancer can be 
caused by mutations in nuclear-encoding genes, such as electron 
transporter chain (ETC) genes. For example, patients suffering 
from paraganglioma often presents dysfunctions in succinate 
dehydrogenase (SDH). Mutations of the same complex have also 
been found in other cancers, such as gastrointestinal stromal 
cancer, breast cancer, or renal carcinomas. Other enzymes such 
as fumarate hydratase (FH) have also found to be mutated in 
other cancers. When the function of these enzymes is lost, the 
metabolic intermediates fumarate and succinate accumulate, 
which in turn function as oncometabolites when found in excess 
(40, 41). In addition, mitochondrial DNA mutations (amplifica-
tions, deletions, point mutations, etc.) have been associated with 
various cancers (42). For example, point mutations in MT-ND1 
gene modify complex I activity, having an influence on the tumo-
rigenic characteristics of cells. Finally, and in order to support 
tumorigenesis, classical oncogenic signaling pathways alter mito-
chondrial functions. These include the c-Myc, p53, mTOR, and 
k-Ras signaling pathways (19). In addition, a main function of 
mitochondria is synthesizing aspartate for nucleotide synthesis, 
inducing cellular proliferation (43).
Mitochondria are complex organelles affecting cancer at many 
levels: initiation, proliferation, survival, or metastasis. One type 
of the various organelles that communicate with mitochondria 
is lysosomes. Mainly, this crosstalk depends on mitochondrial 
stress and/or destabilization of lysosomal membranes (44).
THE ROLE OF LYSOSOMES IN CANCER
Also known as “suicidal bags,” lysosomes were first described 
in 1950s by Christian de Duve as membrane-enclosed vesicles 
containing hydrolases. Functioning as a digestive system, they are 
found in all eukaryotic cells, except for mature erythrocytes. The 
hydrolytic enzymes that they contain include proteases, nucle-
ases, and lipases that can break down proteins, nucleic acids, and 
lipids, respectively, to their simplest subunits (45).
Lysosomes are formed when material from outside the cell is 
internalized in clathrin-coated endocytic vesicles forming early 
endosomes. Endosomal maturation occurs with the delivery 
of lysosomal acid hydrolases from the trans Golgi network, 
which contribute lowering of the internal pH to about 5.5. Late 
endosomes then mature into lysosomes as they acquire a full 
complement of acid hydrolases, which digest the molecules origi-
nally taken up by endocytosis, phagocytosis, and autophagy (46). 
Nevertheless, many investigations have proved that lysosomes are 
not only degradative organelles but also participate in metabo-
lism of the entire cell at different levels, and their modifications 
can promote or repress cell proliferation.
On one hand, lysosomes undergo Ca2+ regulated exocytosis, 
which is secreting their content into the extracellular space, and 
repairing their damaged plasma membranes; when the plasma 
membrane is injured, lysosomes quickly move to the site of 
damage and fuse with the plasma membrane. This allows effec-
tive resealing (47). On the other hand, they can sense nutrient 
availability, which controls energy metabolism and mediates the 
starvation response (48). Zoncu et al. proposed that amino acids 
have to be detected in the lysosomal lumen, signaling to the Rag 
GTPases in a manner that is vacuolar H+-ATPase (V-ATPase)-
dependent. This is known as the “inside-out” mechanism (49). 
Leucine, among other amino acids, must accumulate in the lumen 
of the lysosome to trigger the central regulator of cellular and 
organismal growth, mammalian target of rapamycin complex I 
(mTORC1) (50). mTORC1 is recruited by Rag GTPases on the 
lysosomal surface in response to amino acids, the site of activa-
tion by Rheb (Ras homolog enriched in brain), when growth 
factor-stimulated PI3K–Akt signaling is on (51, 52). Upon amino 
acid and growth factors removal, Rag GTPases releases mTORC1, 
causing it to become cytoplasmic and inactive. In those condi-
tions, the negative regulator of Rheb, tuberous sclerosis complex 2 
(TSC2), is lysosomally localized. Thus, lysosomal proteins change 
depending on the nutrient status of the cells (53, 54).
Lysosomal biogenesis as well as autophagy is controlled by the 
main regulator of lysosomal genes, known as TFEB or transcrip-
tion factor EB; when mTORC1 is active, TFEB remains inactive 
at the lysosomal membrane. Inactivated mTORC1 induces TFEB 
localization to the nucleus to activate lysosomal gene transcrip-
tion (52, 55).
Since lysosomes also serve as platforms of activation of 
mTORC1, it is important to mention the dysregulation of this 
pathway in cancer. Indeed, mTORC1 regulates several anabolic 
processes that are critical for tumorigenesis: it promotes protein 
synthesis, aerobic glycolysis, de novo lipid synthesis, de novo 
nucleotide synthesis, and represses autophagy and lysosomal 
biogenesis (56–59). Genes that encode components of the 
PI3K–Akt–mTOR pathway are frequently mutated in cancer, but 
despite few mutations have been characterized in mTOR, many 
tumor types present mTOR hyperactivation, thus promoting 
tumorigenesis (60, 61).
In addition, lysosomal intracellular positioning is impor-
tant for adhesion and motility (62), and important for mTOR 
signaling, autophagosome formation, and autophagosome-
lysosome fusion, and changes depending on the nutrient avail-
ability. During starvation, mTORC1 activity is repressed, which 
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induces autophagosome formation. Starvation increases pH, 
causing lysosomes to cluster near the microtubule-organizing 
center (MTOC), facilitating autophagosome–lysosome fusion. 
Conversely, nutrient replenishment restores basal pH inducing 
lysosomal scattering, which brings lysosomal mTORC1 to the cell 
periphery and stimulates its activity by increasing its coupling to 
the gradient of signaling molecules emanating from the plasma 
membrane (63). Given that peripheral lysosomes inside the cell 
are responsible for cell adhesion and motility, targeting those 
lysosomes in cancer cells is also a good strategy for cancer treat-
ment (62).
As de Duve already stated in the 1950s, lysosomal membrane 
permeabilization (LMP), consequently leading to the leakage of 
lysosomal content into the cytoplasm, induced what is known as 
“lysosomal cell death” (45, 64). Major players of this mechanism 
are lysosomal cathepsin proteases. They have apoptotic and/
or necrotic features, depending on the cellular context and the 
extent of leakage occurring into the cytosol (65).
Lysosomes in cancer cells undergo major changes. In some 
cases, they have an increased volume and protease activity, along 
with an improved lysosomal protease secretion, as compared to 
lysosomes in normal cells. Thus, they become hyperactivated as a 
reaction to fulfill the needs of the challenging microenvironment 
of the tumorigenic cells (62). For example, they require the inges-
tion of huge amounts of adhesion molecules and extracellular 
matrix molecules, leading to an upregulation in exocytosis. Also, 
they have to move inside the cell to repair damaged membranes 
(66, 67). Recently, a correlation between lysosomal movement 
and tumor cell invasion was also established, which was induced 
by tumor microenvironment stimuli (68). In particular, acidic 
extracellular pH induced lysosomal movement toward the cell 
peripheries, successively leading to Cathepsin B exocytosis from 
the lysosomes. This eventually promoted protease-dependent 
tumor invasion (69, 70). In vitro studies with glioma cells have 
shown that inhibition of lysosomal exocytosis with vacuolin-1 
is a good strategy for fighting against invasion in cancer (71).
As explained above, changes in the lysosomal compartment, in 
the presence of increased secretions of cysteine cathepsins, ren-
der these lysosomes pro-oncogenic. This results in an increased 
neoplastic progression, via proteolytic pathway initiation (72). 
Other than matrix remodeling, lysosomal role in degradation 
is crucial in tumorigenesis. This has been observed in reports 
revealing that specific intracellular cathepsin inhibitors are able 
to block collagen degradation, promoting tumor viability (73). 
However, cathepsins are also depicted as proteases with tumor 
suppressor abilities for their role in inducing cell death through 
LMP (74, 75).
Due to their role in cell death, autophagy, and deregulating 
metabolism, targeting lysosomes have a great therapeutic poten-
tial in cancer. Lysosomal proteins are indeed good targets for 
cancer treatment (76), such as lysosome-associated membrane 
protein 1 (LAMP-1). LAMP-1 is suggested to have a role in cell–
cell adhesion and migration, since it was detected on the surface 
of highly metastatic cancer cells, particularly from colon cancer 
(77). V-ATPase is another significant lysosomal membrane pro-
tein participating in cancer. It functions as a pump of protons to 
create an acidic pH of lysosomes. Also, it regulates endocytotic 
trafficking and affects the tumor microenvironment, by extruding 
protons into the extracellular matrix (78). Moreover, in tumor 
malignancy, V-ATPase participates not only in the dysregulation 
of lysosomal trafficking but also in mTORC1 activation and 
autophagy (79).
In addition, lysosomes are key players in cancer drug resist-
ance. They can sequester cancer drugs into their acidic milieu, 
thus, blunting the drugs’ effects (80). This further proves that 
targeting lysosomes may be a promising new therapeutic strategy 
for cancer.
Since both organelles, mitochondria and lysosomes, share the 
power of majorly impacting the process of tumorigenesis, we 
will next further describe the main crosstalk between these two 
important organelles, shedding light on their interplay in cancer 
and their impact on cancer therapy.
THE MITOCHONDRIAL–LYSOSOMAL 
INTERPLAY IN CANCER
In cancer, several important changes occur in all the organelles. 
However, the interplay between mitochondria and lysosomes 
is of high importance, because both organelles can interact to 
promote, in some cases cell death and in others tumorigenesis. 
There are two processes in which mitochondria and lysosomes 
work together: the first is LMP, a process in which enzymes from 
lysosomes can induce mitochondrial death pathway, and the 
second is mitophagy, a process in which lysosomes can degrade 
mitochondria, resulting in cell survival or cell death. Other than 
these two processes, there are several common effectors that play 
important roles in both organelles, which are also affected in 
cancer.
Mitochondrial–Lysosomal Mechanisms
Lysosomal Membrane Permeabilization
As mentioned above, LMP is a mechanism that induces two types 
of cell death: apoptosis induced by partial and selective LMP, 
and necrosis provoked by the complete disruption of lysosomes. 
One of the causes of apoptosis during LMP is the activation of 
caspases in the mitochondrial death pathway by mitochondrial 
outer membrane permeabilization (MOMP) (65).
Reactive oxygen species (ROS) and cathepsins are well-
known mediators of LMP-triggered cell death (81). It has been 
reported that only cathepsin D in the cytoplasm is enough to 
induce MOMP and apoptosis in human fibroblasts. However, 
cathepsin D alone is not in all cases of LMP sufficient to induce 
cell death (65).
As shown in Figure 1, MOMP can be triggered by LMP in 
two manners: either Bid dependent or Bid independent. Bid is 
known as BH3-interacting-domain death agonist and belongs 
to the pro-apoptotic BH3-only Bcl-2 family. The Bid-dependent 
process occurs when Bid is cleaved by the active cathepsins at 
cytosolic pH (specially cathepsins B and D), after which Bid is 
capable to form pores at the OMM inducing MOMP and releas-
ing cytochrome c from the mitochondria (81). Despite tBid is 
also known to activate BAX and BAK, in some cases, LMP can 
induce MOMP in a Bid-independent manner; cathepsins or 
FIGURE 1 | From lysosomal membrane permeabilization (LMP) to cell death through mitochondrial outer membrane permeabilization (MOMP). LMP is a process in 
which intralysosomal content (mostly cathepsins but also ROS) is leaked to the cytoplasm. Massive disruption of lysosomes induces cell death by necrosis, but 
selective LMP can induce apoptosis by MOMP. Cathepsins can promote, on the one hand, the cleavage of the pro-apoptotic protein Bid; and on the other hand, 
the translocation of Bcl-2-associated killer (BAK) and BAX to the outer mitochondrial membrane (OMM) where they form pores. Truncated Bid (tBid) can itself form 
pores to the OMM but can also activate BAK/BAX. These two processes can induce apoptosis, via release of cytocrome c and in a caspase-dependent way or 
independently of caspases. A positive feedback loop exists given that caspases and cathepsins are also inducers of LMP.
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stress stimuli can directly activate the proteins BAX and/or BAK 
(82, 83). After their activation and translocation to the mito-
chondria, BAX and BAK make pores at the OMM. This permits 
the translocation of numerous molecules bigger than 100 kDa, 
without inducing membrane rupture leading to apoptosis 
(84–86). Furthermore, cathepsin B has a major role in linking 
LMP to MOMP via the generation of lipid mediators, such as 
arachidonic acid that induces MOMP (87). Alternatively, other 
than ROS and cathepsins, there is a large list of agents capable 
of inducing this mitochondrial membrane permeabilization, 
such as sphingolipids, phospholipase A2, etc. (64). Some of these 
stimuli, like the pro-apoptotic proteins or caspases, are derived 
from mitochondria, suggesting that there is a positive feedback 
loop: mitochondrial damage also induces LMP (Figure 1).
In addition, the mechanism by which cathepsins are released 
from the lysosomes is not yet clear. There are three possible 
hypotheses: (i) through the rupture of the lysosomal membrane, 
(ii) through specific pores, or (iii) by special transporters. In an 
attempt to find which of the three hypotheses is valid, fluorescently 
labeled dextran molecules of different sizes were used. When 
inducing LMP, it was shown that only small molecules (size of 
10 kDa) were released to the cytoplasm in most of the cells. In 
almost half of the cells, 40-kDa molecules were redistributed to 
the cytoplasm, and molecules larger that 70 kDa remained inside 
lysosomes. Based on the fact that cathepsins are relatively small 
proteins, around 40 kDa in size, it is inferred that cathepsins are 
among these released molecules. Furthermore, the low intralyso-
somal pH was maintained, suggesting that lysosomes were still 
active (88). However, it is still not enough to rule out any of the 
possible mechanisms.
Until now, several explanations may account for the higher 
vulnerability to LMP of cancer cell lysosomes. Since lysosomes 
are relatively large in cancer cells (89), one possibility would be 
that they are more prone to inducing cell death than lysosomes 
with normal sizes (90). Another possibility lies in the observation 
that cancer cells have higher metabolic rates. This is accompanied 
by an elevated turnover of proteins that contains iron, leading 
to iron accumulation in the lysosomes. Subsequently, these lys-
osomes will undergo an iron-mediated predisposition to a ROS-
induced LMP (91). In other words, a characteristic of cancer 
cells is the increased levels of ROS, which is associated with an 
amplified release of cathepsins from the lysosomes. Since cancer 
cells appear to be more susceptible to LMP, its induction will 
eventually facilitate cancer cell death (92).
Autophagy and Mitophagy
Macroautophagy is a process in which intracellular proteins or 
organelles are degraded in the lysosomes. Degraded products 
are then released from lysosomes and recycled into biosynthetic 
and metabolic pathways. Through the elimination of those dam-
aged components, autophagy basically provides quality control 
over proteins and organelles, as well as sustains mitochondrial 
metabolic function and energy homeostasis (93). More than 
30 proteins coordinate the autophagic processes, generating 
autophagosomes from essentially all membrane sources from 
the cell. Autophagy-related genes (Atg) control the processes of 
autophagy. The products of Atg genes are regulated by nutrients 
(mTOR), energy [AMP-activated protein kinase (AMPK)], and 
stress [hypoxia-inducible factor (HIF)], which can turn the path-
way on and off (94). Nevertheless, autophagy may also induce cell 
FIGURE 2 | Mitochondria and lysosomes downstream mammalian target of 
rapamycin complex I (mTORC1). Under nutrient rich conditions, active 
mTORC1 can induce the transcription of different genes involved in 
mitochondrial function and biogenesis. At the same time, it can repress TFEB 
transcription factor, which is the main responsible for transcription of genes 
involved in lysosomal and mitochondrial biogenesis, autophagy, etc.
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death, known as autophagic cell death (ACD). This specifically 
occurs when chromatin condensation is absent (95).
Autophagy’s role in cancer is still not clear. Some cancers 
are dependent on autophagy for survival and other cancers 
use autophagy as a mechanism of cell death. In some models, 
autophagy suppresses cancer initiation by evading the toxic accu-
mulation of damaged organelles, specifically mitochondria. On 
the short run, this helps in limiting oxidative stress. On the long 
run, it restricts chronic tissue damage and oncogenic signaling. 
So, in this context, autophagy stimulation might help suppress 
and/or prevent cancer initiation. Though, other cancers depend 
on autophagy for survival. In order to fit the high metabolic needs 
of growth and proliferation, cancers (such as the pancreatic) 
use autophagy-mediated recycling to their own advantage (96). 
Hence, inhibiting autophagy in this case could be an insight for 
selective cancer therapy, since these tumors are more dependent 
on autophagy than normal tissues (93).
Degradation of entire organelles can also occur: mitophagy 
(mitochondria), reticulophagy (endoplasmic reticulum), 
lipophagy (lipid droplets), peroxophagy (peroxisomes), and 
xenophagy (microbes). Mitophagy or autophagy of mitochondria 
is required to eliminate dysfunctional mitochondria to maintain 
appropriate metabolic and cell survival signals (97). Here, we will 
focus only on mitophagy, a key process for the control of mito-
chondrial quality. It is of substantial importance for the normal 
development of cells and tissues. The most studied mechanism 
of mitophagy initiation involves the E3 ubiquitin ligase Parkin 
and the serine–threonine kinase PINK1 (PTEN-induced putative 
kinase 1). PINK1 is a mitophagy receptor found at the OMM 
that accumulates when mitochondria are damaged or undergo 
any stress leading to mitochondrial membrane potential loss. 
This PINK1 accumulation at the OMM recruits Parkin from the 
cytosol. Parkin ubiquitinates proteins at the OMM. These ubiquit-
inated proteins are recognized by p62, also known as Sequestrome 
1 (SQSTM 1). P-62 binds to LC3/Atg8 and takes p62-containing 
aggregates to the autophagosome to be degraded (98).
In the recent years, the role of mitophagy in cancer has been 
extensively reviewed. Parkin is frequently genetically inactivated 
in cancer. Although certain cancers, such as sarcomas and uter-
ine cancer, have amplifications in PARK2 gene, the majority of 
tumors with lesions in PARK2, including ovarian, breast, and 
lung cancers, harbor deletions or loss of function mutations. This 
is mainly because the PARK2 gene is found on a fragile location 
on chromosome 6 (99). Parkin has been evidenced to control 
cell cycle regulators, such as cyclin-dependent kinases (CDKs) 
and cyclins, promoting acceleration of cell cycle progression. 
It can also lead to the accumulation of damaged mitochondria 
and elevated ROS production, triggering DNA damage and 
tumorigenesis (100). In addition, PINK1 and Parkin can promote 
apoptosis through targeting and ubiquitinating anti-apoptotic 
Mcl-1 leading to degradation; they operate as molecular switches 
by dictating cell fate as a response to diverse cellular stresses 
(101, 102). However, mitophagy can happen in cancer cells 
without active Parkin, known as mitophagy-independent Parkin 
function. OMM proteins, such as FUNDC1, BNIP3, and NIX, 
are autophagy receptors, independently of ubiquitinization. 
Furthermore, other factors such as the phospholipid cardiolipin 
can induce mitophagy, as well as ubiquitin ligases, such as 
SMURF1 and MAPL (103–105).
During hypoxia, HIFs can induce mitophagy through the 
transcription of NIX and BNIP3. In addition to its transcrip-
tional activation by HIF-1, FoxO3A, PPARα, RB/E2Fs, NF-κB, 
oncogenic Ras, and p53 also transcriptionally regulate BNIP3 
(103), while NIX is transcriptionally regulated by HIF-1 and 
p53 (106, 107). Upon hypoxia or high oxidative phosphoryla-
tion, the small GTPase Rheb translocates to the OMM, where 
it can interact with BNIP3 and NIX to induce mitophagy, 
resulting in mTOR inactivation (108, 109). The role of BNIP3-
dependent mitophagy in cancer presents some controversies. 
BNIP3-dependent mitophagy is required to limit mitochondrial 
mass and ROS levels in growing tumors; its loss leads to HIF-1α-
dependent increases in tumor growth and increased progression 
to metastasis (110). However, other studies show that BNIP3 has 
a pro-tumorigenic role; its inactivation reduced cell migration 
and its upregulation suppressed the mTOR/S6K1 pathway. It is 
hypothesized that the dual role of BNIP3 can be explained by 
alternative splicing or variable transcriptional regulation via 
transcription factor Sp3 (111, 112).
Contrary to BNIP3, the role of NIX and FUNDC1 in tumor 
progression remains relatively unknown, requiring further 
investigation. They can induce mitophagy under hypoxic condi-
tions (113). However, their role in cancer mitophagy is still to be 
raveled (107).
Signaling Pathways Involved in the 
Mitochondria–Lysosomal Crosstalk
As shown in Figure 2, the master regulator of cell growth and 
metabolism mTORC1 and proteins of the same pathway are 
the main linkers of mitochondria and lysosomes. As described 
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earlier, under nutrient-rich conditions, mTORC1 is activated at 
the lysosomal surface. mRNA translation of many genes occurs, 
via the activation and repression of S6K and 4E-BP1, respectively. 
Among the genes repressed by 4E-BP are TFAM, Complex I and 
Complex V of the mitochondria, regulating mitochondrial activ-
ity and biogenesis (114).
On the other hand, under starvation conditions, mTORC1 is 
inhibited and TFEB positively regulates the expression of lysoso-
mal and autophagy genes, as well as the expression of PGC-1α. 
PGC-1α coactivates numerous biological programs in diverse 
tissues; it is a key regulator of lipid metabolism (115), but also it 
promotes mitochondrial biogenesis (30). Notably, TFEB activa-
tion can be induced by mitophagy as well, in an attempt to induce 
mitochondrial biogenesis after eliminating malfunctioning or 
damaged ones. The mechanism of TFEB activation by mitophagy 
is different than that under starvation conditions. Parkin 
promotes TFEB nuclear translocation, inducing lysosomal and 
mitochondrial biogenesis (98). In addition to that, upon energy 
depletion, AMPK is activated. AMPK serves as a fuel gage as it 
becomes active when ATP/AMP ratio is low, thus maintaining 
energy homeostasis (116). AMPK inhibits mTORC1 by the direct 
phosphorylation of Raptor, a molecule of the mTORC1 complex. 
This explains why AMPK has been considered as a tumor suppres-
sor. AMPK activation is essential for increased mitochondrial bio-
genesis under glucose-limited conditions, since AMPK activation 
increases the expression of PGC-1α and TFAM (117) (Figure 2).
When mTORC1 is active, there is an increase of mitochondrial 
biogenesis. This increase in mitochondrial biogenesis will result 
in a gain of ATP production capacity, a mandatory energy source 
for translation (114). By contrast, mitochondrial biogenesis 
induced by AMPK is an attempt to accelerate ATP generation, for 
restoring its level in favor of cell survival. This takes place under 
limiting nutrient availability or metabolic stress (118).
To further emphasize the link between mitochondria and 
lysosomes, it has been shown that mTOR not only binds to 
lysosomes (when mTORC1 is activated when amino acids are 
present) but it can also be associated with MOM. This is needed 
to integrate different stress signals that affect the function of 
mitochondria and regulate a checkpoint implicating p70S6K, 
one of the well-known targets of mTORC1 (119). Recent studies 
link mitochondrial dynamics to the equilibrium between nutri-
ent supply and energy demand, suggesting variations in mito-
chondrial architecture as an adaptive mechanism to metabolic 
demands (120).
Another important regulator is Rab7, which belongs to the 
RAB family, a RAS-related group of GTP-binding proteins. 
This family of proteins includes important regulators of vesicle 
transportation and is localized in certain intracellular compart-
ments (121). Numerous studies indicate that Rab7 plays major 
roles in controlling maturation of endosomes and transportation 
to lysosomes, as well as in phagocytosis, retromere regulation, 
cytoskeleton regulation, autophagy, and mitophagy (122, 123).
Normally, Rab7 is found on late endosomes and this acquisi-
tion is complemented by Rab5 loss, an early endosome marker. 
The switch from Rab5 to Rab7 is a process in which both pro-
teins cooperate sequentially and dynamically. This determines 
Rab5 recruitment to early endosomes and Rab7 recruitment 
and Rab5 loss at late endosomes (124–126). Late endosomes 
can fuse with lysosomes and other late endosomes, only if the 
Rab5 to Rab7 switch is accompanied by variations in fusion 
and tethering machinery. This allows direct contact in between 
organelles (127).
Other than being a marker of late endosomes, Rab7 is vital 
for mitophagy (Figure 3), as it is a downstream effector of Parkin 
(128). This occurs with the help of TBC1D15/17 and Fis1. The 
first protein belongs to the TBC family (Tre2/Bub2/Cdc16), 
having RabGAP functions (129, 130), while the latter is a fission 
protein with cytosolic N-terminal, bound to the OMM at its 
C-terminal (131, 132). In the absence or inactivity of TBC1D15, 
membranes that are labeled with LC3 excessively accumulate and 
lose their cargo orientation. In turn, membrane tubules are sent 
along microtubule tracks away from the mitochondria. Therefore, 
it is inferred that, during mitophagy, TBC1D15 binds to Fis1 and 
LC3 inducing Rab7 activity, which leads to the shaping of the 
autophagosome isolation membrane. In fact, besides promoting 
microtubule-associated trafficking and autophagosomal mem-
brane growth, the activity of Rab7 is affected by TBC1D15/17 
activity, inducing autophagosomal membrane expansion to cor-
rectly surround the mitochondria (128). This indicates that, in 
case of Parkin-regulated mitophagy, Rab7 is essential for expand-
ing LC3-labeled isolation membranes. Otherwise, inactive Rab7 
might help in mediating the release of LC3-positive membranes 
from microtubules (133). The above-described model substan-
tially differs from the well-known role of Rab7 in controlling 
autophagosome maturation and fusion with lysosomes (134, 135). 
In addition, it was shown an increase in the interaction between 
Rab7 and Mitofusin2 (MFN2), a mitochondrial fusion-related 
protein, as a response to starvation. This suggests the contribu-
tion of Rab7 during autophagosomal membrane maturation, as 
an adaptor protein used by MFN2 (136). Hence, Rab7 has a dual 
role in mitophagy, i.e., autophagosome formation and maturation.
As shown in Figure 3, this multifaceted small GTPase also 
participates in other important processes in the cell, such as in 
apoptosis and the activation of stress response pathways (137). 
One of these pathways is the mTORC1 pathway, through which 
mTORC1 moves toward a Rab7-containing compartment in the 
presence of amino acids (138). The direct interaction between 
Rab7 and mTOR has been proved by co-immunoprecipitation 
experiments (139). During bioenergetic stress, several groups 
showed a Rab7-dependent lysosomal crosstalk with apoptosis 
and its regulatory machinery, i.e., intramitochondrial recruit-
ment of endolysosomes mediates apoptosis. As explained 
before, in the presence of growth factors, mTOR and AKT are 
activated initiating downstream signaling cascades. Under these 
conditions, nutrient transporter proteins facilitate the import 
of extracellular nutrients, supporting cellular bioenergetics by 
supplying the mitochondria with metabolic substrates. In this 
case, one important apoptotic mediator, cytochrome c is retained 
at the mitochondrial intermembrane. When there is nutrient 
starvation, these same signaling cascades are silenced, and genes 
are no longer transcribed. Existing transporters are trafficked to 
the lysosomes by Rab7, where they are degraded and removed 
from the cell. This decrease in cellular bioenergetics results in 
substrate limitation at the mitochondrial site, loss of homeostasis, 
FIGURE 3 | Multifaceted Rab7. Rab7 has distinct roles in numerous vital cellular functions: phagosome formation and maturation, lysosomal degradation, 
autophagy, mitophagy, apoptosis, etc.
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and cytochrome c release, eventually leading to apoptosis. This 
process can be rescued by inhibiting Rab7. For example, trans-
porter proteins destined to enter the endocytic pathway and be 
trafficked to lysosomes for degradation, instead, are recycled and 
re-expressed on the cellular surface. As a result, extracellular 
nutrients are continually imported, and cellular bioenergetics is 
maintained, as well as mitochondrial homeostasis, in the absence 
of growth factors (140). In this case, Rab7 has a proapoptotic 
function, by limiting cell autonomous uptake of extracellular 
nutrients (141).
In cancer, the specific role of Rab7 is not fully understood. 
In the literature, Rab7 has been depicted as either a tumor sup-
pressor (68, 141, 142) or a proto-oncogene (143–146), depending 
on tumor type, morphology, and metastatic and invasive abilities 
(122) (Figure 3). Particularly, synergy between HSP90 inhibition 
and Rab7 depletion decreases EGFR and Her2 levels, through 
proteasomal degradation, and promotes apoptosis, depicting 
a proto-oncogenic role of Rab7 (147, 148). During melanoma 
development, Myc is activated, inducing Rab7 overexpression. 
Subsequently, Rab7 expression is downregulated to support the 
invasive and metastatic characteristics of melanoma (145). More-
over, the knockdown of Rab7 in prostate cancer cells led to the 
overexpression of c-Met, a protein involved in the promotion of 
cell invasion and metastasis (149).
In fact, since Rab7 is mainly accountable for intracellular 
trafficking, which is linked to the metastatic/invasive ability of 
tumors, and the degradation of many organelles and molecules, 
such as adhesion molecules and signaling receptors, it is a key 
regulator in governing cellular homeostasis. Certainly, Rab7 is a 
central molecule of cell survival, differentiation, and apoptosis. 
Current data suggest that the regulation of Rab7 expression 
and activity can reduce several pathologies, such as cancer 
(122). Of course, further work will be needed to investigate this 
possibility.
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THERAPEUTIC APPROACHES IN CANCER 
TREATMENT
Cancer cells exhibit a significant number of metabolic alterations 
associated with mitochondria, lysosomes, and other sub-cellular 
organelles. These organelles exhibit a number of deregulations, 
which have been identified as potential drug targets for successful 
rational drug design and therapy. For their involvement in bio-
energetics, redox balancing, and survival, targeting mitochondria 
for therapeutic benefits is already in practice to induce apoptotic 
cell death (150, 151). In addition, the advances in lysosome 
research have highlighted their importance for degradation, 
signaling pathways, and cell death in pathophysiological condi-
tions; thus, targeting lysosomes has also been considered a new 
therapeutic strategy for cancer treatment (76).
In this review, we highlighted the interplay between lysosomes 
and mitochondria and its importance in cell fate. We propose 
that targeting this crosstalk between both organelles might be 
crucial for fighting cancer.
Inducing LMP
Indeed, many compounds are described to induce LMP and subse-
quent cell death in various human cancer cells and animal models 
but are not in clinical use (152, 153). Besides, little is known about 
the endogenous inhibitors preventing LMP and which mecha-
nisms suppress lysosomal hydrolases in the cytoplasm of both, 
normal and cancer cells. Inducing LMP-dependent death could 
activate self-destructive processes in tumor cells, particularly if 
those cells were dependent on such inhibitors. Future investiga-
tions are needed to clarify if antagonists of LMP inducers may be 
useful synergistically with the current clinical treatments (64).
Interestingly, a minimally invasive anticancer modality called 
Photodynamic therapy (PDT) is able to induce LMP. PDT 
combines a drug (a photosensitizing agent) with a precise light 
wavelength, inducing ROS generation and killing tumor cells 
(154). The location where the photosensitizing agent is directed 
is very important, as it determines where the primary damage 
occurs. Usually photosensitizing agents accumulate either in 
mitochondria, inducing rapid apoptosis, or in lysosomes, induc-
ing LMP and subsequent cell death (64). To date, PDT is used for 
treating or relieving the symptoms of non-small cell lung cancer 
patients and esophageal cancer patients. PDT still presents some 
limitations, since only tumors on the skin or just underneath it, 
or in internal organ linings and/or cavities can be treated with 
this technique. But it cannot be used for treating large tumors or 
metastasis (155–158).
Targeting Mitophagy
Targeting mitophagy as an approach to adjuvant chemotherapy 
has been already questioned by Chourasia et al. (107). They claim 
that the deletion or inhibition of Parkin and BNIP3 induces the 
Warburg effect, thus favoring tumorigenesis. Nevertheless, acute 
chemical inhibition of mitophagy is still an effective approach for 
advanced tumors that have switched to glycolytic metabolism 
but still depend on mitochondria for further metabolic purposes 
(107). Of course, this approach has still to be therapeutically 
tested.
Targeting Common Effectors between 
Mitochondria and Lysosomes
Other than targeting processes in which mitochondria and 
lysosomes are linked, inhibitors of their main common effectors, 
i.e., AMPK or mTOR have been already tested for cancer therapy. 
The role of AMPK in cancer cells is paradoxical. It can be a tumor 
suppressor, but can also promote tumorigenesis, stimulating cell 
survival in glucose-deficient situations and preserving metabolic 
homeostasis (117). Despite that, the use of the anti-diabetic 
drug Metformin, non-steroidal anti-inflammatory drugs, such 
as Aspirin, AICAR, and some natural products known to be 
AMPK activators, has shown to decrease tumorigenesis in animal 
models and cancer cell lines (159, 160). In addition, preclinical 
evidence suggests that Metformin appears to prevent the prolif-
eration and growth of certain tumor types. There are currently 
more than 100 ongoing or clinical studies assessing the role of 
metformin in the therapy cancer (161, 162). It is well understood 
that metformin targets the mitochondrial complex I. However, it 
has been suggested that metformin could directly influence the 
V-ATPase activity of lysosomes (163), so this fact further sup-
ports the importance of lysosomal–mitochondrial link for cancer 
treatment.
Targeting mTOR may be crucial for cancer treatment not only 
for cell growth and proliferation but also for reversing the Warburg 
effect characteristic of tumor cells (164). At the molecular level, 
mTORC1 inhibition may induce mitochondrial biogenesis via 
PGC-1α, as well as repression of transcription of mitochondrial 
genes via 4E-BP1 (114) depending on the model. mTORC1 
inhibition induces lysosomal biogenesis and also initiates several 
feedback loops to upstream pathways, activation of which might 
be beneficial for the survival of tumor cells and metastasis. The 
best-known mTOR inhibitor is Rapamycin, which does not 
inhibit directly mTOR’s kinase (catalytic) activity. Together with 
FKBP12, it binds specifically to mTORC1 (at high concentrations 
also to mTORC2). The binding occurs next to the kinase active 
site. Consequently, it can only inhibit a number of mTORC1 
functions. Given this, and the importance of mTOR for cancer, 
several groups have developed other inhibitors to target mTOR’s 
catalytic subunit (PP242, Torin 1 and 2, etc.). As reviewed by Xie 
and al., some mTOR inhibitors are already in clinical trials for 
treating cancer (165). Despite that, the utility of such inhibitors in 
oncology still appears to be limited, given that autophagy can be 
induced by mTOR inhibition, thus promoting cancer cell survival.
As reviewed above, RAB7 is a prominent target for cancer 
treatment (143). In addition, there are already drugs that target 
RAB7. It has been shown that liensinine, a major isoquinoline 
alkaloid that inhibits RAB7A recruitment to lysosomes, not 
autophagosomes. In this way, autophagy/mitophagy is impaired, 
enhancing the efficacy of chemotherapy in breast cancer cell 
lines (166).
Using Nanomedicine for Inducing Cell 
Death
Nanotechnology is the science of controlling matter, at the molec-
ular level, to generate devices with new biological, physical, and/
or chemical characteristics. It is in the spotlight of therapeutic 
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innovation. The use of nanomaterial is a particularly promising 
tool not only to improve the diagnosis but also to generate new 
cancer treatments and overcome the drawbacks of traditional 
therapies (167). In particular, the discovery of gold nanorods 
(GNRs) has provided a new method to induce apoptosis specifi-
cally in cancer cells, while posing a negligible impact on normal 
cells. They are able to induce apoptosis in cancer cells through 
lysosomal permeability, as indicated by cathepsin D release, and 
a decrease in mitochondrial membrane potential (168). These 
findings are promising for the further implementation of nano-
technology at the clinical practice.
CONCLUSION AND FUTURE 
PERSPECTIVES
Intracellular organelles, as thoroughly discussed, are the major 
players of cellular networks. Even though physical contact among 
these organelles was exhaustively described through out the 
years, research is now shifting toward revealing the crosstalk of 
these entities on the signaling levels, as well as their physiological 
relevance. Mainly, organelle interactions are needed for metabo-
lite exchange, and more interestingly, in membrane dynamics, 
intracellular organelle distribution, and the assembly of dynamic 
signaling platforms depending on cellular requirements.
In tumors, cells significantly display metabolic aberrations, 
associated directly or indirectly with mitochondria and lys-
osomes. These anomalies promote cancer cell growth and sur-
vival, while exhibiting distinctive properties that render cancer 
cells vulnerable to specific anticancer agents. In other words, the 
deregulation of these organelles in cancer cells as compared to 
their counterparts in healthy cells is a main reason for promis-
ing targeted drug therapy. Though substantial advancement has 
been made regarding elucidating the role of these anomalies in 
oncogenesis and chemotherapy-resistance, a better interpretation 
of the main pathophysiological differences between organelles of 
normal and tumor cells can undoubtedly compliment the efforts 
to improve selective targeted anti-cancer agents.
Lysosomes and mitochondria have common regulators and 
can physically interact to maintain cell homeostasis or induce 
cell death. However, in cancer everything becomes a paradox; all 
of the processes in which lysosomes and mitochondria interact, 
except for LMP, and the common regulators (mTOR, AMPK, 
Rab7, etc.) present a dual role: on the one hand, they can pro-
mote tumorigenesis and, on the other hand, they can induce cell 
death. The relative contribution of these pathways would depend 
on tumor type, state, metastatic ability, microenvironment, 
metabolic reprograming, etc. This reflects the importance of 
these two organelles for cancer treatment. New potential targets 
have been proposed, i.e., PGC-1α, TFEB, Rab7, etc. However, will 
these targets overpass the problem of having a paradoxical role in 
cancer treatment? As we have seen already, every case needs to 
be studied independently, in order to predict whether the treat-
ment would be beneficial or not. This is known as personalized 
medicine.
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This paper describes a new metabolic function of CDK4 in the regulation of 
AMPK, and its implications, specially in muscle tissue. Here, it is shown that CDK4 
can repress AMPK by phosphorylating its α2 subunit in mouse embryonic fibroblasts 
and in mouse muscles. This results in an increase of anaerobic glycolysis and in a 
repression of fatty acid oxidation. Thus, CDK4 -/- mice showed increased oxidative 
metablism and exercice capacity, in an AMPK-dependent manner. This represents a 
novel mechanism by which CDK4 is promoting anabolism by blocking a catalytic 
process (fatty acid oxydation) through AMPK phosphorylation.  
 I contributed to demonstrate this finding by testing the exercise capacity of 
different mice strains, as well as by analyzing the activation of AMPK in muscle 
tissues from the same mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 106 
 
 
 
 
 
 
 
 
 
 
 
 
  
Article
CDK4 Phosphorylates AMPKa2 to Inhibit Its Activity
and Repress Fatty Acid Oxidation
Graphical Abstract
Highlights
d CDK4 promotes glycolysis and inhibits fatty acid oxidation
d CDK4 inhibits AMPK activity through direct phosphorylation
of the AMPK-a2 subunit
d Mice treated with CDK4 inhibitor have AMPK-dependent
increased oxidative metabolism
Authors
Isabel C. Lopez-Mejia,
Sylviane Lagarrigue, Albert Giralt, ...,
Benoıˆt Viollet, D. Grahame Hardie,
Lluis Fajas
Correspondence
lluis.fajas@unil.ch
In Brief
Lopez-Mejia et al. show in this study that
CDK4, a protein that is usually involved in
the control of cell division, is an important
regulator of the energy balance of the cell
through the direct inhibition of the activity
of AMPK, which is a major regulator of
energy consuming processes.
Lopez-Mejia et al., 2017, Molecular Cell 68, 336–349
October 19, 2017 Crown Copyright ª 2017 Published by Elsevier Inc.
https://doi.org/10.1016/j.molcel.2017.09.034
Molecular Cell
Article
CDK4 Phosphorylates AMPKa2 to Inhibit
Its Activity and Repress Fatty Acid Oxidation
Isabel C. Lopez-Mejia,1,2 Sylviane Lagarrigue,2 Albert Giralt,1 Laia Martinez-Carreres,1 Nade`ge Zanou,2,3
Pierre-Damien Denechaud,1,2 Judit Castillo-Armengol,1 Carine Chavey,4 Meritxell Orpinell,2 Brigitte Delacuisine,1,2
Anita Nasrallah,1 Caterina Collodet,5,6 Lianjun Zhang,7 Benoıˆt Viollet,8,9,10 D. Grahame Hardie,11 and Lluis Fajas1,2,12,*
1Center for Integrative Genomics, University of Lausanne, 1015 Lausanne, Switzerland
2Department of Physiology, University of Lausanne, 1005 Lausanne, Switzerland
3Institute of Sport Sciences, University of Lausanne, 1015 Lausanne, Switzerland
4IGMM, Universite´ de Montpellier, UMR 5535 CNRS, 34293 Montpellier, France
5Nestle´ Institute of Health Sciences SA, EPFL Innovation Park, 1015 Lausanne, Switzerland
6E´cole Polytechnique Fe´de´rale de Lausanne, School of Life Sciences, 1015 Lausanne, Switzerland
7Ludwig Center for Cancer Research, University of Lausanne, 1066 Epalinges, Switzerland
8Institut Cochin, INSERM U1016, Paris, France
9CNRS, UMR 8104, Paris, France
10Universite´ Paris Descartes, Sorbonne Paris Cite´, Paris, France
11School of Life Sciences, University of Dundee, Dundee, Scotland, UK
12Lead Contact
*Correspondence: lluis.fajas@unil.ch
https://doi.org/10.1016/j.molcel.2017.09.034
SUMMARY
The roles of CDK4 in the cell cycle have been exten-
sively studied, but less is known about the mecha-
nisms underlying the metabolic regulation by CDK4.
Here, we report that CDK4 promotes anaerobic
glycolysis and represses fatty acid oxidation in
mouse embryonic fibroblasts (MEFs) by targeting
the AMP-activated protein kinase (AMPK). We also
show that fatty acid oxidation (FAO) is specifically
induced by AMPK complexes containing the a2 sub-
unit. Moreover, we report that CDK4 represses FAO
through direct phosphorylation and inhibition of
AMPKa2. The expression of non-phosphorylatable
AMPKa2 mutants, or the use of a CDK4 inhibitor,
increased FAO rates in MEFs and myotubes. In addi-
tion, Cdk4!/! mice have increased oxidative meta-
bolism and exercise capacity. Inhibition of CDK4
mimicked these alterations in normal mice, but not
when skeletal muscle was AMPK deficient. This
novel mechanism explains how CDK4 promotes
anabolism by blocking catabolic processes (FAO)
that are activated by AMPK.
INTRODUCTION
Promitotic signals such as growth factors increase the levels of
D-type cyclins (cyclins D1, D2, and D3), which bind and activate
CDK4/6 to trigger the phosphorylation of the retinoblastoma-
associated protein pRB and other pocket proteins (i.e., p107
and p130) (Malumbres and Barbacid, 2005). Rb phosphorylation
enables release of the E2F transcription factors that promote the
transcription of genes necessary for the replication of the
genome (Malumbres and Barbacid, 2005). The role of CDK4 in
the regulation of cell-cycle progression has been extensively
studied in eumetazoan organisms, and alterations in CDK4 activ-
ity have been associated with cancer development and progres-
sion (Malumbres and Barbacid, 2001, 2009; O’Leary et al., 2016).
For example, the R24Cmutation, which is used in this study, ren-
ders CDK4 resistant to inhibition by INK4 inhibitors and has been
reported to confer a genetic predisposition to melanoma (Rane
et al., 1999, 2002; Wo¨lfel et al., 1995).
Cell division requires substantial amounts of ATP, and
numerous metabolic intermediates to support biosynthesis of
essential molecules, such as lipids and nucleic acids. Prolifer-
ating cells preferentially use anaerobic glycolysis to generate
large amounts of ATP and provide metabolic intermediates to
support cell growth (Jones and Thompson, 2009). Growing evi-
dence demonstrates that regulatory crosstalk exists between
metabolic pathways and regulators of cell-cycle progression.
Mitochondrial respiration and metabolism are coordinated with
cell-cycle progression by cell-cycle regulators (Lopez-Mejia
and Fajas, 2015; Salazar-Roa and Malumbres, 2016). Our labo-
ratory and others have demonstrated that CDK4 is one such
‘‘metabolic’’ cell-cycle regulator (Blanchet et al., 2011; Icreverzi
et al., 2012; Lagarrigue et al., 2016; Lee et al., 2014). Indeed,
we have previously shown that CDK4 regulates oxidative meta-
bolism via the E2F1 transcription factor in muscle and brown
adipose tissue (Blanchet et al., 2011) and promotes the insulin-
signaling pathway in mature adipocytes (Lagarrigue et al.,
2016). Overall, the participation of cell-cycle regulators in the
control of energy homeostasis occurs mainly through the activa-
tion of anabolic processes (Aguilar and Fajas, 2010). The AMP-
activated protein kinase (AMPK) is a central inhibitor of such
anabolic processes andmight therefore be repressed by cell-cy-
cle regulators. Under conditions of low cellular energy, AMP and
ADP are increased relative to ATP, and this is sensed by AMPK.
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AMPK exists as heterotrimeric complexes composed of a cata-
lytic subunit (a) and two regulatory subunits (b and g); the a and b
subunits exist as two isoforms (a1/a2 and b1/b2, encoded by the
PRKAA1/2 and PRKAB1/2 genes), and the g subunit exists as
three isoforms (g1/g2/g3, encoded byPRKAG1/2/3), thus gener-
ating up to 12 combinations of heterotrimeric complex (Carling,
2004; Grahame Hardie, 2016; Hardie et al., 2012; Ross et al.,
2016b). AMPK is regulated both by phosphorylation/dephos-
phorylation and by the relative cellular concentrations of adenine
nucleotides, with the two mechanisms being intimately linked.
First, the upstream kinases LKB1 (liver kinase B1) (Hawley
et al., 2003; Shaw et al., 2004; Woods et al., 2003) or CaMKK2
(calmodulin-dependent kinase kinase-2/-b) (Hawley et al.,
2005; Hurley et al., 2005; Woods et al., 2005) activate AMPK
through the phosphorylation of Thr172 of the a subunit (Hawley
et al., 1996). Second, AMPK is regulated through the competitive
binding of ATP or AMP and ADP at up to three sites on the g sub-
unit. When cellular energy levels are low, binding of AMP or ADP
enhances Thr172 phosphorylation by LKB1 and inhibits Thr172
dephosphorylation by protein phosphatases, while binding of
AMP (but not ADP) causes further allosteric activation (Ross
et al., 2016a). Metabolic stresses that reduce intracellular ATP
concentrations are therefore the best-characterized activators
of AMPK, although it has recently been shown that glucose
deprivation can activate AMPK by an adenine nucleotide-inde-
pendent mechanism (Zhang et al., 2017). Once activated,
AMPK promotes catabolic pathways that generate ATP (e.g.,
fatty acid oxidation [FAO]) while switching off anabolic pathways
and other ATP-requiring processes to restore cellular ATP levels
(Carling, 2004; Grahame Hardie, 2016; Hardie et al., 2012; Ross
et al., 2016b).
Other kinase activities that are induced by growth stimuli are
known to inhibit AMPK. This includes AKT a key effector of the
insulin/insulin growth factor 1 (IGF1)-signaling pathway that
antagonizes the AMPK pathway through phosphorylation of
AMPKa1 on Ser487 (Horman et al., 2006), or extracellular
signal-regulated kinase (ERK), which was shown to phosphor-
ylate the same residue (Lo´pez-Cotarelo et al., 2015). The
cyclic-AMP-dependent protein kinase (PKA) also phosphory-
lates and negatively regulates AMPK (Djouder et al., 2010;
Hurley et al., 2006), and Thr481 and Ser477 on AMPKa1 are
phosphorylated by glycogen synthase kinase 3 (GSK3) (Suzuki
et al., 2013), following a ‘‘priming’’ phosphorylation of Ser487
by AKT.
Muscle function requires a finely tuned balance between
anabolism and catabolism in order to respond to physiological
challenges within the available energy supply. AMPK is a
major coordinator of energy intake and utilization in exercising
muscle (Hoffman et al., 2015), functioning to enhance energy
availability. Among other effects, AMPK promotes FAO to
maintain ATP cellular stores, although the exact role of AMPK
in regulation of muscle FAO has been controversial (Mounier
et al., 2015).
In this study, we sought to determine whether CDK4 partici-
pates in energy homeostasis by inhibiting catabolic processes.
Themechanisms bywhich the activity of AMPK is inhibited under
anabolic conditions, such as during cell-cycle progression or in
resting muscle, have not been thoroughly studied. We report
here that CDK4 enhances anaerobic glycolysis and represses
fatty acid oxidation. Surprisingly, the AMPKa1 and a2 subunits
play distinct roles. We provide here a molecular mechanism
whereby CDK4-CycD3 complexes directly repress a2-contain-
ing complexes to inhibit FAO. We show that chemical and ge-
netic inhibition of CDK4 also promotes oxidative metabolism
in vivo, as evidenced by decreased respiratory exchange ratio
(RER) and increased exercise performance in mice lacking
CDK4 activity.
RESULTS
CDK4 Modulates FAO in an E2F1-Independent Manner
Wepreviously demonstrated that CDK4 is amajor mediator of in-
sulin signaling and therefore contributes to the positive regula-
tion of biosynthetic processes, such as fatty acid synthesis,
and the inhibition of catabolic pathways, such as lipolysis (Lagar-
rigue et al., 2016). To further investigate the contribution of CDK4
to metabolic regulation, Seahorse analyses were performed.
Cdk4R24C/R24C mouse embryonic fibroblasts (MEFs), which ex-
press a hyperactive CDK4 mutant, exhibited a significant in-
crease in anaerobic glycolysis, as measured by the extracellular
acidification rate (ECAR), whereas Cdk4!/! MEFs had impaired
anaerobic glycolysis (Figures 1A and 1B). In contrast, CDK4
activity was inversely correlated with FAO. Cdk4R24C/R24C
MEFs metabolized palmitate at a low rate, whereas Cdk4!/!
MEFs showed increased palmitate oxidation (Figures 1C and
1D). Interestingly, the effects of CDK4 on substrate use were
independent of E2F1 activity, since deletion of E2F1 in
Cdk4R24C/R24C MEFs failed to reverse the effects of Cdk4R24C
on anaerobic glycolysis or palmitate oxidation (Figures 1E–1H).
These results suggest that CDK4 controls substrate utilization
in MEFs independently of E2F1.
CDK4 Regulation of FAO Is AMPK Dependent
The decrease in FAO observed in response to constitutive acti-
vation of CDK4 is the opposite of the effect seen with AMPK acti-
vation (Fullerton et al., 2013; Hardie, 2015; Hardie and Pan, 2002;
O’Neill et al., 2014). Therefore, we analyzed the involvement of
AMPK in the CDK4-mediated regulation of FAO in MEFs. Basal
levels of phosphorylated ACC (pACC), which is a known target
and marker of AMPK activity, were decreased in Cdk4R24C/R24C
MEFs but increased 3-fold in the Cdk4!/! cells (Figures 2A,
2B, S1A, and S1B), suggesting that CDK4 antagonizes AMPK
function. Moreover, the activation of AMPK by the specific acti-
vator A769662 (Go¨ransson et al., 2007; Moreno et al., 2008) was
reduced inCdk4R24C/R24CMEFs (Figures 2A and 2B), suggesting
that CDK4 can prevent AMPK activation. In addition, increased
AMP/ATP and ADP/ATP ratios were observed in MEFs express-
ing the hyperactive CDK4mutant, which suggested a lower cata-
bolic rate (Figures 2C and 2D). Interestingly, in Cdk4!/! MEFs,
comparable pACC levels were measured both in the basal state
and upon AMPK stimulation (Figures 2A and 2B). This finding im-
plies that in the absence of CDK4, AMPK reaches its activated
state without need for any further stimulation. Likewise in
Cdk4!/! cells and wild-type (WT) MEFs treated with A769662,
we observed a significant decrease of AMP/ATP and ADP/ATP
ratios (Figures 2C–2F).
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Next, we studied the physiological relevance of the increase in
AMPK activity in Cdk4!/! cells using FAO assays in MEFs
treated with A769662 and with the non-selective AMPK inhibitor
compound C. As expected, the levels of palmitate oxidation in
WTMEFswere at least 25%higher in A769662-treated cells (Fig-
ures 2G, S1C, and S1D). However,Cdk4!/! cells did not respond
in the same assay to A769662 treatment. By contrast, AMPK
activation by A769662 in Cdk4R24C/R24C MEFs was only able to
Figure 1. CDK4 Modulates FAO in an E2F1-Independent Manner
(A–D) Cdk4+/+, Cdk4!/!, and Cdk4R24C/R24C MEFs were submitted to a glycolysis assay, during which ECAR was measured at the basal level and upon glucose
injection (A), or to a FAO assay, in which the palmitate induced OCR was measured (in % OCR compared to the basal OCR) (C). The glycolytic rate was
calculated (B). The area under curve of the palmitate induced OCR was quantified (D).
(E–H) E2f1+/+, E2f1!/!, Cdk4R24C/R24C E2f1+/+, and Cdk4R24C/R24C E2f1!/!MEFs were submitted to a glycolysis assay, during which ECAR was measured at the
basal level and upon glucose injection (E), or to a FAO assay, in which the palmitate induced OCRwasmeasured (in%OCR compared to the basal OCR) (G). The
glycolytic rate was calculated in (F). The area under curve of the palmitate induced OCR was quantified in (H).
Data are expressed as mean ± SEM.
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restore WT levels of FAO (Figures 2G, S1C, and S1D). AMPK in-
hibition in Cdk4!/! cells (albeit by the non-selective inhibitor
compound C) produced consistent results. The levels of pACC
in CDK4-null MEFs, as well as the increased FAO levels, were
restored back to basal levels (Figures S1E–S1G). Taken together,
these results suggest that CDK4 inhibits the AMPK pathway.
The AMPKa2 Subunit Is Required for Efficient FAO
in MEFs
Our results suggested that CDK4 has a negative effect on FAO
via the regulation of AMPK activity, raising the question of which
AMPK subunits contribute to this effect. Interestingly, the dele-
tion of either AMPKa subunit in MEFs resulted in increased
Figure 2. CDK4 Regulation of FAO Is AMPK Dependent
(A)Cdk4+/+, Cdk4!/!, andCdk4R24C/R24CMEFs were starved for 3 hr and then stimulated with 50 mMA769662; western blot analysis shows the A769662-induced
ACC phosphorylation in Cdk4+/+, Cdk4!/!, and Cdk4R24C/R24C cells.
(B) Quantification of pACC levels.
(C and D) SV40 immortalized cells were placed in KHB medium containing 1.5 mM carnitine and 300 mM oleate for AMP, ADP, and ATP quantification by HPLC,
and AMP/ATP (C) and ADP/ATP (D) ratios are shown.
(E and F) AMP/ATP (E) and ADP/ATP (F) ratios of WT SV40 immortalized cells treated with 50 mM A769662 for 8 hr.
(G) Cdk4+/+, Cdk4!/!, and Cdk4R24C/R24C MEFs were treated with DMSO or 50 mM A769662 for 2 hr in KHB medium and submitted to a FAO assay in which the
palmitate induced OCR was measured (in % OCR compared to the basal OCR). The area under curve of the palmitate-induced OCR was quantified.
Data are expressed as mean ± SEM. See also Figure S1.
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ECAR, indicating increased glycolysis, whereas the complete
abrogation of AMPK activity had no effect, perhaps due to
disruption of glucose transport into the cells (Figures 3A and
3B). However, although AMPKa1 knockout (KO) MEFs metabo-
lized palmitate as efficiently as control cells, both AMPKa2KO
and AMPK a1/a2 double-knockout (DKO) cells exhibited signifi-
cantly reduced levels of FAO (Figures 3C and 3D). Consistently,
A769662 failed to trigger FAO in cells lacking the a2 subunit (both
a2KO and DKO). Thus, despite being more abundant in MEFs
(Morizane et al., 2011), the AMPKa1 subunit cannot substitute
for the a2 subunit in the control of FAO, even when allosterically
activated by A769662 (Figures 3E, 3F, S1H, and S1I). In addition,
ACC phosphorylation could be detected upon stimulation with
A769662 in both AMPK a1KO and AMPK a2KO MEFs (Fig-
ure S1J), suggesting that both AMPK subunits can phosphory-
late ACC1 and therefore inhibit lipid synthesis, but only AMPKa2
can promote FAO. Taken together, these results suggest that
AMPK complexes containing a2 specifically control FAO.
CDK4 Phosphorylates the AMPK a2 Subunit
The inhibition of AMPKa2-dependent FAO could be the result of
a direct phosphorylation by CDK4. In vitro kinase assays showed
Figure 3. The AMPKa2 Subunit Is Required for Efficient Fatty Acid Oxidation in MEFs
(A–D) AMPKWT, AMPK a1 KO, AMPK a2 KO, and AMPKDKOSV40-immortalizedMEFswere submitted to a glycolysis assay, duringwhich ECARwasmeasured
at the basal level and upon glucose injection (A), or to a FAO assay, in which the palmitate induced OCR was measured (in % OCR compared to the basal OCR)
(C). The glycolytic rate was calculated (B). The area under curve of the palmitate induced OCR was quantified (D).
(E and F) AMPK WT and AMPK a2 KO SV40-immortalized MEFs were treated for 2 hr with DMSO or 50 mM A769662 for 2 hr in KHB medium and submitted to a
FAO assay in which the palmitate induced OCR was measured (in % OCR compared to the basal OCR) (E). The area under curve of the palmitate induced OCR
was quantified (F).
Data are expressed as mean ± SEM. See also Figure S2.
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Figure 4. CDK4 Phosphorylates the AMPKa2 Subunit
(A) Cyclin D3-CDK4 directly phosphorylates full-length GST-AMPK subunits in vitro (n = 3). Asterisks mark the proteins of interest.
(B) Phosphorylation score (in percentage of RB phosphorylation).
(C) CDK consensus sites in human AMPKa2 (PRKAA2).
(D) In vitro phosphorylation of WT and mutated (Ser or Thr to Ala) GST-AMPK a2 fragments (D1, 1–245 aa; D2, 246–356 aa; D3, 357–422 aa; D4, 432–522; and
D2–D3, 246–422 aa) by cyclin D3/CDK4 (n = 3).
(legend continued on next page)
Molecular Cell 68, 336–349, October 19, 2017 341
that recombinant CDK4/CycD3 phosphorylated all glutathione
S-transferase (GST) fusions of AMPK subunits tested at different
levels (Figure 4A; loading control in Figure S2A). Interestingly,
AMPKa2 and AMPKg2 were phosphorylated by CDK4 to a
greater extent than pRB, which is the canonical CDK4 substrate
(Figure 4B). Since the specificity of CDKs is partially determined
by substrate docking on the cyclin subunit, kinase assays were
also performed using recombinant CDK4/CycD1 instead of
CDK4/CycD3. The phosphorylation of the AMPK subunits was
very low under these conditions (Figure S2B), suggesting that
AMPK phosphorylation by CDK4 requires recognition by cy-
clin D3.
AMPKa2 was predicted to contain 6 CDK4 phosphorylation
sites (Thr85, Ser176, Ser345, Ser377, Thr485, and Ser529). Out of
these six potential sites, fivewere listed in the phosphoNET data-
base (Figure 4C). Site-directedmutagenesis (S > A or T > A) com-
bined with protein truncation studies (Figure S3C) identified
Ser345, Ser377, Thr485, and Ser529 as CDK4 phosphorylation sites
(Figures 4D and 4E; loading control in Figure S3D). Phosphoryla-
tion by CDK4 was completely abrogated in a full-length recom-
binant protein carrying Ser to Ala or Thr to Ala mutations at the
four CDK4 phosphosites (a2 S > A mutant), suggesting that the
four newly identified residues account for all sites phosphory-
lated on GST-AMPKa2 by CDK4 in cell-free assays (Figure 4F
and 4G; loading control in Figure S2E). The phosphorylation of
Ser377 and Thr485 has been previously described in proteomic
studies (Figure S2F) (Dinkel et al., 2011; Gnad et al., 2011; Horn-
beck et al., 2015), including cell-cycle-related phosphopro-
teomes (Daub et al., 2008; Kettenbach et al., 2011), and in liver
upon insulin stimulation (Humphrey et al., 2015), suggesting
that the regulation of AMPK by CDK4 is important for cell-cycle
progression and for the insulin signaling pathway. Moreover, we
found the four newly identified CDK4 phosphosites to be
conserved among the AMPKa2 subunits of several mammalian
species (Figure S3A), but not between the AMPKa1 and
AMPKa2 isoforms (Figure S3B).
In intact cells, AMPK is found as a heterotrimeric complex;
therefore recombinant kinase-inactive a2b2g1 complexes were
also used as substrate for recombinant CDK4-CycD3 com-
plexes. After mass spectrometry analysis, we obtained 83%
coverage of the AMPKa2 subunit and observed the phosphory-
lation in Ser176 and Ser377 (Figure 4H). A targeted analysis to in-
crease coverage showed phosphorylation of Thr485 and Ser529
with low detectability. The phosphorylation of Ser345 and
Ser377 was also detected in myotubes and muscle tissue, which
express high levels of the a2 subunit (Figures S4A and S4B;
Table S1). Interestingly, our results suggest that these phosphor-
ylations are present when AMPK is inactive, since the activating
Thr172 phosphorylation was not found in 5 out of 6 experiments
(Figures S4A and S4B). Taken together, these data indicate
that the a2 subunit of AMPK is a substrate for CDK4-CycD3
complexes in cell-free assays and that some of these phosphor-
ylations occur in vivo, in conditions in whichCDK4 is active (Blan-
chet et al., 2011; Lagarrigue et al., 2016) but AMPK is inactive.
AMPKa2 Phosphorylation Is Necessary and Sufficient
for FAO Repression by CDK4
To elucidate the functional relevance of the phosphorylation of
AMPKa2 by CDK4, we compared the regulatory activities of
AMPKa2 S > A, AMPKa2, and AMPKa1 in the context of FAO.
Transfection of AMPKDKOMEFswith the AMPKa2 S > Amutant
conferred ACC phosphorylation levels that where higher than
those observed in AMPKa1- or a2-transfected cells in the basal
state and upon stimulation by A769662 (Figure 5A). Similarly,
ectopic expression of the AMPKa2 S > A mutant in the FAO-
defective AMPK DKO MEFs rescued palmitate oxidation to a
greater extent than that observed upon transfection with WT
AMPKa2 (Figures 5B and S5A). Taken together, these results
indicate that defective targeting of AMPKa2 by CDK4 at
Ser345, Ser377, Thr485, and Ser529 results in increased AMPKa2
FAO-promoting activity.
In order to demonstrate that CDK4 represses FAOby inhibiting
AMPK activity, WT and AMPK mutant cells were treated with
CDK4 inhibitors. Inhibition of CDK4 activity by LY2835219 signif-
icantly increased FAO after 24 hr (Figures 5C and S5B) or 2 hr
(Figure S5C) of treatment. Strikingly, the CDK4 inhibitor failed
to increase FAO in both AMPK a2KO and AMPK DKO cells,
but not in AMPK a1KO cells, demonstrating that CDK4 targets
AMPKa2 to alter cellular metabolism (Figures 5C, S5B, and
S5E–S5G). The overall positive effect of CDK4 inhibition on
AMPK activity was confirmed by analyzing ACC phosphoryla-
tion. Indeed, LY2835219 treatment induced a dose-dependent
increase in the phosphorylation of ACC (Figures S5H and S5I).
This effect correlated with decreased CDK4 activity given that
phosphorylation of RB Ser780 was also reduced (Figure S5I). Of
note, increased ACC phosphorylation and increased FAO could
be detected after 2 hr of CDK4 inhibition, whereas inhibition
of RB phosphorylation required longer treatments. Moreover,
LY2835219 had an effect comparable to that of A769662, signif-
icantly decreasing AMP/ATP and ADP/ATP ratios in WT MEFs
(Figures 2E, 2F, 5D, and 5E). The use of LY2835219 suggests
that CDK4 inhibition promotes catabolic processes in an
AMPKa2-subunit-dependent manner.
We next decided to validate our findings in a more physiolog-
ical cellular model. LY2835219 treatment induced an increase in
FAO in C2C12myotubes, which are known to express high levels
of AMPKa2 (Figures S6A and S6B). In this model, CDK4 inhibi-
tion correlated with a dose-dependent increase of the
(E) Phosphorylation score (in percentage of the WT fragment).
(F) In vitro phosphorylation of full-length WT GST-AMPKa2 and full-length S > A GST-AMPKa2 by cyclin D3/CDK4 (n = 3).
(G) Phosphorylation score (in percentage of RB phosphorylation).
(H) Kinase-dead AMPK a2b2g1 trimers were used as a substrate for cyclin D3-CDK4 complex and analyzed by mass spectrometry. A graphical overview of the
sequence coverage of AMPKa2 human protein in samples displayed by MsViz is depicted. The thickness of the green bars is a function of the number of spectra
matching the sequence region, while modification sites are labeled and shown as circles with size proportional to the number of spectra matching a given
position. A truncated form of RB (hRB; 379–928 aa) was used as a positive control. A representative autoradiography for each kinase assay is shown.
See also Figure S3.
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Figure 5. AMPKa2 Phosphorylation Is Necessary and Sufficient for FAO Repression by CDK4
(A) AMPK DKO SV40-immortalized MEFs were electroporated with plasmids encoding Myc-tagged AMPK a1, Myc-tagged AMPK a2 and Myc-tagged AMPK
a2 S > A. 48 hr later, MEFs were starved for 3 hr and treated for 2 hr with DMSO or 50 mM A769662 before protein extraction. Western blot analysis shows the
A769662-induced ACC phosphorylation in transfected cells.
(B) Electroporated MEFs were submitted to a FAO assay 48 hr after transfection, in which the palmitate induced OCRwas measured (in %OCR compared to the
basal OCR). The area under curve of the palmitate induced OCR was quantified.
(C) AMPK WT and AMPK DKO SV40-immortalized MEFs were treated with DMSO or LY2835219 (1.5 mM) for 24 hr and submitted to a FAO assay, in which the
palmitate-induced OCR was measured (in % OCR compared to the basal OCR). The area under curve of the palmitate induced OCR was quantified.
(legend continued on next page)
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phosphorylation of ACC, without significant increase of AMPK
Thr172 phosphorylation (Figures S6C–S6E). The direct involve-
ment of AMPKa2 was confirmed by analyzing myotubes lacking
AMPKa2 or both the a1 and a2 subunits (Lantier et al., 2010).
Like in MEFs, FAO was impaired in the a2KO and DKO myo-
tubes. Similarly, the CDK4 inhibitor failed to increase FAO in
a2KO and DKO myotubes (Figures 5F and S6F). Rescue of
AMPK DKO myotubes with the AMPKa2 S > A mutant triggered
ACC phosphorylation levels that where higher than those
observed in AMPK a2-transfected cells both in the basal state
or upon stimulation with A769662 (Figure 5G). Similarly, ectopic
expression of the AMPKa2 S > A mutant in the FAO-defective
AMPK DKO myotubes rescued palmitate oxidation to levels
similar to those of WT myotubes (Figures 5H and S6G). Taken
together, these results in muscle cells confirm that CDK4 modu-
lates FAO through the specific inhibition of AMPKa2 activity and
that a non-phosphorylatable AMPKa2 mutant has a FAO-pro-
moting activity.
CDK4 Modulates Oxidative Metabolism and Exercise
Capacity In Vivo
Wenext investigated the contribution of CDK4 to oxidativemeta-
bolism and muscle function in vivo. Isolated mitochondria from
Cdk4!/!muscles showed increased oxygen consumption, sug-
gesting increased fatty acid oxidation capacity (Figures 6A and
6B). Increased FAO was further demonstrated by using intact
muscle fibers from flexor digitorum brevis (FDB) muscle (Fig-
ure 6C). Fibers fromCdk4!/! FDBmuscle metabolized palmitate
at a higher rate (Figures 6C and 6D) and were capable to reach a
higher maximal respiration (Figures 6C and 6E). The increased
capacity of the muscles of Cdk4!/! mice to oxidize fatty acids
suggested an overall metabolic phenotype in these mice.
Cdk4!/! mice have decreased body weight (Figure 6F).
Consistent with increased AMPK activity, Cdk4!/! mice exhibit
increased exercise capacity and decreased RER, indicating a
preference toward fat oxidation (Figures 6G–6I). An 8-day treat-
ment with LY2835219 did not trigger significant alterations in
body weight and food intake (Figures 6J and S7D), although it
induced a consistent albeit non-significant decrease in fat
mass (Figure S7C) and a modest but significant increase in exer-
cise performance (Figure 6K). A decrease in RER was observed
after 4–5 days of treatment (Figures 6L and 6M). In vivo, the inhi-
bition of CDK4 triggered an increase in the phosphorylation of
ACC in quadriceps muscle (Figures S7E and S7G), suggesting
increased AMPK activity. This was accompanied by an increase
of the slow-twitch fiber marker MyHC I (Figure S7I). MyHC I
mRNA levels were also increased in gastrocnemius and tibialis
muscles from LY2835219-treated animals (Figures S7H–S7J).
Overall, these data suggest that CDK4 is a negative regulator
of exercise capacity and whole-body oxidative metabolism
in mice.
CDK4 Regulation of Oxidative Metabolism and Exercise
Capacity In Vivo Requires Muscle AMPK
To determine if the effects of CDK4 inhibition in exercise perfor-
mance and whole-body oxidative metabolism require muscle
AMPK, we treated muscle-specific AMPK a1/a2 KO mice
(MDKO) (Lantier et al., 2014) with the CDK4 inhibitor. Consis-
tently, treatment with LY2835219 did not trigger significant
alterations in body weight or food intake (Figures 7A and S7M)
in control or in AMPK MDKO animals. In control animals,
LY2835219 was sufficient to trigger a decrease (albeit not signif-
icant [p = 0.1243]) in fat mass, a modest increase in exercise per-
formance, and a decrease in RER (Figures 7B–7D and S7L). In
agreement with previous reports (Lantier et al., 2014; O’Neill
et al., 2011), AMPK MDKO animals showed decreased RER
and decreased exercise capacity (Figures 7B–7D). However,
they were not affected by the treatment with LY2835219 under
our experimental conditions (Figures 7A–7D and S7K–S7M).
Taken together, these results show that the negative effects of
CDK4 in oxidative metabolism and exercise performance in vivo
involve muscle AMPK activity.
DISCUSSION
The contribution of CDK4 to the control of cell-cycle progression,
via pocket proteins and E2F transcription factors, has been
extensively studied (Malumbres, 2014) for more than two de-
cades. However, the CDK4/6-pRB/E2F1 pathway was only
recently implicated in metabolic regulation (Aguilar and Fajas,
2010; Blanchet et al., 2011; Denechaud et al., 2016; Lagarrigue
et al., 2016; Lee et al., 2014; Lopez-Mejia and Fajas, 2015; Petrov
et al., 2016; Salazar-Roa and Malumbres, 2016). Our study pro-
vides evidence that the cell-cycle kinase CDK4 is a key player in
the control of cellular energy homeostasis and can also act inde-
pendently of E2F1 to regulate metabolic pathways.
Three major findings are described here. First, we found that
CDK4 negatively regulates the AMPK pathway and thus inhibits
FAO through phosphorylation of the AMPKa2 subunit. Indeed,
Cdk4!/!MEFs behaved like cells treated with an AMPK activator
and exhibited high FAO levels and low levels of anaerobic glycol-
ysis. Consistently, Cdk4R24C/R24C cells exhibited increased
anaerobic glycolysis and very low FAO levels. A similar pheno-
type was observed in AMPK a2KO MEFs. Therefore, CDK4
activity is inversely correlated with AMPKa2-dependent activity.
These findings indicate that CDK4 plays a central role in
(D and E) AMPK WT SV40 immortalized cells were treated for 8 hr with DMSO or LY2835219 (1.5 mM). AMP, ADP, and ATP were quantified by HPLC. The AMP/
ATP (D) and ADP/ATP (E) ratios are shown.
(F–H) AMPK WT, AMPK a2 KO and AMPK DKO myotubes were treated with DMSO or 1.5mM LY2835219 for 24, and submitted to a FAO assay, in which the
palmitate induced OCR was measured (in % OCR compared to the basal OCR). The area under curve of the palmitate induced OCR was quantified in (F). AMPK
DKO myotubes were transfected with plasmids encoding Myc-tagged AMPK a2 and Myc-tagged AMPK a2 S > A. B. 48 hr later, myotubes were treated for 2 hr
with DMSO or 50 mM A769662 before protein extraction; western blot analysis shows the A769662-induced ACC phosphorylation in transfected cells (G).
Transfected myotubes were submitted to a FAO assay in which the palmitate-induced OCR was measured (in % OCR compared to the basal OCR). The area
under curve of the palmitate-induced OCR was quantified in (H).
Data are expressed as mean ± SEM. See also Figure S4 and S5.
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Figure 6. CDK4 Modulates Oxidative Metabolism and Exercise Capacity In Vivo
(A–E) Mitochondria isolated from gastrocnemius (A) and quadriceps (B) muscle from Cdk4+/+ and Cdk4!/!mice were submitted to a respiration assay using fatty
acids as a substrate. Isolated FDB muscle fibers from Cdk4+/+ and Cdk4!/! mice were submitted to a FAO assay in which the palmitate-induced OCR was
measured (in%OCR compared to the basal OCR) (C). The area under curve of the palmitate-induced OCR is shown (D). Themaximal respiration was induced by
FCCP (E).
(F) Body weight of 25- to 30-week-old male Cdk4+/+ and Cdk4!/! mice was measured.
(G) Cdk4+/+ and Cdk4!/! were submitted to an exercise capacity testing on treadmill, and the time before exhaustion was recorded.
(H and I) RER of the aforementioned mice is depicted.
(J and K) 30-week-old WT mice were gavaged with 37 mg/kg LY2835219 or vehicle for 8 days. Body weight (K) and exercise capacity (K) were measured the day
after the last treatment.
(L and M) RER of the aforementioned mice after 5 days of treatment is depicted.
Data are expressed as mean ± SEM. See also Figure S6.
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mitochondrial FAO that involves AMPKa2 inhibition and is inde-
pendent of other downstream effectors, such as E2F1.
Cell division requires high cellular energy levels. Despite the
recent evidence that underscores the existence of a crosstalk
between cell-cycle regulators and energy metabolism (Lopez-
Mejia and Fajas, 2015; Salazar-Roa and Malumbres, 2016), the
molecular mechanisms coupling energy production and cell-cy-
cle progression remain to be elucidated. Based on our results,
we propose that to exert its role in both cell-cycle progression
and the insulin-signaling pathway, CDK4 represses catabolism
by directly targeting at least one of the catalytic subunits of
AMPK, namely the a2 subunit. Interestingly, AKT, another key
player of the insulin-signaling pathway, phosphorylates the a1
subunit of AMPK, thus reducing a1 Thr172 phosphorylation
and the subsequent activation of the AMPK heterotrimer (Hawley
et al., 2014; Horman et al., 2006). Remarkably, previous evi-
dence from our laboratory demonstrates that CDK4 is a key
effector of the AKT pathway (Lagarrigue et al., 2016). Surpris-
ingly, GSK3 has been reported to inhibit AMPK activity after
phosphorylation of the a subunit by AKT (Suzuki et al., 2013).
This finding is somehow unexpected, since GSK3 activity is
negatively regulated via phosphorylation by AKT upon insulin
stimulation. Moreover, GSK3 is known to inhibit rather than pro-
mote anabolic pathways, like the synthesis of glycogen (Cohen
and Frame, 2001).
The second major finding in our study is the observation that
the function of AMPK heterotrimers can differ depending on their
a subunit isoform. Few studies have focused on the specific
function of each AMPK subunit (but see a recent review by
Ross et al., 2016b), and models completely lacking AMPK activ-
ity are often used to study the function of AMPK. Liver-specific
deletion or overexpression of the AMPKa2 subunit suggested
that this isoform is involved in regulating the balance between
lipid synthesis and FAO (Andreelli et al., 2006; Foretz et al.,
2005), but these studies did not assess the differences in spec-
Figure 7. CDK4 Regulation of Oxidative Meta-
bolism and Exercise Capacity In VivoRequires
Muscle AMPK
(A) Body weight of 12- to 16-week-old AMPKWT and
AMPK MDKO females gavaged with 37 mg/kg
LY2835219 or vehicle for 8 days was measured.
(B–D) Bodyweight of 12–16weeks old AMPKWTand
AMPK MDKO females gavaged with 37mg/kg of
LY2835219 or vehicle for 8 days wasmeasured in (A).
To measure exercise capacity on treadmill, the time
before exhaustion was recorded in (B). RER of the
aforementioned mice is depicted in (C) and (D).
Data are expressed as mean ± SEM. See also Fig-
ure S7.
ificity between a1 and a2. Interestingly, lep-
tin was shown to directly trigger FAO in
muscle (Minokoshi et al., 2002) and trigger
an anorexigenic response in hypothalamus
(Minokoshi et al., 2004) in an AMPKa2-
dependent manner. The effect on food
intake may be triggered through AKT
signaling via phosphorylation of AMPKa2
by p70S6K (Dagon et al., 2012). Other positive energy balance
signals can also reduce food intake via AMPKa2 activity in the
brain (Claret et al., 2007; Kim et al., 2004). The isoform-specific
roles of the different AMPK subunits in whole-body energy ho-
meostasis were further highlighted by the fact that the AMPKa2
subunit is essential for nicotine-triggered lipolysis in adipocytes
(Wu et al., 2015). However, the specific regulation of energy ho-
meostasis by AMPKa2, and the molecular mechanisms regu-
lating a2-isoform specific AMPK activity have remained largely
unknown.
The third major finding in our study is that the modulation of
CDK4 activity in vivo can result in modifications in whole-body
energy homeostasis and exercise performance. These modifi-
cations require the expression of AMPK in skeletal muscle.
Our results are in agreement with previous studies demon-
strating that the use of 5-aminoimidazole-4-carboxamide ribo-
nucleotide (AICAR) can increase exercise performance in
sedentary mice while increasing the proportion of slow-twitch
fibers (Narkar et al., 2008). However, the exact mechanisms
that mediate this phenotype remain to be studied. Global ap-
proaches to determine muscle reprograming at the prote-
omics and gene expression level will allow further study of
the involvement of CDK4 in muscle biology, particularly during
exercise. Given that muscle expresses the AMPKa2 subunit
highly and responds to exercise by downregulating CDK activ-
ity (Hoffman et al., 2015), we believe that the study of the
CDK4-AMPKa2 interaction in skeletal muscle will be very rele-
vant to the discovery of pharmacological interventions to pro-
mote or enhance the beneficial effects of exercise on general
health.
By identifying 4 new specific CDK4 phosphosites in the a2
subunit of AMPK, we have discovered a specific role for this sub-
unit in the control of fatty acid metabolism that we could not
demonstrate for the a1 subunit. Interestingly, we detected the
phosphorylation of two of these residues, Ser377 and Ser345, in
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muscle samples from resting mice and myotubes stimulated
with insulin or IGF1.
FAO repression by CDK4 emerges as an additional level of
metabolic regulation by this kinase, which also mediates other
effects of the insulin-signaling pathway (Lagarrigue et al.,
2016), including lipid synthesis, glycolysis (Denechaud et al.,
2016), and proliferation (Malumbres and Barbacid, 2005).
In conclusion, our results demonstrate that CDK4 is a major
regulator of cellular energy homeostasis. By combining experi-
mental data from cellular metabolism analyses, biochemistry
and molecular biology studies, and in vivo experiments, our
work provides insights into the complex regulation of anabolic
and catabolic pathways. These novel findings can have broad
implications not only in the regulation of cell metabolism during
proliferation but also in the control of energy utilization at the
level of the whole organism. Moreover, they highlight the need
to delve deeper into the specific functions of the different
AMPK heterotrimers, as well as in the regulation of AMPK
inactivation.
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Rabbit polyclonal anti-Phospho-ACC Cell Signaling Technology Cat#3661
Rabbit polyclonal anti-AMPKa Cell Signaling Technology Cat#2532
Rabbit monoclonal anti-Phospho-AMPKa(Thr172)(40H9) Cell Signaling Technology Cat#2535
Mouse monoclonal anti-Myc-Tag (9B11) Cell Signaling Technology Cat#2276
Rabbit monoclonal anti-Phospho Rb (ser780)(D59B7) Cell Signaling Technology Cat#8180
Rabbit polyclonal anti-Cdk4 (C-22) Santa Cruz biotechnology Sc-260
Mouse monoclonal anti-Rb (C-2) Santa Cruz biotechnology Sc-74562
Goat polyclonal anti-AMPK a2 (C-20) Santa Cruz biotechnology Sc-19131
Goat polyclonal anti-Actin (C11) Santa Cruz biotechnology Sc-1615
Rabbit polyclonal anti-Myc-Tag Abcam Ab9106
Mouse monoclonal anti-a-Tubulin Sigma-Aldrich T6199
Chemicals, Peptides, and Recombinant Proteins
LY2835219 MedChemExpress HY-16297
PD0332991 MedChemExpress HY-50767
LEE011 MedChemExpress HY-15777
A769662 MedChemExpress HY-50662
Compound C MedChemExpress HY-13418
FCCP Sigma Aldrich C2920
Antimycine A Sigma Aldrich A8674
CDK4/CycD3 ProQinase 0142-0373-1
CDK4/CycD1 ProQinase 0142-0143-1
Recombinant kinase dead AMPK trimers (a2b2g1) DG. Hardie lab.
Experimental Models: Cell Lines
C2C12 ATCC CRL-1772
Primary and SV40 immortalized Cdk4!/! MEFs This paper N/A
Primary and SV40 immortalized Cdk4+/+ MEFs, This paper N/A
Primary and SV40 immortalized Cdk4R24C/R24C MEFs This paper N/A
Primary E2f1+/+ MEFs This paper N/A
Primary E2f1!/! MEFs This paper N/A
Primary Cdk4R24C/R24C E2f1+/+ MEFs This paper N/A
Primary Cdk4R24C/R24C E2f1!/! MEFs This paper N/A
Prkaa1-/ -SV40 immortalized MEFs (Laderoute et al., 2006) N/A
Prkaa2!/! SV40 immortalized MEFs (Laderoute et al., 2006) N/A
Prkaa1!/!; Prkaa2!/! double KO SV40 immortalized MEFs (Laderoute et al., 2006) N/A
AMPK alpha2 KO Myoblasts (Lantier et al., 2010) N/A
AMPK alpha1, alpha2 double KO Myoblasts (Lantier et al., 2010) N/A
AMPK WT Myoblasts (Lantier et al., 2010) N/A
Experimental Models: Organisms/Strains
Skeletal muscle AMPK-deficient mice [AMPK_1fl/fl _2fl/fl human skeletal
actin (HSA)-Cre_ mice on a C57Bl6- 129Sv mixed background]
(Lantier et al., 2014) N/A
The generation of Cdk4!/!, that lack CDK4 in all tissues except
pancreatic beta cells andwere referred asCdk4nc/nc in our previous study.
(Lagarrigue et al., 2016) N/A
C57BL/6JRj mice. Janvier Labs
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will fulfilled by Lluis Fajas (lluis.fajas@unil.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture
MEFswere derived fromembryos that were dissected 13.5 days after vaginal plugs. TheCdk4!/! (Cdk4nc),Cdk4R24C/R24C andE2f1!/!
mice have been previously described (Denechaud et al., 2016; Lagarrigue et al., 2016).
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Oligonucleotides
See Table S2 N/A
See Table S3 N/A
Recombinant DNA
pDONR223-hPRKAA1 Addgene (ref:23871)
pDONR223-hPRKAA2 Addgene (ref:23671)
pDONR223-hPRKAB1 Addgene (ref:23360)
pDONR223-hPRKAB2 Addgene (ref:23647)
pDONR223-hPRKAG1, Addgene (ref:23718)
pDONR223-hPRKAG2 Addgene (ref:23689)
pDONR223-hPRKAG3 Addgene (ref:23549)
pDEST pGEX-2T-hPRKAA1 This paper N/A
pDEST pGEX-2T -hPRKAA2 This paper N/A
pDEST pGEX-2T -hPRKAB1 This paper N/A
pDEST pGEX-2T -hPRKAB2 This paper N/A
pDEST pGEX-2T -hPRKAG1, This paper N/A
pDEST pGEX-2T -hPRKAG2 This paper N/A
pDEST pGEX-2T -hPRKAG3 This paper N/A
pDEST pGEX-2T -hPRKAA2 D1 This paper N/A
pDEST pGEX-2T -hPRKAA2 D1 S176A This paper N/A
pDEST pGEX-2T -hPRKAA2 D2 This paper N/A
pDEST pGEX-2T -hPRKAA2 D2 S345A This paper N/A
pDEST pGEX-2T -hPRKAA2 D3 This paper N/A
pDEST pGEX-2T -hPRKAA2 D3 S377A This paper N/A
pDEST pGEX-2T -hPRKAA2 D4 This paper N/A
pDEST pGEX-2T -hPRKAA2 D4 T485A This paper N/A
pGEX-2T -hPRKAA2 D4 T485A S529A This paper N/A
pDEST pGEX-2T -hPRKAA2 D2-D3 This paper N/A
pDEST pGEX-2T -hPRKAA2 D2-D3 S345A S377A This paper N/A
pDEST pGEX-2T -hPRKAA2 S377A S345A T485A S529A This paper N/A
pCDNA3 MYC hPRKAA1 This paper N/A
pCDNA3 MYC hPRKAA2 This paper N/A
pCDNA3 MYC hPRKAA2 S377A S345A T485A S529A This paper N/A
Software and Algorithms
Protein Prophet algorithm (Nesvizhskii et al., 2003) N/A
MsViz software (Martı´n-Campos et al., 2017) N/A
Fiji image processing package (Schindelin et al., 2012). N/A
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Prkaa1!/!, Prkaa2!/! individual KOs; and Prkaa1!/!; Prkaa2!/! double KO SV40 immortalized MEF cells were prepared as
described (Laderoute et al., 2006). They are referred in the manuscript as AMPK a1KO, AMPK a2KO and AMPK DKO.
MEFs were cultured in DMEM/F12 supplemented with 10% fetal bovine serum (FBS, PAA Laboratories), glutamax (1mM), sodium
pyruvate (1mM), non-essential amino-acids, 2-Mercapto-ethanol (50mM) and antibiotics in 5% CO2 37"C incubator.
C2C12 myoblasts were obtained from ATCC and were cultured in low-glucose DMEM with 10% FBS in 5% CO2 37"C incubator.
For myotube differentiation, when the cells reached 80%–90% confluency, the culture medium was switched to DMEM containing
2% horse serum. The medium was changed every 2 days until day 5 to 7 of differentiation.
Primary myoblasts were grown in collagen coated plates cultured DMEM/F12 supplemented with 20% fetal bovine serum, 2mM
Glutamine and FGF (5ng/ml) in 5% CO2 37"C incubator. For myotube differentiation, cells were plated on matrigel-coated plates
when the cells reached 80%–90% confluency, the culture mediumwas switched to DMEM/F12 supplemented with 2% horse serum
and 2mMGlutamine. Themediumwas changed every 2 days until day 4-5 of differentiation. For rescue experiments, myotubes were
transfected using lipofectamine 3000 (Thermo Fisher Scientific), at day 1 and day 3 of differentiation. The cells were assayed 48 hr
after the 2nd round of transfection.
PrimaryCdk4+/+, Cdk4!/! andCdk4R24C/R24CMEFs, as well as primary E2f1+/+, E2f1!/!,Cdk4R24C/R24C E2f1+/+ andCdk4R24C/R24C
E2f1!/! MEFs, between P2 and P5, were used for Figures 1 and 2. SV40 immortalized MEFs were used for all other figures.
Animal studies
The generation of Cdk4!/!, that lack CDK4 in all tissues except pancreatic beta cells and were referred as Cdk4nc/nc in our previous
study, was described in (Lagarrigue et al., 2016). Male mice were used.
For gavage experiments, C57BL/6J male mice were obtained from Janvier Labs. Animals were gavaged daily with 37mg/kg of
LY2835219 or vehicle for 8 days. Mice were acclimated and submitted to indirect calorimetry between day 4 and day 6. Exercise
capacity testing was performed the day after the last gavage. Body weight was controlled daily. Food intake was measured in the
metabolic cages.
To obtain skeletal muscle AMPK-deficient mice [AMPK_1fl/fl _2fl/fl human skeletal actin (HSA)-Cre_ mice on a C57Bl6- 129Sv
mixed background], AMPK_1fl/fl_2fl/fl mice were interbred with transgenic mice expressing Cre recombinase under the control of
the HSA promoter. Female mice were used.
The mice were housed in a facility on a 12-h light-dark cycle with free access to standard rodent chow and water.
Mice were familiarized to themotorized rodent treadmill (Columbus Instruments, Columbus OH) on the J-2 and J-1 before the eval-
uation of exercise capacity. Familiarization consisted of an initial 10min period where the treadmill speed and incline were set to zero
with a slight electric shock grid at the back of the carpet set to 20 V, 0.34 mA, and 2 Hz. The treadmill speed was then increased
steadily to 10 m/min (J-2) and 12 m/min (J-1) for an additional 10 min.
The day immediately following familiarization to the treadmill, mice were subjected to an exercise capacity test. For this, the mice
were acclimated to the treadmill for 10 min, with the speed and incline set initially to zero. The treadmill speed was then increase to
8.5 m/min with an angle of inclination set to 0" for 9 min. Next, the treadmill speed and incline was increased to 10 m/min and 5",
respectively, for 3 min. The speed was then increased by 2.5 m/min every 3 min to a maximum speed of 40 m/min, while inclination
was increased by 5" every 9 min until a maximum incline of 15".
Strict a priori criteria for exercise-induced exhaustion consisted in: (1) 10 consecutive seconds on the electric grid; (2) spending
more than 50% of time on the grid; and/or (3) lack of motivation to manual prodding. Mice were immediately removed from their
respective lane once one or more of these criteria were reached.
Following the protocol, mice were killed by cervical dislocation and skeletal muscles were isolated for analysis.
All animal care and treatment procedures were performed in accordance with Swiss guidelines and were approved by the Canton
of Vaud, Service de la Consommation et des Affaires Ve´te´rinaires (SCAV) (authorization VD 3121.a).
METHOD DETAILS
Materials
All cell culture reagents were purchased from GIBCO (Thermo Fisher Scientific). All chemicals, except if stated otherwise, were pur-
chased from Sigma-Aldrich. The CDK4 inhibitor (LY2835219) and Compound C. were purchased from MedChem Express. Experi-
ments were done using 1mM of LY2835219, unless stated otherwise. The AMPK allosteric activator was purchased from Abcam or
MedChem Express. Unless stated otherwise, A769662 was used at a concentration of 50mM. g-33P-ATP was purchased from
Perkin Elmer.
Immunoblot
For western blot analysis, the cells were seeded in 6-well plates 48 hr before the experiment, serum starved for 3 hr, and treated with
either LY2835219 or A769662 for 2 hr.
Total proteins extracts were subjected to SDS-PAGE analysis and transferred to nitrocellulose membranes for immunoblotting.
The following antibodies were obtained from Cell Signaling Technology: ACC (no. 3662), phosphorylated ACC (ser79) (no. 3661),
AMPK (no.2532), phosphorylated AMPK (Thr172) (no 2535), Myc-tag (no. 2276), phosphorylated RB (Ser780) (no. 8180). The
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following antibodies were obtained from Santa Cruz Technology: Cdk4 (C-22; sc-260), Rb (C-2; sc-74562), AMPK a2 (sc-19131).
A second Myc-tag antibody was used to analyze myotube samples (Abcam ab9106)
The a Tubulin (no. T6199) antibody was obtained from Sigma Aldrich, the actin (sc-1615) was obtained from Santa Cruz
Technology.
The levels of total proteins and the levels of phosphorylation of proteins were analyzed on separate gels. The band intensities on
developed films, fusion FX images or chemidoc images or were quantified using Fiji image processing package (Schindelin
et al., 2012).
Plasmid constructs and mutagenesis
pDONR223-hPRKAA1 (ref:23871), pDONR223-hPRKAA2 (ref:23671), pDONR223-hPRKAB1 (ref:23360), pDONR223-hPRKAB2
(ref:23647), pDONR223-hPRKAG1 (ref:23718), pDONR223-hPRKAG2 (ref:23689), pDONR223-hPRKAG3 (ref:23549) were provided
from Addgene. The different GST subunits of human AMPK were obtained using the pDEST pGEX-2T vector of Gateway Cloning
Technology (Invitrogen) starting from previously described pDONR223AMPK constructs. The different serine-to-alanine mutants
of GST-hPRKAA2were generated using aQuick-Change Site-DirectedMutagenesis kit (Stratagene) with the following primers (Table
S2). A similar strategy was used to obtain the truncated versions of GST-hPRKAA2 and the different serine-to-alanine mutants using
the following primers (Table S2).
The Myc-hPRKAA1, the Myc-hPRKAA2 and the Myc-hPRKAA2-S345A-S377A-T485A-S529A were obtained using the pDEST
pCDNA3 MYC vector previously and the above described pDONR223-human AMPK constructs. pDONR-hRB 379-928aa was
subcloned from pCMV human RB and generated using the pDONR221 vector of Gateway Cloning Technology. The pGEX-2T
hRB 379-928aa was obtained using the pDEST pGEX-2T from Gateway Cloning Technology.
GST production
Independent AMPK subunits were cloned in the pDEST pGEX-2T and expressed in BL21 bacteria. GST-purified proteins were re-
suspended in 50mM Tris.HCl [pH 8], 100 mM NaCl, 5 mM DTT and 20% glycerol buffer.
CDK4 Kinase assay
Kinase assays were performed using independent AMPK subunits proteins and 500ng of recombinant RB protein (Santa Cruz) as a
substrate in kinase buffer (25 mM Tris.HCl [pH 7.5], 150 mM NaCl, 10 mM MgCl2, 1 mM DTT, 5 mM Na4P2O7, 50 mM NaF, 1 mM
vanadate and protease inhibitor cocktail) with 40 mM ATP and 8 mCi g-33PATP (Perkin Elmer) for 30 min at 30!C. Recombinant
CDK4/cyclin D3 kinase and CDK4/Cyclin D1 (ProQinase) were used. RB was used as a positive control.
Boiling the samples for 5 min in the presence of denaturing sample buffer stopped the reaction. Samples were subsequently sub-
jected to SDS–PAGE, and transferred to a nitrocellulose membrane before being exposed to an X-ray film at "80!C during 4 hr or
over night. Recombinant protein loading was confirmed by SYPRO Ruby protein Blot Staining (Life Technologies).
For mass spectrometry, recombinant kinase dead AMPK trimers (a2b2g1) were used as a substrate for CDK4/CyCD3. Recombi-
nant kinase dead AMPK trimers (a2b2g1) were produced by the DG. Hardie lab.
Mitochondrial isolation
Quadriceps muscle from Cdk4+/+ or Cdk4-/- mice were homogenized in 2ml cold buffer I. Tissue homogenization was obtained at
1500rpm after 30 strokes. The homogenized extract was then centrifuged at 600 g for 10min at 4!C in order to remove cellular debris.
This step was performed three times. The mitochondrial fraction was pelleted at 10000 g for 10 min at 4!C and subsequently washed
using buffer II. The mitochondrial pellet was suspended in 80ul cold buffer II. Mitochondria were immediately used for seahorse anal-
ysis. Buffers I composition is as follows: 210 mMmannitol, 70 mM sucrose, 5 mMHEPES, 1 mMEGTA, 0.5%BSA pH to 7.4. Buffer II
composition is as follows: 210 mM mannitol, 70 mM sucrose, 10 mM MgCl2, 5 mMK2HPO4, 10 mM MOPS, 1 mM EGTA pH to 7.4.
Isolation of adult skeletal muscle fibers
Flexor digitorum brevis (FDB) muscles were incubated for 45 min at 37!C in an oxygenated ‘Krebs-HEPES’ solution containing 0.2%
collagenase type IV (GIBCO). Muscles were then washed twice in DMEM/F12 supplemented with 2% fetal bovine serum and me-
chanically dissociated by repeated passages through fire-polished Pasteur pipettes of progressively decreasing diameter. Dissoci-
ated fibers were plated directed onto Seahorse XF24 tissue culture dishes coated with Matrigel and allowed to adhere to the bottom
of the dish for 2h. After checking the adhesion of the fibers, a seahorse Fatty acid oxidation was performed as described
The Krebs-HEPES solution contains NaCl 135.5mM,MgCl2 1.2mM, KCl 5.9mM, glucose 11.5mM, HEPES 11.5mMandCaCl2 mM.
Seahorse analyses
For seahorse analysis, the cells were seeded 16 hr before the experiment.
Mitochondrial function was determined with an XF-24 extracellular flux analyzer (Seahorse Bioscience). Oxygen consumption Rate
(OCR) and Extracellular acidification rate (ECAR) wasmeasured in adherentMEFs. Control andmutant fibroblast cells were seeded in
an XF 24-well cell culture microplate at a density of 73 105 cells per cell in 200 mL DMEM/F12media. Cells were incubated for 16 hr at
37!C in 5%CO2 before the assay. OCRwas expressed as pmol of O2 perminute andwas normalized by protein content a Pierce BCA
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Protein Assay protocol (Thermo Fisher Scientific). ECARwas expressed asmpH per minute and was normalized by protein content a
Pierce BCA Protein Assay protocol (Thermo Fisher Scientific).
For glycolysis experiments, just before the experiment the cells were washed, and the growth medium was replaced with DMEM
medium containing only 2mMGlutamine. Cells were then pre-incubated for 1 hr at 37!C without CO2 to allow cells to pre-equilibrate
with the assay media before starting the glycolysis test procedure. After measuring baseline ECAR, ECAR was measured after an
acute injection of 25mM Glucose. The glycolytic rate was calculated as glucose dependent ECAR. It was calculated as follows:
Glucose induced ECAR-basal ECAR.
For fatty acid oxidation experiments, just before the experiment the cells are washed, and the growth medium was replaced with
KHB containing 2.5mMGlucose and 1.5mM of carnitine. Cells were then pre-incubated for 1 hr at 37!C without CO2 to allow cells to
pre-equilibrate with the assay media before starting the fatty acid oxidation procedure. After measuring baseline OCR as an indica-
tion of basal respiration, OCR was measured after an acute injection of 400mM or 150mM of palmitate coupled to BSA (for MEFs and
myotubes respectively).
For FDB muscle fibers 125mM of palmitate coupled to BSA, 400nM of FCCP and 1mM of Antimycine A were injected directly onto
the fibers using the seahorse analyzer. Fatty acid oxidation was induced by the palmitate injection. The uncoupling agent FCCP
induced the maximal respiration.
OCR was expressed as pmol of O2 per minute and was normalized by total DNA content.
For mitochondrial respiration, 50 mL of mitochondrial suspension (containing 10mg of freshly isolated mitochondria) were used per
well. The XF24 cell culture microplate was centrifuged at 2000 g for 20 min at 4!C. The assay medium contained 250 mM sucrose,
15 mMKCl, 1 mM EGTA, 5 mMMgCl2, 30 mMK2HPO4, 2mMHEPES and 0.2% FFA-Free BSA. 0.5mMMalate, 80mMPalmitoylCoA,
240mM Carnitine and 4mM ADP diluted in assay medium were added after the centrifugation of the mitochondria to obtain a final
volume of 525ml per well. After 10 min of incubation at 37!C without CO2 the mitochondrial respiration was measured using the sea-
horse analyzer.
Immunoprecipitation
Myotubes or liquid N2 grinded muscle samples were lysed in M-PER buffer (Thermo Fisher Scientific) and incubated in agitation for
one hour at 4!C. 2-5 mg of protein was immunoprecipitated overnight with an AMPKa2 antibody (Santa Cruz, sc-19131) and Protein
G coupled with magnetic beads (Sigma, 1004D) in the following buffer (IP buffer): 25 mM TRIS pH 7.9, 5 mM MgCl2, 10% Glycerol,
100 mM KCl, 0.1%NP40, 0.3 mMDTT. Next day, beads were washed for times with the IP buffer and frozen. Samples were used for
mass spectrometry.
Mass spectrometry
In the in vitro assays, protein samples were loaded on a 12% mini polyacrylamide gel and migrated about 3 cm, while in the immu-
noprecipitation experiments proteins were loaded on an 8% gel and fully migrated. After Coomassie staining, visible band between
50 and 75 kDa corresponding to AAPK2 was excised and digested with sequencing-grade trypsin (Promega). Extracted tryptic pep-
tides were dried and resuspended in 0.05% trifluoroacetic acid, 2% (v/v) acetonitrile for mass spectrometry analyses.
Tryptic peptidemixtureswere injected on anUltimate RSLC 3000 nanoHPLC system (Dionex, Sunnyvale, CA, USA) interfaced via a
nanospray source to a high resolution mass spectrometer based on Orbitrap technology: Fusion Tribrid or QExactive Plus (Thermo
Fisher, Bremen, Germany), depending on the experiments considered. Peptides were loaded onto a trapping microcolumn Acclaim
PepMap100 C18 (20mm x 100 mm ID, 5 mm, Dionex) before separation on a C18 reversed-phase analytical nanocolumn at a flowrate
of 0.25 ml/min, using a gradient from 4 to 76% acetonitrile in 0.1% formic acid (total time: 65min).
The in vitro experiments were analyzedwith a Fusionmass spectrometer interfaced to a custom packed 40-cmC18 column (75 mm
ID, 100A˚, Reprosil Pur 1.9 um particles). Full MS survey scans were performed at 120’000 resolution. Data-dependent acquisition
was controlled by Xcalibur 3.0 software (Thermo Fisher) and applied a top speed precursor selection strategy tomaximize acquisition
of peptide tandemMS spectra with amaximum cycle time of 3 s. Multiple-charge precursor ions were isolated in the quadrupole with
awindowof 1.6m/zwidth and then dynamically excluded from further selection during 60 s. HCD fragmentation was performed in the
ion routing multipole with 32% normalized collision energy and fragment ions were measured in the ion trap.
The immunoprecipitation experiments were analyzed with a Q-Exactive Plus instrument interfaced to an Easy Spray C18 PepMap
column (50cm x 75mm ID, 2mm, 100A˚, Dionex). Full MS survey scans were performed at 70’000 resolution. In data-dependent acqui-
sition controlled by Xcalibur 3.1 software (Thermo Fisher), the 10 most intense multiple-charge precursor ions detected in the full MS
survey scan were selected for higher energy collision-induced dissociation (HCD, normalized collision energy NCE = 27%) and anal-
ysis in the orbitrap at 17’500 resolution. The window for precursor isolation was of 1.5 m/z units around the precursor and selected
fragments were excluded for 60 s from further analysis.
MS data were analyzed using Mascot 2.6 (Matrix Science, London, UK) set up to search the UniProt database (www.uniprot.org)
restricted to Homo sapiens (in vitro experiments) or Mus musculus (immunoprecipitation experiments) taxonomy (SwissProt,
November 2016 version: 20’130 and 16’846 sequences, respectively). Trypsin (cleavage at K,R) was used as the enzyme definition,
allowing 3 missed cleavages. Mascot was searched with a parent ion tolerance of 10 ppm and a fragment ion mass tolerance of 0.5
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(Fusion MS data) or 0.02 Da (QExactive MS data). Iodoacetamide derivative of cysteine was specified in Mascot as a fixed modifi-
cation. N-terminal acetylation of protein, oxidation of methionine, and phosphorylation of serine, threonine or tyrosine were specified
as variable modifications.
Scaffold software (version 4.7.5, Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and protein
identifications, and to perform dataset alignment. Peptide identifications were accepted if they could be established at greater than
90.0% probability by the Scaffold Local FDR algorithm. Protein identifications were accepted if they could be established at
greater than 95.0% probability and contained at least 2 identified peptides. Protein probabilities were assigned by the Protein
Prophet algorithm. Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were
grouped to satisfy the principles of parsimony. Proteins sharing significant peptide evidence were grouped into clusters.
MsViz software (Martı´n-Campos et al., 2017) was used to compare sequence coverage and phosphorylation of the AMPK alpha 2
protein in the in vitro experiments.
HPLC
Cells were grown in 10 cm dishes and treated as indicated in the figure legends. Culture medium was removed by aspiration, rinsed
with ultra pure water, flash frozen with liquid nitrogen, thawed on ice, and followed by immediate addition of ice-cold 0.4M perchloric
acid (500 ml). Cells were scrapped off thoroughly, and transferred to 1.5 mL microfuge eppendorf tubes. Samples were incubated at
4!C for 45 min, and centrifuged at 14,000 rpm at 4C for 10 min. The supernatant (500 ml) was collected, mixed with 500ml K2CO3 4M,
and incubated at least 1h at "80!C. The samples were again centrifugated at 4C for 10 min, the supernatant collected and tested
on HPLC.
External standards stocks were prepared in ultra pure water, at 10 mg/ml, and treated in exactly the same way as the samples.
For normalization, protein measurements were performed using a Pierce BCA Protein Assay protocol (Thermo Fisher Scientific). In
parallel DNA was extracted from the pellets and quantified.
The gradient elution was performed as described (Manfredi et al., 2002) on a 4.6-mmi.d, 150-mm, Kinetex 5u EVOC18 100A HPLC
column (Phenomenex) with two buffers at a rate of 0.5ml/min. Buffer A contained 25mMNaH2PO4, 100mg/liter tetrabutylammonium
hydrogen sulfate, pH 5. Organic buffer B was composed of 10% (v/v) acetonitrile in 200mMNaH2PO4, 100 mg/liter tetrabutylammo-
nium hydrogen sulfate, pH 4.0. Buffers were filtered and degassed. The gradient was 100% buffer A from 0–5 min, 100% buffer A to
100% buffer B from 5–20min, and 100% buffer A from 20 to 31min for column reequilibration, which was sufficient to achieve stable
baseline conditions. 25 ml of prepared sample was autoinjected and UV monitored at 260nm from 0 to 31 min for phosphorylated
nucleotides. Peaks were identified by their retention times and by using co-chromatography with standards.
Each standard of interest was first subjected to chromatography individually to obtain its retention time (Manfredi et al., 2002) and
to be able to later identify each compound in a standard mixture. A standard curve for each compound was constructed by plotting
peakheight s (lV) versus concentration. Linear curves were obtained with R2 values > 0.95. The quantification of nucleotides in the
sample was performed using the external standard calibration, integrating sample peak heights against corresponding standard
curves.
mRNA analysis
Muscle tissues were grinded to powder in liquid nitrogen. mRNAs from muscle was isolated using TRIREAGENT according to the
manufacturer’s protocol. One microgram of the RNA was subsequently reverse-transcribed (Superscript II, Life Technologies)
and quantified via real-time quantitative PCR using an ABI 7900HT instrument. qPCR analysis was performed using a 7900HT
Fast Real-Time PCR System (Applied Biosystems) and SYBR Green detection of the amplified products. The relative quantification
for a given gene was corrected to RS9 mRNA values (oligonucleotide sequences are provided in Table S3).
QUANTIFICATION AND STATISTICAL ANALYSES
The results were expressed asmeans ± standard error of themeans (s.e.m). Comparisons between 2 groups were performedwith an
unpaired 2-tailed Student’s t test and multiple group comparisons were performed by unpaired 1-way ANOVA followed by Tukey’s
test and 2-way ANOVA, followed by Tukey’s test. All p-values below 0.05 were considered significant. Statistical significance values
were represented by asterisks corresponding to *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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3. CDK4 is an essential insulin effector in adipocytes 
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Castillo-Armengol, J., Jimenez, V., Chavey, C., Giralt, A., Lai, Q., 
Zhang, L., et al. (2016). CDK4 is an essential insulin effector in 
adipocytes. The Journal of clinical investigation 126, 335-348. 
 	
This paper shows that CDK4 is a major regulator of insulin signaling in white 
adipose tissue. Three major findings are described in this paper. Firstly, that CDK4 
represses lipolysis and promotes lipogenesis. Secondly, that CDK4 is activated by 
insulin, and third, that CDK4 is able to phosphorylate IRS2 protein in adipocytes, thus 
maintaining the insulin signaling pathway activated in the presence of growth factors. 
 Given my previous experience in mice surgery, I tested to transplant white 
adipose tissue from CDK4 knock-out mice to wild-type mice to reveal that CDK4 was 
the responsable of IRS2 phosphorylation in adipocytes. However, we could not 
include this data in the paper, because, due to the re-vascularization the transplanted 
pieces had CDK4 expression, we could not validate wether the transplanted tissue was 
from CDK4 knock-out mice. Despite this, I contributed to the histological procedure 
and analysis of the adipose tissue from different mice genotypes.  
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Introduction
Insulin signaling is a versatile system that coordinates growth, 
proliferation, and development of multiple tissues and organs by 
controlling metabolic processes that accommodate the energy 
needs of cellular function (1). Defects in insulin signaling con-
tribute to insulin resistance, a common complication of obesity 
that occurs early in the pathogenesis of type 2 diabetes and car-
diovascular disease (2, 3). Insulin response depends on tissue and 
cellular functions. In white adipose tissue (WAT), insulin signal-
ing regulates lipid synthesis (1) and glucose transport (4–6) and 
represses lipolysis (7). However, the exact mechanism by which 
insulin signaling coordinates regulated cellular functions is not 
fully understood. Cyclin-dependent kinase 4 (CDK4) plays an 
important role in the G1/S transition of the cell cycle. Its kinase 
activity is regulated through interaction with the D-type cyclins 
(CCND1, CCND2, and CCND3) (8). The resulting cyclin D–
CDK4 complexes catalyze the phosphorylation of the members 
of the retinoblastoma (RB) protein family (RB1, RBL1, and RBL2). 
Phosphorylation of RB1 by cyclin D–CDK4 releases the E2F 
transcription factors, thereby ensuring the expression of genes 
required for cell-cycle progression (9). Conversely, members of 
the family of CDK inhibitors (INK and CIP/KIP) block CDK activ-
ity in response to quiescence stimuli. Many studies have assessed 
the roles of CDK4 in cell growth, proliferation, and cancer (10), 
but the role of CDK4 in adipose tissue function has never been 
explored. The most marked phenotypes of mice lacking CDK4 
(Cdk4neo/neo) are reduced body size and insulin-deficient diabetes 
due to a severe decrease in pancreatic ȕ cell growth (11). ȕ Cell–
specific reexpression of the Cdk4R24C allele renders CDK4 resis-
tant to the inhibitory effects of INK4 proteins (12) and restores 
ȕ cell proliferation and normoglycemic conditions (13). Interest-
ingly, CDK4 reexpression in pancreatic ȕ cells does not rescue 
body size reduction, suggesting that this phenotype is not due 
to endocrine defects secondary to decreased insulin levels. We 
previously demonstrated that CDK4 regulates adipogenesis, sug-
gesting a role of CDK4 in WAT function (14).
Results
CDK4 activity is positively correlated with WAT mass. The first sug-
gestion of a role of CDK4 in adipose tissue biology came from the 
finding that CDK4 and 2 D-type cyclins (CCND2 and CCND3) 
are highly expressed in epididymal WAT (eWAT) compared with 
the other tissues analyzed (Figure 1A). The high levels of expres-
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Protein expression analysis in visceral adipose tissue (VAT) cellular 
fractions showed that CDK4 was better expressed in mature adi-
pocytes compared with the stromal vascular fraction (SVF) (Figure 
1B and Supplemental Figure 1C). Furthermore, CDK4 expression 
sion of CCND3 in eWAT (Figure 1A and Supplemental Figure 1, 
A and B; supplemental material available online with this article; 
doi:10.1172/JCI81480DS1) are consistent with previous findings 
showing increased CCND3 expression during adipogenesis (15). 
Figure 1. Positive correlation between CDK4 activity and WAT mass. (A) Expression levels of CCND1, CCND2, CCND3, CDK4, and CDK6 proteins in mouse 
eWAT, BAT, brain, muscle, heart, kidney, lung, spleen, and liver. Representative blot of several animals analyzed is shown. (B) CDK4 protein level in the 
SVF and mature adipocytes isolated from VAT. (C) Subcellular localization of CCND1, CCND2, CCND3, and CDK4 proteins in cytoplasm and nuclear frac-
tions of eWAT and mature 3T3-L1 adipocytes. LMNA was used as a control for the nuclear fraction. (B and C) Representative blots out of 3 independent 
experiments are shown. (D and E) Body weight and percentage of fat mass of 20-week-old Cdk4+/+ and Cdk4nc mice (n = 9) (D) and 30-week-old Cdk4+/+ and 
Cdk4R24C/R24C mice (n = 8) (E) as obtained using EchoMRI technology. (F) H&E staining of eWAT sections from Cdk4+/+, Cdk4nc, and Cdk4R24C/R24C mice. (G) Body 
weight, ǻ fat mass of 20-week-old Cdk4flox/flox mice infected with AAV8-mini/aP2-null (n = 5) or AAV8-mini/aP2-cre (n = 4) analyzed by EchoMRI technol-
ogy (we show the difference between the percentage of fat before and the percentage of fat 3 weeks after infection). (H) H&E staining of eWAT sections 
from Cdk4flox/flox mice infected with AAV8-mini/aP2-null or AAV8-mini/aP2-cre. (I) Body weight and percentage of fat mass of 30-week-old E2f1+/+ (n = 4), 
Cdk4R24C/R24C E2f1+/+ (n = 6), and Cdk4R24C/R24C E2f1–/– mice (n = 12). (J) H&E staining of eWAT sections from E2f1+/+, Cdk4R24C/R24C E2f1+/+, and Cdk4R24C/R24C E2f1–/– 
mice. Statistically significant differences were determined with unpaired 2-tailed Student’s t tests (D, E, and G) or 1-way ANOVA followed by Tukey’s 
multiple comparisons test (I). *P < 0.05. Original magnification, ×100.
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engineering of white and brown adipocytes in adult mice and has 
very poor tropism for macrophages (17). We infected Cdk4flox/flox 
mice (Supplemental Figure 1I) with AAV8 vectors expressing the 
Cre recombinase under the control of the mini/aP2 adipose tis-
sue–specific promoter (AAV8-mini/aP2-cre) or with the control 
vector (AAV8-mini/aP2-null). First of all, we determined the tis-
sues that were infected by assessing the presence of viral genome 
(vg) using Cre PCR. The vg was only present in brown adipose tis-
sue (BAT), eWAT, s.c. WAT, and liver, whereas we could not detect 
it in pancreas and muscle (Supplemental Figure 1J). Quantitative 
reverse-transcription–PCR (RT-qPCR) analysis showed a significant 
decrease of Cdk4 mRNA in eWAT and s.c. WAT, whereas no changes 
were observed in liver and BAT (Supplemental Figure 1K). After 3 
weeks, the systemic administration of AAV8-mini/aP2-cre triggered 
a decrease in fat mass gain; indeed, AAV8-mini/aP2-cre–infected 
mice gained significantly less fat mass (Figure 1G) and experienced 
a reduction in adipocyte size (Figure 1H). However, no differences 
were found in body weight and lean mass in Cdk4flox/flox mice infected 
with AAV8-mini/aP2-cre vector (Figure 1G and Supplemental Figure 
1L). The use of this adipose tissue–specific Cdk4 depletion model 
supports a cell-autonomous contribution for CDK4 in adipose tissue. 
Overall, these 3 models (Cdk4nc, Cdk4R24C/R24C, and Cdk4flox/flox mice 
infected with AAV8 mini/aP2-cre) clearly demonstrate a positive 
correlation between CDK4 activity and WAT mass/size.
E2F1, a known proproliferative downstream effector of CDK4, 
was previously shown to promote adipogenesis (16). Therefore, 
in order to determine whether adipocyte proliferation was not 
affected with the modulation of CDK4 activity, we generated 
Cdk4R24C/R24C E2f1–/– mice. No significant changes were observed 
in adiposity, adipocyte size, lean mass, or adipocyte proliferation 
as measured by Ki67 expression in Cdk4R24C/R24C E2f1–/– compared 
with Cdk4R24C/R24C E2f1+/+ mice (Figure 1, I and J, and Supplemen-
tal Figure 1, M and N). These results demonstrate that when 
CDK4 is hyperactive, the deletion of E2f1 does not affect fat mass, 
mature adipocyte size, and proliferation. Because Cdk4R24C/R24C 
mice develop a wide spectrum of tumors (18, 19), we investigated 
to determine whether the WAT phenotype observed in these mice 
could be secondary to tumor development. We could not find any 
correlation between fat mass and tumor development. Indeed, 
all mice used in this study were tumor free (Supplemental Figure 
1O). Moreover, tumor development was negatively correlated 
with fat mass in 60-week-old Cdk4R24C/R24C mice, proving that the 
increased WAT mass in these mice was not secondary to tumor 
formation (Supplemental Figure 1P).
CCND3 is positively correlated with WAT mass in human subjects. 
Our data suggesting the involvement of CCND3-CDK4 in adipose 
tissue was further supported by the positive correlation between 
CCND3 protein expression in visceral WAT samples from human 
subjects and their BMI (Figure 2A and Supplemental Figure 1, Q 
was also higher in differentiated 3T3-L1 adipocytes compared with 
nondifferentiated 3T3-L1 preadipocytes (Supplemental Figure 1C). 
Interestingly, the subcellular localization of CDK4 and CCND3 as 
well as of the other D-type cyclins revealed that these proteins are 
not only found in the nucleus; rather, they are mainly localized in 
the cytoplasm of adipocytes (Figure 1C and Supplemental Figure 
1D), suggesting a role for CDK4 that is independent of the RB/
E2F pathway in these cells. Moreover, since the duplication rate 
in mature adipocytes is low (16), these results suggested a novel 
cell-cycle independent role for CDK4. In order to analyze the par-
ticipation of CDK4 in adipose tissue biology, we set to determine 
the phenotype of CDK4 mutant mice. The previously generated 
Cdk4neo/neo mice are diabetic and have impaired pancreatic ȕ cell 
development and decreased insulin levels (11). Analysis of adi-
pose tissue function in these mice would be confusing, since any 
observed effect could be secondary to insulin deficiency. We there-
fore used Cdk4neo/neo Rip-Cre (Cdk4neo/neo;cre/cre; herein referred to as 
Cdk4nc) mice that reexpress Cdk4 in ȕ cells and thus have normal 
insulin levels (13). We also used a mouse model of CDK4 hyper-
activation, the R24C model. Cdk4R24C/R24C mice express a mutant 
CDK4 protein that is not sensitive to INK4a inhibitors (11) and is 
consequently more active. A first analysis showed that Cdk4nc mice 
had decreased body weight, whereas Cdk4R24C/R24C mice exhib-
ited increased body weight compared with Cdk4+/+ mice (Figure 
1, D and E). Significant changes in WAT mass accounted for body 
weight variation. Cdk4nc and Cdk4R24C/R24C mice had decreased and 
increased WAT mass, respectively, as measured by EchoMRI (Fig-
ure 1, D and E, and Supplemental Figure 1, E and F). Changes in 
fat mass were consistent with variation in adipocyte size (Figure 
1F and Supplemental Figure 1G). Overall, severe atrophy could be 
observed in fat pads from Cdk4nc mice, whereas Cdk4R24C/R24C mice 
developed adipose tissue hypertrophy (Supplemental Figure 1H).
To demonstrate that the effects of Cdk4 deletion in adipose 
tissue were cell autonomous, we used an approach involving sys-
temic administration of adeno-associated viral vectors of serotype 
8 (AAV8), which has been previously reported as leading to genetic 
Figure 2. Positive correlation between CCND3 expression and human 
VAT mass. (A–D) Correlation between the CCND3/ACTB ratio (n = 32, 
Pearson’s r = 0.3717, P < 0.05) (A), the CCND1/ACTB ratio (n = 32, Pear-
son’s r = –0.04574, P < 0.05) (B), the CCND2/ACTB ratio (n = 32, Pearson’s 
r = 0.06203, P < 0.05) (C), and the CDK4/ACTB ratio (n = 30, Pearson’s 
r = 0.2875, P < 0.05) (D) and BMI in VAT of human subjects. Data are 
normalized to ACTB. *P < 0.05.
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compared with their respective control mice (Figure 3, A–C). Insulin 
quantification in plasma showed, however, a significant decrease in 
Cdk4R24C/R24C mice, whereas no differences were observed in Cdk4nc 
or Cdk4flox/flox mice infected with AAV8-mini/aP2-cre vector in fed 
conditions (Figure 3, D–F). Decreased insulin levels are indicative of 
either better insulin sensitivity or of a defect in insulin secretion by 
pancreatic ȕ cells. Cdk4nc mice were glucose intolerant (Figure 3G) 
and R). No association was found for CCND1, CCND2, or CDK4 
(Figure 2, B–D). These results confirmed a positive correlation 
between WAT mass and CCND3-CDK4 expression and activity 
and suggested that these proteins participate in WAT function.
CDK4 promotes insulin sensitivity in vivo. No differences in fast-
ing and feeding glycemia were observed in Cdk4nc or Cdk4flox/flox 
infected with AAV8-mini/aP2-cre vector and Cdk4R24C/R24C mice 
Figure 3. CDK4 promotes insulin sensitivity in vivo. (A–C) Fasting glycemia in Cdk4+/+ and Cdk4nc (n = 8) mice (A), Cdk4flox/flox infected with AAV8-mini/
aP2-null or AAV8-mini/aP2-cre vectors (n = 5–4) (B), and Cdk4+/+ and Cdk4R24C/R24C (n = 12) mice (C). (D–F) Fed serum insulin in Cdk4+/+ and Cdk4nc (n = 7) 
(D), Cdk4flox/flox infected with AAV8-mini/aP2-null or AAV8-mini/aP2-cre vectors (n = 5–4) (E), and Cdk4+/+ and Cdk4R24C/R24C mice (n = 8) (F). (G–I) GTT in 
Cdk4+/+ and Cdk4nc (n = 7) (G), Cdk4flox/flox infected with AAV8-mini/aP2-null or AAV8-mini/aP2-cre (n = 5–4) (H), and Cdk4+/+ and Cdk4R24C/R24C (n = 6) mice 
(I). (J–L) ITT in Cdk4+/+ and Cdk4nc (n = 5) (J), Cdk4flox/flox infected with AAV8-mini/aP2-null or AAV8-mini/aP2-cre vectors (n = 5–4) (K), and Cdk4+/+ and 
Cdk4R24C/R24C (n = 12) mice (L). AUC for GTT and ITT was analyzed and is shown below the curves. Data were expressed as mean ± SEM. Statistically signifi-
cant differences were determined with unpaired 2-tailed Student’s t tests. *P < 0.05.
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adipocytes with a chemical CDK4 inhibitor (PD0332991) (21) 
resulted in the delipidation of these adipocytes and in a 40% 
decrease in their TG content (Supplemental Figure 2, A and B). 
Lipolysis experiments in eWAT explants from mice revealed 
a 4-fold increase of nonesterified fatty acid (NEFA) release in 
Cdk4nc eWAT compared with Cdk4+/+ eWAT (Figure 4C). Simi-
larly, glycerol release was also increased in these mice (Supple-
mental Figure 2C). Conversely, Cdk4R24C/R24C eWAT showed 
significantly decreased NEFA (Figure 4D) and glycerol release 
(Supplemental Figure 2D), which suggested impaired lipolysis. 
Interestingly, eWAT explants from Cdk4nc mice, in addition to 
increased lipolysis, had reduced lipogenesis, as measured by ace-
tate incorporation into the distinct TG, diacyclycerols (DG), and 
phospholipid (PL) lipid fractions (Figure 4E). On the other hand, 
eWAT explants from mice expressing the hyperactive Cdk4R24C 
allele showed increased lipogenesis (Figure 4F). However, we 
could not detect any differences in liver TG content in Cdk4+/+, 
Cdk4nc, and Cdk4R24C/R24C mice (Supplemental Figure 2, E and F). 
This validated a positive correlation between CDK4 activity and 
lipogenesis and a negative correlation between CDK4 activity 
and lipolysis. Strikingly, these are exactly the effects of insulin 
in adipocytes, suggesting that CDK4 could mediate the effects of 
insulin in adipose tissue.
and cleared glucose at a slower rate than Cdk4+/+ mice, a character-
istic of insulin resistance (Figure 3J). We did not observe any signifi-
cant differences in glucose tolerance tests (GTTs) in Cdk4flox/flox mice 
infected with AAV8-mini/aP2-cre vector; however, these mice had 
a trend toward insulin resistance compared with Cdk4flox/flox mice 
infected with AAV8-mini/aP2-null vector (P = 0.0829) (Figure 3, 
H and K). In contrast, Cdk4R24C/R24C mice were more glucose tol-
erant and insulin sensitive than Cdk4+/+ mice (Figure 3, I and L). 
Together, these results show that CDK4 activity is positively cor-
related with insulin sensitivity.
CDK4 represses lipolysis and stimulates lipogenesis. We previ-
ously showed the participation of CDK4 and CCND3 in adipo-
genesis. We proved that these proteins control the activity of 
the master regulator of adipocyte differentiation, PPARȖ (14). In 
this study, we analyze the participation of CDK4 in the function 
of mature adipocytes. Lipids are mobilized from WAT through 
lipolysis, a breakdown of triglycerides (TG) into glycerol and free 
fatty acids (FFA) (20). As expected, changes in WAT mass were 
positively correlated with alterations in TG content in our mouse 
models: Cdk4nc and Cdk4R24C/R24C mice had less and more TG in 
eWAT, respectively (Figure 4, A and B). Decreased TG content in 
Cdk4nc eWAT was likely the result of an imbalanced lipogenesis/
lipolysis ratio. Indeed, treatment of fully differentiated 3T3-L1 
Figure 4. CDK4 represses lipolysis and is a positive modulator of lipogenesis. (A) Quantification of TG content of eWAT from Cdk4+/+ and Cdk4nc mice 
(n = 3). (B) Quantification of TG content of eWAT of Cdk4+/+ and Cdk4R24C/R24C mice (n = 3). (C) Rate of NEFA release in eWAT explants from fasting Cdk4+/+ 
and Cdk4nc mice (n = 3). (D) Rate of NEFA release in eWAT explants from fasting Cdk4+/+ and Cdk4R24C/R24C mice (n = 6). (E) Ex vivo lipogenesis experiments 
in eWAT explants using labeled 14C-acetate incorporation to detect TG, DG, and PL synthesis in Cdk4+/+ and Cdk4nc mice (n = 3). (F) Ex vivo lipogenesis 
experiments in eWAT explants from Cdk4+/+ and Cdk4R24C/R24C mice. 14C-acetate incorporation was used to detect TG, DG, and PL synthesis by TLC (n = 3). 
Data are expressed as mean ± SEM. Statistically significant differences were determined with unpaired 2-tailed Student’s t tests. *P < 0.05.
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Figure 5. CDK4 is activated by insulin and translates insulin signaling in adipocytes. (A) CDK4 activity in vivo. SDS-PAGE autoradiography showing 
RB1 phosphorylation by CDK4 immunoprecipitated from 3T3-L1 mature adipocytes after insulin stimulation. The left panel shows RB1 phosphorylation 
by recombinant CDK4 used as a positive control. (B) Western blot analysis showing the inhibition of insulin-induced RB1 phosphorylation on Ser780 by 
CDK4 knockdown in mature 3T3-L1 adipocytes. (C) CCND3 and CDK4 association is increased upon insulin stimulation, but decreased upon cotreatment 
with insulin and AKT inhibitor in mature 3T3-L1 adipocytes. (D) Volcano plot showing differences in putative kinase activities between control and Cdk4nc 
mice injected (portal vein) with insulin for 3 minutes (n = 4). Kinases with a positive kinase statistic show higher activity in Cdk4nc samples compared with 
control samples, whereas kinases with negative kinase statistic show lower activity in Cdk4nc samples compared with control samples. (E) Based on the 
upstream kinase activity (D) results and on the GeneGO analysis of the PamGene experiment, the putative role of CDK4 upstream of AKT in the insulin sig-
naling pathway is represented. (F) Immunoblot showing AKT phosphorylation on Thr308 and Ser473 in response to insulin injection (3 minutes) in fasted 
control and Cdk4nc mice (n = 2 for NaCl and n = 4 for insulin treatment). (G and H) Coimmunoprecipitation experiments showing the interaction between 
endogenous IRS2 and PIK3R1. IRS2 (G) and PIK3R1 (H) were immunoprecipitated and the presence of PIK3R1 (G) and IRS2 (H) was detected by Western 
blot analysis in Cdk4+/+ and Cdk4nc mice treated with insulin for 3 minutes (n = 2 for NaCl and n = 3 for insulin treatment). (I and J) Coimmunoprecipitation 
experiments showing the interaction between endogenous PIK3R1 or IRS2 and CDK4. CDK4 was immunoprecipitated and the presence of PIK3R1 (n = 3) (I) 
and IRS2 (n = 1) (J) was detected by Western blot analysis in 3T3-L1 mature adipocytes treated with insulin. A representative Western blot is shown. Unless 
specified otherwise, all experiments are representative of 3 independent experiments.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3 4 1jci.org   Volume 126   Number 1   January 2016
CDK4 is activated by insulin and mediates insulin signaling in 
adipocytes. We wanted next to uncover the mechanisms of CDK4 
activation following insulin stimulation in adipocytes. CDK4 
activity was stimulated by insulin in differentiated 3T3-L1 cells, 
as suggested by increased phosphorylation of PIK3R1 by immu-
noprecipitated CDK4 (Figure 5A). Similar results were observed 
when eWAT from insulin-treated mice was used (Supplemental 
Figure 3A). Interestingly, CDK4 knockdown (Figure 5B) or treat-
ment of 3T3-L1 adipocytes with PD0332991 (Supplemental Figure 
3B) abrogated the effects of insulin on PIK3R1 phosphorylation. 
Furthermore, association of CDK4 with its regulatory subunit 
CCND3 was dependent on the insulin signaling pathway, since 
AKT inhibition abolished this association (Figure 5C).
Next, we addressed how CDK4 could participate in the insu-
lin-signaling pathway in adipocytes. Since the insulin signaling 
cascade is dependent on the rapid activation of a series of tyro-
sine and serine/threonine protein kinases (STKs), we used a new 
technology developed by PamGene to determine differential 
global kinase activity in Cdk4nc and control mice in response to 
insulin. We used arrays that consisted of 140 immobilized serine/
threonine-containing peptides that are targets of most known 
kinases (STK PamChips) (22). These chips were incubated with 
lysates prepared from eWAT from Cdk4nc or control mice injected 
with insulin. The same experiment was performed using lysates 
from cells treated with PD0332991 and stimulated with insulin. 
Peptides whose phosphorylation varied significantly between 
the control and Cdk4nc-treated mice or between the control and 
PD0332991-treated samples (Supplemental Figure 3, C and D) 
were indicative of differential specific kinase activities. Putative 
upstream kinase analysis underscored significant differences in 
the AKT pathway (Figure 5D and Supplemental Figure 3, E and F). 
This suggested that CDK4 activity played a role upstream of AKT, 
as indicated in Figure 5E. Western blot analyses further proved 
that AKT activity, as measured by phosphorylation in Ser473 and 
Thr308, was decreased in Cdk4nc mice in response to insulin (Fig-
ure 5F). Similarly, chemical inhibition of CDK4 also attenuated 
AKT signaling in 3T3-L1 adipocytes (Supplemental Figure 3G). 
This further supports the hypothesis that CDK4 regulates insulin 
signaling upstream of AKT. Upon insulin stimulation, the intrinsic 
tyrosine kinase domain of the insulin receptor leads to receptor 
autophosphorylation at tyrosine residues. The subsequent recruit-
ment and phosphorylation of insulin receptor substrate 1 (IRS1) 
and IRS2 are the pivotal events that, in turn, activate the down-
stream PI3K-PDK1-AKT axis to regulate lipogenesis and lipolysis 
in adipocytes (23). We therefore investigated whether CDK4 regu-
lated the insulin-signaling pathway by facilitating the recruitment 
of IRS into PIK3R1, the PI3K subunit p85a. We found that Cdk4 
deletion greatly impaired the ability of IRS2 to bind with PIK3R1 in 
response to insulin stimulation (Figure 5, G and H). Furthermore, 
CDK4 was recruited to PIK3R1 (Figure 5I) and IRS2 (Figure 5J) 
complexes in adipocytes. However, we only detected an increase 
of interaction in response to insulin between PIK3R1 and CDK4.
IRS2 is a substrate of CDK4. Interestingly, in silico analysis 
highlighted the presence of CDK4 consensus phosphorylation sites 
in the p85A subunit of PI3K (PIK3R1), phosphoinositide-depen-
dent kinase 1 (PDK1), IRS1, and IRS2 (Table 1). However, in vitro 
kinase assays showed no phosphorylation of PIK3R1, or PDPK1 by 
CDK4 (data not shown). In vitro kinase assays showed, however, 
that CDK4 could phosphorylate recombinant glutathione S–trans-
ferase–purified (GST-purified) IRS2 protein (Figure 6A). IRS2 con-
tains 5 CDK4 consensus sites distributed along the protein (Ser388, 
Thr576, Ser980, Ser1004, and Ser1226) (Table 1 and Supplemen-
tal Figure 4A). Site-directed mutagenesis (serine to alanine) and 
protein truncation approaches helped us to map the CDK4 phos-
phorylation sites of IRS2 at Ser388 and Ser1226 (Figure 6, B and 
C). Interestingly, these 2 potential phosphorylation sites are highly 
conserved through evolution (Supplemental Figure 4B).
We next evaluated the functional relevance of IRS2S388A and 
IRS2S1226A mutants that cannot be phosphorylated by CDK4. Res-
cue of IRS2 activity in Irs2–/– preadipocytes with ectopic expres-
sion of WT IRS2 resulted in the restoration of insulin signaling 
as assessed by immunofluorescence staining of AKT phosphory-
lation (Figure 6, D and E). In contrast, IRS2S388A mutants, which 
cannot be phosphorylated by CDK4, could not restore insulin sig-
naling in these cells (Figure 6, D and E). No significant phenotype 
was observed for IRS2S1226A mutants (data not shown). Moreover, 
IRS2S388A mutants were not recruited to PIK3R1 protein complexes 
upon insulin stimulation when ectopically expressed in 293T cells 
(Figure 6, F and G). This demonstrated that the phosphorylation of 
IRS2 on Ser388 by CDK4 is essential for its activity.
CDK4 regulates insulin signaling in vivo via IRS2Ser388 phos-
phorylation. To determine the potential roles of CDK4 on IRS2 
phosphorylation, we generated a phosphospecific antibody to 
Ser388 of IRS2 that we validated by in vitro CDK4 kinase assay 
(Supplemental Figure 5A). IRS2 Ser388 was highly phosphorylated 
in the adipose tissue of Cdk4+/+ mice after 50 minutes of insulin 
stimulation (Figure 7, A and B). This phosphorylation was almost 
abrogated in the adipose tissue of insulin-treated Cdk4nc mice. 
Moreover, decreased IRS2 Ser388 phosphorylation resulted in 
impaired insulin signaling pathways, as demonstrated by reduced 
AKT phosphorylation (Figure 7, A and B). In sharp contrast, 
CDK4 hyperactivity, as observed in Cdk4R24C/R24C mice, resulted 
in a robust increase in IRS2 Ser388 phosphorylation (Figure 7, C 
and D). Consequently, AKT phosphorylation was also increased 
(Figure 7, C and D). Chemical inhibition of CDK4 also resulted 
in the abrogation of both IRS2 Ser388 and AKT phosphorylations 
(Figure 7, E and F). From these results, we can conclude that this 
Table 1. CDK consensus sites in mouse IRS1, IRS2, PDKP1, and 
PIK3R1
Protein Site position Sequence CDK4 Interaction
PIK3R1 Thr86 TPKP +
PDPK1 Thr357 TPPP –
Thr521 TPNP
IRS1 Ser1209 SPRR +
IRS2 Ser388 SPGP +
Thr576 TPAR
Ser980 SPKP
Ser1004 SPYP
Ser1226 SPMR
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Figure 6. CDK4 phosphorylates IRS2. (A) CCND3-CDK4 complex directly phosphorylates full-length GST-IRS2 in vitro (n = 3). (B) In vitro phosphorylation 
of GST-IRS2 fragments (1–494aa, 495–744aa, 745–993aa, 994–1099aa, 1100–1321aa) by CCND3/CDK4. Left panel, SDS-PAGE stained with Coomassie blue 
for the loading control. Middle panels, autoradiography of the SDS-PAGE gels containing the different GST-IRS2 fragments, incubated with CCND3/CDK4. 
Right panel, RB1 recombinant protein was used as a positive control (n = 3). (C) Defective IRS2S388A and IRS2S1226A phosphorylation by CCND3-CDK4. Upper 
panel, autoradiography; lower panel, SDS-PAGE gel stained with Coomassie blue for the loading control. (n = 2). (D) Decrease in pAKT Ser473 phosphoryla-
tion in Flag-IRS2S388A electroporated Irs2–/– cells upon insulin stimulation, compared with the WT Flag-IRS2–transfected cells (n = 3). Original magnifica-
tion, ×400. (E) Quantification of pAKT Ser473 fluorescence intensity for untransfected, Flag-IRS2–transfected, and Flag-IRS IRS2S388A electroporated 
Irs2–/– preadipocytes was performed with ImageJ software (http://imagej.nih.gov/ij/). At least 100 cells were quantified per condition. (F) Representative 
Western blot analysis showing impaired interaction between PIK3R1 and Flag-IRS2S388A mutant after insulin stimulation compared with cells transfected 
with Flag-IRS2 in 293T cells. (G) Quantification of the blot shown in F. A representative Western blot is shown. Data are expressed as mean ± SEM. Statis-
tically significant differences were determined with 2-way ANOVA followed by Tukey’s multiple comparisons test (E–G). *P < 0.05.
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Figure 7. CDK4 phosphorylates in vivo the IRS2 protein at the Ser388. (A–D) Immunoblot analysis of IRS2 phosphorylation on Ser388 and AKT phos-
phorylation on Thr308 and Ser473 in control and Cdk4nc (n = 2 starved/5 insulin for Cdk4+/+and n = 2 starved/5 insulin for Cdk4nc) mice (A). (B) Quantifi-
cation of the blot shown in A using ImageJ software. Cdk4R24C/R24C (n = 2 starved/3 insulin for both Cdk4+/+and CdkR24C/R24C). (C) Mice were treated for 50 
minutes with insulin. (D) Quantification of the blot shown in C using ImageJ software. (E) Immunoblot analysis of IRS2 phosphorylation on Ser388 and 
AKT phosphorylation on Thr308 and Ser473 in 3T3-L1 mature adipocytes during a time course insulin stimulation with or without PD0332991 (n = 1). (F) 
Quantification of the blot shown in E using ImageJ software. (G) Correlation between the pIRS2 Ser388/ACTB ratio in VAT and the BMI of the subjects 
(n = 45, Pearson’s r = 0.3307, P < 0.05). (H) Correlation between the pIRS2 Ser388/ACTB ratio in VAT and the glycemia of the subjects (n = 27, Pearson’s 
r = –0.3900, P < 0.05). Data are expressed as mean ± SEM. Statistically significant differences were determined with 2-way ANOVA followed by Tukey’s 
multiple comparisons test (B–D). *P < 0.05.
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Interestingly, IRS proteins are also involved in the activation 
of several growth factor receptor pathways other than the insu-
lin receptor pathway, such as the IGF 1 receptor (IGF1R) pathway 
(27). The prooncogenic activities of IGF1R (26) are mediated by 
its downstream effectors, IRS1 and IRS2. IRS proteins transduce 
mitogenic, antiapoptotic, and antidifferentiation signals to the 
cell, mainly through the PI3K–AKT module (28). Although antion-
cogenic synergistic effects have been observed using either CDK4 
and IGF1R inhibitors or CDK4 and PI3K inhibitors, no crosstalk 
between both pathways has been described (29–32). The CDK4/
CDK6 inhibitor (PD0332991, palbociclib) has been approved 
for the treatment of breast cancer (33). Two other CDK4/CDK6 
inhibitors, LY-2835219 (also known as abemaciclib) and LEE011 
(also known as ribociclib), are also currently in advanced stages 
of clinical trials (34). Interestingly, it has previously been reported 
that a major enzyme of de novo lipogenesis, the fatty acid synthase 
(FASN), is increased in numerous cancers, including breast can-
cer (35). The activity of FASN is known to be stimulated by insulin 
through the PI3K/AKT pathway, and here, we demonstrate that 
CDK4 is a key effector of insulin, thus promoting de novo lipid 
synthesis. Based on our findings, we can speculate that CDK4, 
through phosphorylation and regulation of IRS activity, could 
simultaneously sustain de novo lipid synthesis and the oncogenic 
activity of the aforementioned pathways in transformed cells.
The second major finding of our study is the discovery of a resi-
due in IRS2 that is phosphorylated by CDK4 in response to insulin. 
A large number of publications previously focused on the effects of 
IRS1 and IRS2 phosphorylation on the insulin-signaling pathway. 
Both positive and negative phosphorylation sites finely regulate 
IRS1 and IRS2 activity and are a paradigm of the flexibility of insulin 
and IGF signaling (36). The final serine/threonine phosphorylation 
state of IRS proteins is a consequence of the combined action of sev-
eral kinases that are activated by different pathways in a spaciotem-
poral manner. Multiple site phosphorylation of these proteins by 
distinct kinases, such as JNK (37), GSK3 (38), ERK1, or mTOR (39), 
provides a large number of combinations of phosphorylating events 
that generate a very complex network (40). We show that CDK4 
phosphorylates IRS2 at the new Ser388 site. Moreover, we show 
that this phosphorylation renders IRS2 more active. Our results 
add more complexity to the understanding of the physiology of the 
phosphorylation of the IRS proteins. Phosphorylation by CDK4 may 
also have an impact on the phosphorylation of IRS2 by other kinas-
es; however, the relative contribution of CDK4 to the final activa-
tion or inhibition of IRS compared with other kinases and the iden-
tification of which serine/threonine residues are the most critical in 
regulating IRS function in response to insulin remain to be elucidat-
ed. Similarly, we still do not understand why CDK4 activates IRS2 
whereas AKT inhibits it through a negative feedback loop. The same 
stimulus, insulin, triggers concomitantly inhibitory and stimula-
tory phosphorylations in IRS. The fine regulation of these positive 
versus negative phosphorylation events requires further investiga-
tion. Interestingly, we were able to observe the stimulation of IRS2 
Ser388 phosphorylation with insulin not only in adipocytes, but also 
in other cell types, such as C2C12 myotubes and primary hepato-
cytes. IRS2 Ser388 phosphorylation could also be detected in Min6 
cells, but was not so insulin responsive. As shown in Supplemental 
Figure 6, A–C, upon insulin stimulation, IRS2 Ser388 phosphoryla-
newly identified site in IRS2, which is phosphorylated by CDK4, 
maintains the activation of the insulin signaling pathway. To fur-
ther investigate the status of IRS2 Ser388 in type 2 diabetic mouse 
models, such as db/db mice, that are known to be hyperinsulin-
emic, we analyzed this phosphorylation in the basal state and 
upon insulin stimulation in adipose tissue. The db/db mice have a 
tendency toward an increased IRS2 Ser388 phosphorylation under 
basal conditions, compared with db/+ mice (P = 0.0511) (Supple-
mental Figure 5B). However, insulin-resistant db/db mice did not 
show increased IRS2 Ser388 phosphorylation upon insulin stimu-
lation (Supplemental Figure 5B). Most important was the finding 
that IRS2 Ser388 phosphorylation in human visceral WAT samples 
was positively correlated with the BMI of the subjects (Figure 7G 
and Supplemental Figure 5, C and D). Interestingly, we found a 
negative correlation between IRS2 Ser388 phosphorylation and 
fasting glucose in human subjects. This further advocates for a 
role of CDK4 in both adipose tissue biology and glucose homeo-
stasis (Figure 7H and Supplemental Figure 5E).
Discussion
We showed throughout this study that the cell-cycle regulatory 
kinase CDK4 is a key regulator of adipocyte function. The partici-
pation of this kinase in the control of proliferation through the con-
trol of the activity of E2F transcription factors has been extensive-
ly studied (24). The results of our study provide 3 lines of evidence 
that CDK4 acts independently of E2F to regulate adipocyte func-
tion. First, we discovered a role of the cell-cycle kinase CDK4 in 
the control of the insulin-signaling pathway. CDK4, through phos-
phorylation of IRS2, maintains insulin action in adipocytes. This is 
consistent with the phenotypes of genetic CDK4 mouse models. 
Indeed, adipose tissue from Cdk4nc mice has decreased lipogen-
esis as well as increased lipolysis. In contrast, mice that express 
hyperactive CDK4R24C exhibit decreased lipolysis and increased 
lipogenesis in WAT. These findings place CDK4 at the initiation of 
the insulin-triggered adipocyte-signaling pathway.
We show in this study a function of CDK4, that of a mediator 
of insulin signaling. Indeed, we show that the effects of CDK4 in 
adipocytes are independent of E2F activity and, therefore, most 
likely independent of the control of the cell cycle. E2F1 is the most 
studied member of the E2F family. E2F1 has numerous metabolic 
functions, such as the participation in adipose tissue metabolism 
through the transcriptional regulation of the master adipogenic 
factor PPARȖ during early stages of adipogenesis (16). Here, we 
demonstrate, by generation of Cdk4R24C/R24 E2f1+/+ and Cdk4R24C/R24C 
E2f1–/– mice, that CDK4 has E2F1-independent functions in mature 
adipose tissue. Indeed, the genetic deletion of E2F1 in the R24C 
background does not affect adiposity or adipocyte proliferation 
(Figure 1, I and J, and Supplemental Figure 1N).
Based on our results, we propose that CDK4 is integrated in 
the insulin-signaling pathway as follows. In response to insulin, the 
canonical cascade of events is elicited. This includes the sequential 
activation of IR, IRS1-2, PI3K, PDPK1, and AKT. AKT then acti-
vates CDK4 (because inhibition of AKT blocks CDK4 activation), 
which then phosphorylates IRS2, creating a positive feedback loop. 
The activation of CDK4 by AKT is likely an indirect event. Several 
studies previously reported that AKT phosphorylates and inhibits 
p21 and p27, which are both CDK4 inhibitors (25, 26).
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FLPo]10Sykr/J) in order to remove the Neo resistance cassette. With 
one subsequent cross with B6 animals, the Flp transgene was removed 
and the obtained Cdk4flox/+ mice were then intercrossed in order to gen-
erate the Cdk4flox/flox mice used in this study.
Animals were maintained in a temperature-controlled animal 
facility with a 12-hour light/12-hour dark cycle and had access to 
food and water according to the Swiss Animal Protection Ordinance 
(OPAn). Only male animals were used in this study. For the GTT, mice 
were starved for 16 hours and then injected i.p. with glucose (2 g/kg). 
Tail vein blood glucose was measured at the indicated times. For the 
insulin tolerance test (ITT), 6-hour–fasted mice were injected i.p. with 
0.75 U/kg insulin and tail vein blood glucose was then measured at the 
indicated times. For the in vivo insulin-stimulation assay, mice were 
fasted overnight and injected in the portal vein or i.p. with 0.75 U/kg 
insulin or an equal volume of saline. After 3 or 50 minutes, the mice 
were sacrificed via cervical dislocation. For insulin level measure-
ments, tail vein blood was collected under fed conditions 2 hours after 
the beginning of the 12-hour dark cycle.
Plasmid constructs and mutagenesis. pDONR-IRS2 was subcloned 
from pBS mouse IRS-2 (Addgene plasmid catalog 11372) (43) and 
generated using the pDONR221 vector of Gateway Cloning Technol-
ogy (Invitrogen). Flag-IRS2 and GST-IRS2 were obtained using the 
pDEST pCMV14-3XFlag and pGEX-2T vectors of Gateway Cloning 
Technology starting from the above-described pDONR-IRS2 con-
structs. A similar strategy was used to obtain the truncated versions of 
GST-IRS2. The Flag-PIK3R1 and Flag-PDPK1 plasmids were obtained 
from the Montpellier Genomic Collection (MGC). pDONR-hRB 379–
928aa was subcloned from pCMV human RB1 and generated using 
the pDONR221 vector of Gateway Cloning Technology. pGEX-2T 
hRB 379–928aa was obtained using the pDEST pGEX-2T from Gate-
way Cloning Technology. The different serine-to-alanine mutants of 
GST-IRS2 were generated using a QuikChange Site-Directed Muta-
genesis Kit (Stratagene).
Cell culture. 3T3-L1 and 293T were obtained from ATCC. Irs2–/– 
cells were cultured in DMEM with 10% FBS (PAA Laboratories) in 
5% CO2 in an incubator set at 37°C. Two days after reaching conflu-
ence, 3T3-L1 cells were differentiated with DMEM, 10% FBS, 0.5 mM 
3-isobutyl-1methylxanthine (IBMX), 1.7 ȝM insulin, 1 ȝM dexametha-
sone, and 1 ȝM rosiglitazone for 2 days. From day 3 onward, the cells 
were incubated with DMEM, 10% FBS, and 10 ȝg/ml insulin, and the 
medium was changed every 2 days until day 8 of differentiation. 3T3-L1 
mature adipocytes were maintained in medium containing FBS only. 
For insulin (100 nM) or isoproterenol (100 nM) treatments, fully differ-
entiated 3T3-L1 adipocytes were incubated in serum-free DMEM con-
taining 0.2% fatty acid–free BSA. Primary hepatocytes were obtained 
from B6 mice. Mouse hepatocytes were harvested and cultured as 
previously described (44). Min6 cells were provided by Christian Wid-
mann (Department of Physiology, Université de Lausanne, Lausanne). 
They were maintained as previously described (45) and incubated in 
DMEM supplemented with 15% FBS and 5 mM glucose overnight. The 
day after, cells were incubated in serum-free DMEM containing 0.1% 
fatty acid–free BSA for 6 hours. C2C12 myoblasts were obtained from 
ATCC and were cultured in low-glucose DMEM with 10% FBS in 5% 
CO2 in an incubator set at 37°C. For myotube differentiation, C2C12 
myoblasts were seeded in 6-cm plates. When the cells reached 95% 
confluency, the culture medium was switched to DMEM containing 
2% horse serum. The medium was changed every 2 days until day 5 of 
tion was stronger after 1 hour of treatment, which is in agreement 
with our findings in mature adipocytes. These results open inter-
esting perspectives into the contribution of CDK4 to IRS2 Ser388 
phosphorylation in other insulin-sensitive tissues; CDK4 could, for 
instance, participate in the control of de novo lipid synthesis in liver 
upon insulin stimulation.
RNAi-mediated depletion of CDK6, the CDK4 ortholog, sug-
gests that this kinase is also able to phosphorylate IRS2 at Ser388 
in mature adipocytes upon insulin stimulation, but to a lesser 
extent (Supplemental Figure 6D). The effects of CDK6 on IRS2 in 
other tissues remain to be studied.
Defects in insulin action and insulin secretion are both fea-
tures of type 2 diabetes. In line with previous publications report-
ing that CDK4 regulates ȕ cell growth (11) and insulin secretion 
in ȕ cells (41), it would be interesting to explore the relative con-
tribution of this IRS2 Ser388 phosphorylation in ȕ cell function. 
The involvement of IRS2 in the pathogenesis of type 2 diabetes is 
highlighted by the phenotype of Irs2–/– mice. Indeed, these animals 
develop type 2 diabetes with impaired peripheral insulin signaling 
and pancreatic ȕ cell function without compensation by IRS1 (42).
Third, the importance of our findings goes beyond the control of 
adipocyte biology in normal physiology. Here, we also report a signif-
icant (P = 0.0362) correlation between CCND3 expression and BMI 
in human subjects. Our model is further supported by the observed 
increase in the phosphorylation of the Ser388 of IRS2 in human 
obese subjects (BMI > 27). Insulin resistance is a major feature in 
various metabolic disorders, such as obesity and type 2 diabetes. We 
show here an inverse correlation of IRS2 Ser388 levels in VAT with 
the blood glucose levels from the subjects (Figure 7H). This strongly 
supports the notion that this phosphorylation participates in glucose 
homeostasis in humans.
In conclusion, our results demonstrate that CDK4 is a regula-
tor of adipocyte insulin signaling. By combining experimental data 
from cellular and mouse models and data obtained using human 
samples, our study provides insights into the complex pathogen-
esis of obesity and insulin resistance.
Methods
Materials. All experiments with the CDK4 inhibitor (PD0332991, 
Azasynth Co.) were done using 1 ȝM of PD0332991 in mature 3T3-L1 
adipocytes. All chemicals, unless stated otherwise, were purchased 
from Sigma-Aldrich. Actrapid human recombinant insulin was pur-
chased from Novo Nordisk Pharma SA. AKT inhibitor (catalog 124017) 
was purchased from Calbiochem and used at 10 ȝM for 30 minutes. 
14C-acetate, and Ȗ-33P-ATP were purchased from PerkinElmer.
Animals. The generation of Cdk4nc and Cdk4R24C/R24C mice has 
been previously described (11, 13). The 8- to 12-week-old male db/+ 
and db/db as well as C57BL/6J (B6) mice were obtained from Janvier. 
E2f1+/+ and E2f1–/– mice (B6;129S4-E2f1tm1 Meg/J) were purchased 
from The Jackson Laboratory. Cdk4flox/flox mice were generated for this 
study in collaboration with Cyagen Biosciences. The targeting vec-
tor included a Neo resistance cassette flanked by FRT sites as well as 
CRE-dependent lox P sites in introns 1 and 8 (Supplemental Figure 1I).
C57BL/6 embryonic stem cells were used for gene targeting, and 
the positive cells were bred into albino B6 female mice. This strat-
egy allowed us to have a pure B6 background. Cdk4flox/+ mice were 
then crossed with mice expressing Flp recombinase (B6.Cg-Tg[Pgk1-
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of these cells used to immunoprecipitate CDK4, as described above. 
Additionally, CDK4 was immunoprecipitated from eWAT collected 
from mice that had fasted for 16 hours and were injected i.p. with 
insulin (0.75 U/kg) for 30 minutes. Kinase assays were performed 
using immunoprecipitated CDK4 and 500 ng of recombinant RB1 
protein (Santa Cruz Biotechnology Inc.) as a substrate in kinase buffer 
(25 mM Tris/HCl, pH 7.5, 150 mM NaCl, 10 mM MgCl2, 1 mM DTT, 
5 mM Na4P2O7, 50 mM NaF, 1 mM vanadate, and protease inhibitor 
cocktail) with 40 ȝM ATP and 8 ȝCi Ȗ-33PATP for 30 minutes at 30°C. 
Recombinant CDK4/CCND3 (ProQinase) was used as positive con-
trol. Boiling the samples for 5 minutes in the presence of denaturing 
sample buffer stopped the reaction. Samples were subsequently sub-
jected to SDS-PAGE, and the gels were then dried in a gel dryer for 1 
hour and exposed to an x-ray film at –80°C.
When using GST-purified proteins as substrates, kinase assays 
were performed using 500 ng of recombinant RB1 protein (Santa 
Cruz Biotechnology Inc.) as a positive control and recombinant 
CDK4/CCND3 kinase (ProQinase) and incubated in kinase buffer 
(described above) supplemented with 40 ȝM ATP and 8 ȝCi Ȗ-33PATP 
for 30 minutes at 30°C.
PamChip peptide microarrays for kinome analysis following insulin 
stimulation. For kinome analysis, STK microarrays were purchased 
from PamGene International BV. Each array contained 140 phos-
phorylatable peptides as well as 4 control peptides. Sample incu-
bation, detection, and analysis were performed in a PamStation 12 
according to the manufacturer’s instructions. Briefly, extracts from 
Cdk4+/+and Cdk4nc mice or mature 3T3-L1 adipocytes were made 
using M-PER mammalian extraction buffer (Thermo Scientific) con-
taining 1:50 Halt phosphatase inhibitor cocktail (Thermo Scientific) 
and 1:50 Halt protease inhibitor cocktail, EDTA-free (Thermo Sci-
entific), for 20 minutes on ice. The lysates were then centrifuged at 
15,871 g for 20 minutes to remove all debris. The supernatant was ali-
quoted, snap-frozen in liquid nitrogen, and stored at –80°C until fur-
ther processing. Prior to incubation with the kinase reaction mix, the 
arrays were blocked with 2% BSA in water for 30 cycles and washed 
3 times with PK assay buffer. Kinase reactions were performed for 
1 hour with 5 ȝg of total extract for the mouse experiment or 2.5 ȝg 
of total extract for the mature adipocyte and 400 ȝM ATP at 30°C. 
Phosphorylated peptides were detected with an anti-rabbit–FITC 
antibody that recognizes a pool of anti–phospho serine/threonine 
antibodies. The instrument contains a 12-bit CCD camera suitable 
for imaging of FITC-labeled arrays. The images obtained from the 
phosphorylated arrays were quantified using the BioNavigator soft-
ware (PamGene International BV), and the list of peptides whose 
phosphorylation was significantly different between control (3 min-
utes of insulin treated in Cdk4+/+ mice or 5 minutes of insulin stimula-
tion in cells starved in the presence of DMSO) and test (3 minutes of 
insulin treated in Cdk4nc mice or 5 minutes of insulin stimulation in 
cells starved in the presence of PD0332991) conditions was upload-
ed to GeneGo for pathway analysis. The list of the significantly dif-
ferent peptides is shown in Supplemental Figure 3, C and D. The Bio-
Navigator software was used to perform the upstream STK analysis 
that is shown in Figure 4D.
Statistics. All statistics are described in the figure legends. The 
results were expressed as mean ± SEM. Pearson’s correlation coef-
ficient was calculated to test for correlation between 2 parameters. 
Comparisons between 2 groups were performed with an unpaired 
differentiation. C2C12 myotubes were incubated in Į-MEM overnight 
to induce starvation. Primary hepatocytes, Min6 cells, and C2C12 myo-
tubes were stimulated with insulin (100 nM).
Proteins extraction, coimmunoprecipitation assays, and immunoblot 
analyses. For endogenous immunoprecipitation experiments between 
CDK4 and IRS2, mature 3T3-L1 adipocytes were lysed in a buffer 
containing 0.3% CHAPS, 40 mM Hepes, pH 7.5, 120 mM NaCl, 1 mM 
EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, and protease 
inhibitor cocktail. Lysates were precleared with protein A/G–agarose 
beads (Life Technologies) and 4 ȝg of control antibody (HA antibody) 
for 1 hour. After this step, anti-CDK4 antibodies or HA antibodies 
were added to the precleared lysates overnight to immunoprecipitate 
CDK4 or for the control immunoprecipitation, respectively. For endog-
enous immunoprecipitation experiments, mature 3T3-L1 adipocytes 
or eWAT from mice was lysed in a buffer containing 20 mM Tris, pH 
7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM Na3VO4, 1 
mM ȕ-glycerophosphate, 50 mM NaF, and protease inhibitor cock-
tail. Whole protein extracts were precleared with protein A/G–agarose 
beads (Life Technologies) for 1 hour, and anti-CDK4 antibody (Santa 
Cruz Biotechnology Inc., sc-260AC) and negative control (Rabbit 
IgG) (Santa Cruz Biotechnology Inc., sc-2345) were added to immu-
noprecipitate CDK4 overnight at 4°C. For IRS2 and PIK3R1 immuno-
precipitation experiments from mature adipocytes and mice, whole 
protein extracts were precleared with protein A/G–agarose beads 
(Life Technologies) and 4 ȝg of control antibody (HA antibody) for 1 
hour. Then anti-IRS2 anti-PIK3R1 antibody and negative control (HA 
antibody) were added to the precleared lysates for immunoprecipita-
tion overnight at 4°C. Immunoprecipitation experiments in 293T cells 
were performed using the same buffer as above. Anti-CDK4 antibody 
(Santa Cruz Biotechnology Inc., sc-601) and negative control (rabbit 
IgG) (Santa Cruz Biotechnology Inc., sc-2027) were used for the immu-
noprecipitation. Flag-PIK3R1, Flag-PDKP1, and Flag-IRS2 were trans-
fected with Lipofectamine 2000 (Invitrogen) and immunoprecipitated 
with Flag beads (Sigma-Aldrich A2220). Proteins were extracted with 
the same lysis buffer described above and subjected to SDS-PAGE elec-
trophoresis. Protein extractions from the different tissues (eWAT, BAT, 
brain, muscle, heart, kidney, lung, spleen, and liver) were prepared 
using M-PER mammalian extraction buffer (Thermo Scientific) con-
taining 1:100 Halt phosphatase inhibitor cocktail (Thermo Scientific) 
and 1:100 Halt protease inhibitor cocktail, EDTA-free (Thermo Sci-
entific). All the tissues were snap-frozen and then ground with Liquid 
N2 before lysis. The following antibodies were used for Western blot 
analysis: anti-CCND1 (NeoMarkers Rb-010-P0), anti-CCND3 (clone 
sc-6283), anti-CDK4 (clone sc-260), anti-HSL (clone sc-25843), anti-
HA (clone sc-805), anti-IRS2 (clone sc-8299) (Santa Cruz Biotechnol-
ogy Inc.); anti-CCND2 (clone ab3085), anti-CDK4 (clone DSC-35), 
anti-Ki67 (clone ab15580) (Abcam); anti–LMNA (clone 2032), anti–
pHSL Ser573 (clone 4139), anti–RB1 Ser780 (clone 9307), anti–pAKT 
Thr308 (clone 4056), anti–pAKT Ser473 (clone 4060), anti-AKT 
(clone 9272), anti-CDK6 (clone DCS83) (Cell Signaling Technology); 
anti-Flag (clone F3165), anti-actin (clone A2066), anti-tubulin (clone 
T6199) (Sigma-Aldrich); anti-PI3K3R1 (clone 06-195) (Upstate); and 
anti-IRS2 (Millipore MABS15). The phosphospecific antibody against 
IRS2 Ser388 was synthesized and purchased from GenScript.
Kinase assays. 3T3-L1 mature adipocytes were incubated over-
night in serum-free DMEM containing 0.2% fatty acid–free BSA and 
either stimulated with insulin (100 nM) or left untreated with lysates 
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LZ performed the tail-vein injections. CRK provided pBS mouse 
IRS-2 and Irs2–/– cells. JV and FJT provided human VAT samples. 
SL, ICLM, and LF wrote the manuscript.
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